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SUMMARY
The aim of the work described in this thesis was to 
identify gene (s) involved in determining the neurovirulence 
of HSV-2 strain HG52 in the mouse model system using 
deletion variants. The availability of variants with 
deletions in specific regions of the genome afforded the 
unique opportunity to determine the possible role of 
specific sequences in virulence. The phenotype of the 
parental wild type virus has also been determined by 
examining the neurovirulence of individual plaque stocks to 
identify the baseline from which to evaluate the deletion 
variants.
Twenty well separated plaques were picked from the elite 
stock of HG52 and passaged twice at 37°C. Restriction 
endonuclease analysis of the DNA from each of the twenty 
plaque stocks showed no differences in the size of fragments 
and distribution of the sites. To determine their 
neurovirulence, ten of the individual plaque stocks were 
selected randomly for mice inoculation. Following 
intracranial inoculation of 3 week old BALB/c mice, the 
plaque stocks segregated into three classes of
3
neurovirulence on the basis of their L D ^  values; high (<10 
pfu/mouse), intermediate (10^-10^ pfu/mouse) and low 
virulence (>10 pfu/mouse). The particle : pfu ratios of 
the plaque stocks were within the acceptable range for 
HSV-2. Restriction endonuclease analysis of viruses 
reisolated from the brains of infected mice showed no 
apparent difference in their DNA profiles compared to the 
initial infecting viruses.
Two plaque stocks of high, one of intermediate and one
of low virulence were selected on the basis of their LD_n50
values and particle : pfu ratios. These stocks retained
their original values compared to the non-plaque
2purified elite stock of HG52 (<10 pfu/mouse) when retested
in mice. Following intraperitoneal inoculation, the
selected plaque stocks showed differences in their LD_n50
values comparable to the differences seen following 
intracranial inoculation.
The selected plaque stocks grew as well as the parental 
HG52 in one step growth experiments in BHK-21 C13 cells. 
However, they showed differences in the growth kinetics in 
vivo in mouse brain where the high virulence stocks showed 
comparable growth to HG52, while the intermediate and low 
virulence stocks grew less well.
The selected plaque stocks were passaged five times in 
BHK-21 C13 cells and ten plaques from each were picked and 
stocks grown. Restriction endonuclease analysis of their 
DNA showed no differences compared to the wild type HG52. 
Following intracranial inoculation of the virus stock 
derived from the fifth passage, those derived from 
intermediate or low virulence virus remained stably of 
intermediate or low virulence, while those derived from high 
virulence virus showed in some cases a shift to intermediate 
levels of virulence.
These results clearly demonstrate virulence 
heterogeneity within the elite stock of HSV-2 strain HG52. 
The LDj.q value of high virulence virus was chosen as a 
baseline from which to evaluate the virulence of deletion 
variants
A number of deletion variants of HSV-2 strain HG52 with 
deletions ranging in size from 1.5 to 9 kb have been tested
for virulence following intracranial inoculation of 3 week
old BALB/c mice. The variants were segregated into three
categories of virulence on the basis of their LDC~ values;51)
7 5 6avirulent (>10 pfu/mouse), reduced (10 -10 pfu/mouse) and
4 2attenuated (10 pfu/mouse) compared to <10 pfu/mouse for
the elite stock of HG52.
Analysis of the variants with deletions in U /TRb b
indicated that the US4, US10, USll and US12 genes have a 
role in neurovirulence. Deletion of one copy of orig and 
one copy of the IE3 gene has a minor effect on 
neurovirulence.
Analysis of the variants with deletions in IR /TR
L j l i
regions of the genome implies that deletion of one copy of
the IEl gene and part of LAT transcripts in IRT has a minor
La
effect on neurovirulence. The analysis demonstrated that
none of the deleted genes appear to be a unique determinant
of neurovirulence with the exception of the DNA sequences
between 0-0.02 and 0.81-0.83 m.u.
The variant JH2604 whose genome is deleted by 1.5 kb in
both copies of the BamHI v fragment between 0-0.02 and
0.81-0.83 m.u. in TR_ and IR respectively was avirulent for
La Li
mice following intracranial and footpad inoculation with
7 8LD^q values of >10 and >10 pfu/mouse respectively compared 
2
to <10 pfu/mouse for the elite stock of HG52. Therefore, 
the variant JH2604 is at least 6 logs less neurovirulent 
than the wild type virus. The variant JH2604 grew as well 
as the wild type virus in vitro in BHK-21 C13 and 3T6 cells, 
but it failed to grow in mouse brain in vivo demonstrating 
that the lack of neurovirulence was due to inefficient 
replication in mouse brain. The variant JH2604 synthesises 
TK as efficiently as the wild type virus and its infected
cell polypeptide profile shows no detectable differences.
The lack of growth in mouse brain in vivo of JH2604 has 
been confirmed by neuropathological studies which showed 
that JH2604 did not cause necrotising encephalitis but there 
was infiltration of lymphocytes and perivascular cuffing 
around the blood vessels localised to the site of 
inoculation. The wild type HG52 infected brains showed 
necrotising encephalitis throughout. Using polyclonal 
anti-HSV antibodies in immunohistochemical studies, viral 
antigens were seen along the needle track in JH2604 infected 
brains, while they were widely distributed in HG52 infected 
brains.
Correction of the deletion in JH2604 by cotransfection 
in vitro using large wild type Xbal fragments resulted in 
the isolation of recombinants which gave values
comparable to those of individual plaque stocks of the 
parental HG52. Correction of the deletion by the small wild 
type BamHI cj fragment using in vivo selection in mouse brain 
resulted in recombinant viruses which displayed wild type 
LD,-q values.
Introduction of the deletion into the wild type genome
by in vitro cotransfection resulted in recombinants which on
intracranial inoculation of mice were avirulent. These
results imply that the sequences within BamHI g_ most
probably within both copies of the BamHI v fragment between
0-0.02 and 0.81-0.83 m.u. in TRt and IRT are required for
L  -Li
maximum demonstration of virulence in HSV-2 strain HG52.
Cloning of the deleted fragment of JH2604 in pATl53 and 
restriction enzyme and Southern blot analysis of the 
positive clones confirmed that the deletion was 
approximately 1.5 kb in both copies of the BamHI v fragment
with apparently identical end points. Sequencing analysis 
revealed that the deletion in each copy of the BamHI v 
fragment was 1488 bp and was contained within the 
XhoI-HincII fragment within BamHI v. It includes a complete 
17 bp DR1 element, four copies of a 19 bp reiterated 
sequence and terminates 522 bp upstream of the IEl gene. 
These results clearly demonstrate that the deleted sequence 
has a function in vivo which may suggest that the region is 
protein coding.
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C H A P T E R
INTRODUCTION
The subject of this thesis is the identification of 
genes involved in neurovirulence of herpes simplex virus 
type 2 (HSV-2) using HSV-2 deletion variants. The 
introduction provides background information on the general 
biology and molecular biology of HSV with particular 
reference to advances in the understanding of virulence and 
pathogenesi s.
1.1 Herpesviridae family and its classification
At least 80 viruses which comprise the family, 
herpesviridae, have been isolated from a wide variety of 
animal species and man. The members of the herpesviridae 
can be identified by the presence of double stranded DNA in 
the core of the virion, an icosahedral capsid containing 162 
capsomeres which is assembled in the nucleus and an envelope 
derived from the nuclear membrane (Roizman and Batterson, 
1986 ) .
The herpesvirion consists of four structural elements 
(Figure 1.1) (i) an electron-opaque core containing DNA (ii)
an icosahedral capsid containing 162 capsomeres (iii) an 
electron-dense amorphous proteinaceous layer (the tegument) 
distributed around the capsid and (iv) an 
outer membrane, or envelope, which surrounds the capsid and 
tegument (Wildy et al., 1960; Roizman and Furlong, 1974). 
Herpesviruses can not be differentiated from each other by 
electron microscopic examination but are differentiated with 
respect to virion antigenic properties, biological 
properties and composition, size and arrangement of their 
genomes (Roizman, 1982).
Figure 1.1
Schematic diagram of a HSV virion. The virion consists 
of four structural elements; the core, capsid, tegument 
and envelope. The viral DNA is within the core and is 
spooled around a cylindrical protein mass. The virion 
envelope contains a number of glycoproteins, visible on 
electron microscopy as spikes protruding from the 
envelope. The capsid contains the capsomeres.
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21.1.1 Classification on the basis of biological properties
Using biological properties, the members of the family 
herpesviridae have been classified into three subfamilies, 
alphaherpesvirinae, betaherpesvirinae and
gammaherpesvirinae. The biological properties include host 
range, cytopathogenicity, duration of the replicative cycle 
and characteristics of the latent infection (Matthews,
1982 ) .
Members of alphaherpesvirinae have
a short replicative cycle and grow rapidly in tissue 
culture resulting in mass destruction of infected cells.
They have also the capacity to establish latent infections
Thi s
subfamily contains herpes simplex virus types 1 and 2 (HSV-1 
and HSV-2), bovine mammilitis virus (BMV), pseudorabies 
virus (PRV), varicella zoster virus (VZV) and equine herpes 
virus-1 (EHV-1).
Betaherpesvirinae have restricted host range, long 
replicative cycles and grow slowly in tissue culture 
resulting in enlargement of infected cells. The virus can 
be maintained in a latent form in secretory glands, 
lymphoreticular cells, kidney and other tissue. This 
subfamily contains human cytomegalovirus (HCMV) and murine 
cytomegalovirus (MCMV).
Gammaherpesvirinae have limited host range, replicate in 
lymphoid cells and some cause lytic infections in some types 
of epithelioid and fibroblastic cells. Latent infections 
can be established in lymphoid tissue. This subfamily 
contains herpes virus saimiri (HVS), Epstein-Barr virus 
(EBV), Mareks disease virus (MDV) and herpes virus ateles.
31.1.2 Classification on the basis of genomic structure
There are three characteristic features of herpesvirus 
genomes; base composition, size of the genome and 
arrangement of the reiterated sequences. Molecular weights 
(Mr) range from 80 to 150 x 10^, base composition from 32 to 
75% G+C and the different sequence arrangements are 
illustrated in Figure 1.2. On the basis of genomic 
structure, the viral genomes fall into five groups (Roizman, 
1982) .
Group A
This group is represented by channel catfish virus (CCV) 
and their genomes contain a single set of reiterated 
sequences in the same orientation at the termini 
(Chousterman et al., 1979).
Group B
The genomes of the members of this group contain 
multiple reiterations of the same set of sequences at both 
termini in the same orientation and is represented by HVS 
(Bornkamin et al. , 1976).
Group C
Group C genomes contain multiple reiterations of one set 
of sequences at both termini in the same orientation and 
variable numbers of internal tandem reiterations of 
different sequences. This group is represented by EBV 
(Raab-Traub et al., 1980).
Group D
Figure 1.2
Schematic diagram of the genomic arrangement of channel 
catfish virus (CCV), herpesvirus saimiri (HVS), 
Epstein-Barr virus (EBV)f pseudorabies virus (PRV) and 
herpes simplex virus (HSV) representing subgroups A, B, 
C, D and E respectively of the family Herpesviridae. 
Lines represent unique sequences (long and short).
Repeat sequences larger than lkb are shown in open boxes 
and those of small reiterated sequences are shown in 
shaded boxes. Arrowheads above boxes indicate the 
orientation of the repeat sequences. Letters an and b^ 
signify multiple tandem repeat sequences. The small 
terminal direct and internal inverted repeats of HSV 
('a' sequence) are indicated. The type of genomes and 
number of isomers are also indicated.
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4This group is represented by PRV (Ben-Porat et al.,
1979) and their genomes contain a single set of reiterated 
sequences from one terminus inverted internally plus a 
subset of reiterated sequences at the other terminus in the 
same orientation.
Group E
Genomes of group E viruses contain a single set of 
sequences from both termini reiterated internally in 
inverted form as well as a subset of terminal sequences 
reiterated at both termini in the same orientation. This 
group is represented by HSV.
1.2 Human herpesviruses
There are six known human herpesviruses which are HSV-1, 
HSV-2, VZV, EBV, HCMV (Roizman, 1982) and human herpesvirus 
6 (HHV-6) (Salahuddin et al., 1986).
Infection with HSV is commonly associated with lesions 
of mucous membranes where HSV-1 causes mouth and lip lesions 
(cold sores), while HSV-2 classically is encountered in 
genital tract infections. Other diseases caused by HSV 
include eye infection, encephalitis and meningitis (see 
section 1.10). A characteristic feature of HSV following 
primary infection at the peripheral site is the 
establishment of latency in neurons of the peripheral 
nervous system and reactivation upon stimulation (see 
section 1.9).
VZV infection causes chicken pox during primary 
infection whereas in adults the disease shingles is more 
severe and is a consequence of reactivation from latency 
(Gleb, 1985).
Infection with HCMV is usually subclinical, but it 
causes severe problems in immunocompromised patients 
especially those on transplant therapy and with acquired 
immunodeficiency syndrome (AIDS) (Hamilton, 1982).
EBV infects B-lymphocytes, is implicated in causing 
infectious mononucleosis and is strongly associated with 
Burkitts lymphoma and nasopharyngeal carcinoma (Epstein et 
al., 1964) .
HHV-6 was first described in 1986 and was then termed 
human B-lymphotropic virus (Salahuddin et al., 1986). It is 
associated with exanthem subitum, a transient childhood 
illness (Yamanishi et al., 1988).
1.3 Genomic structure of HSV
1.3.1 General properties of the HSV genome
The HSV genome is a linear double stranded DNA molecule.
The genome of HSV-1 strain 17 has been sequenced and
contains 152260 base pairs (McGeoch et al., 1985; 1986;
1988; Perry and McGeoch, 1988). The DNA consists of two
covalently joined segments, designated as the long (L) and
short (S) regions (Figure 1.3.A) (Roizman, 1979). The L
region consists of a long unique sequence (U ) flanked by a
Li
pair of oppositely oriented repeated elements termed long
repeat (R ) with the terminal and internal copies designated L
(TR ) and (IRr) respectively. Similarly the S region 
L D
consists of a short unique (Ug ), a short terminal repeat
(TR ) and a short internal repeat (IRC ) region. The TR /IR S b n Jj
sequences flanking the UL segment are designated ab and b'a1
while IR /TRC flanking U are designated a'c1 and ca 
S b b
respectively. The sequences of R^ and Rg are distinct, 
except for the 'a' sequence, at least one further copy of
Figure 1.3
A. The structure of the HSV-1 genome. The long region
(L) is composed of unique long (UT ) bounded by a
Li
terminal sequence (TR ) which is repeated internally in
Li
an inverted orientation (IR ) . Similarly, the short
Li
region (S) is composed of a unique region (Ug ) bounded 
by a terminal sequence (TR ) which is repeatedb
internally in an inverted orientation (IR ) . The 'a'
b
sequence at the termini of the L and S regions and in
inverted orientation at the L/S junction (a') is also
shown. The remaining sequences within TR /IR and
Li Li
TRC/IR are designated b/b' and c/c' respectively, 
b  b
B. The four genome isomers 
P = prototype.
I = inversion of the long region (L).
Xj
I = inversion of the short region (S).
b
I = inversion of both short and long regions.
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6which is found at the L/S joint in the orientation opposite 
to the terminal copies (Roizman, 1979; Davison and Wilkie, 
1981). Each terminus possesses an overhanging residue with 
its 3'-hydroxyl (OH) group free and lacking a complementary 
residue on the opposite strand (Mocarski and Roizman, 1982). 
Preparations of HSV DNA contain equimolar amounts of
four sequence-oriented isomers, in which U and U are
JLi o
independently in one of two possible orientations with 
respect to the joint between L and S (Roizman, 1979). The 
isomers are shown in Figure 1.3.B and are designated as 
prototype (P), inversion of the S region (IQ), inversion of
u
the L region (IT) and inversion of both S and L regionsJ_j
(ISL >-
HSV-1 DNA has an overall base composition of 68.3% G+C 
(McGeoch et al., 1988) which is not uniform throughout 
the genome e.g the 6.6 kb R elements have a G+C value ofO
79.5% (McGeoch et al., 1986). In the HSV genome there are 
families of short, directly repeated sequences ranging in 
size from 10 to 100 bp (McGeoch, 1989). The copy number of 
these repeats differs between virus stocks (Rixon et al.,
1984). Three of these repeats are located within the coding 
region of the US7 gene and in the intergenic region of the 
US9 and US10 genes (McGeoch et al., 1985). The other 
repeats present in the S region are (i) in the introns of IE 
mRNA4 and 5 (Murchie and McGeoch, 1982) and (ii) downstream 
of the IE mRNA3 (Rixon et al., 1984). There are also other 
repeats in the 'a' sequence (Davison and Wilkie, 1981;
opsfcr^ cim
Mocarski and Roizman, 1981Uand downstream of the IE mRNAl 
(Perry et al., 1986). The only repeat family in the UL 
region is present within the coding region of the UL36 gene
(McGeoch et al., 1988).
71.3.2 Organisation of HSV genes
The open reading frames (ORF) corresponding to the
proposed HSV-1 genes in Glasgow strain 17 are shown in
Figure 1.4. It has been shown that U contains 56 genes 
* L
termed UL1 to UL56 (McGeoch et al., 1988) , while Ur contains
12 genes designated US1 to US12 (McGeoch et al., 1985).
There is also one gene in each copy of R and R , giving a
L S
total of 72 genes encoding for 70 distinct proteins. Chou
and Roizman (1986) and Ackermann et al. (1986) have
postulated another gene upstream of the IEl gene and in the
same orientation, but their interpretation has been
questioned (Perry and McGeoch, 1988) . In addition, there is
a 3500 bp region in R downstream of IEl, whose functional
Li
potential is obscure. The latency associated transcripts
(LAT), which are the major virus-specific transcripts in
latently infected neurons lie in R downstream of the IElL
gene (Stevens et al., 1987; Wagner et al., 1988; see section 
1.9) .
The genes in HSV-1 are classified into three categories; 
those with control functions; those involved in DNA 
replication and associated functions and those encoding 
structural and assembly proteins. During HSV infection, the 
IE genes are first expressed. Five IE genes have been 
identified, IEl, IE2 (UL54), IE3, IE4 (US1) and IE5 (US12) 
encoding for VmwIEllO, VmwIE63, VmwIEl75, VmwIE68 and 
VmwIE12 respectively (see section 1.5.2). The functions of 
the products of the first three IE genes are transcription 
and regulation, controlling the expression of later classes 
of genes and autoregulation of the IE genes (Everett, 1987; 
see section 1.5.2). The functions of the products of the
Figure 1.4
Organization of the genes of HSV-1, represented on four 
successive lines of 40 kbp each. Locations of the 
reading frames are shown by arrows and the splicing 
within the coding regions is indicated. Genes UL1-UL56 
are shown on the top three lines as 1-56 and genes 
US1-US12 are shown in the bottom line as 1-12.
Locations of origins of DNA replication are indicated by 
vertical arrows. This Figure is taken from McGeoch 
(1989) .

8IE4 and IE5 genes remain unknown.
The Vmw65 trans-inducing factor (Vmw65 TIF) encoded by 
the UL48 gene (Campbell et al., 1984), has a clear 
regulatory role. It acts in combination with one or more 
cellular proteins to activate IE gene expression through the 
upstream sequences of these genes (O'Hare and Goding, 1988; 
Preston et al., 1988). Another regulatory protein, is the 
product of UL41, which acts by shutting off host cell 
macromolecular synthesis by degradation of mRNA (Kwong et 
al., 1988). Two other genes, US3 and UL13, which have 
recently been identified and proposed to encode protein 
kinases may have a role in control and modulation of HSV 
infection.
The second class of genes include those whose products 
are involved in nucleotide or nucleoside metabolism, DNA 
replication and DNA metabolism and repair. Of those 
involved in nucleotide and nucleoside metabolism, thymidine 
kinase (TK) has been extensively studied (see section
1.8.4.a). More recently ribonucleotide reductase (see 
section 1.8.4.a) encoded by the UL39 and UL40 genes (Preston 
et al., 1984; Frame et al., 1985) and deoxyuridine 
triphosphatase (dUTPase) encoded by the UL50 gene (Preston 
and Fisher, 1984) have been identified and analysed. Seven 
genes were found to be necessary for DNA replication; UL5, 
UL8, UL9, UL29, UL30, UL42 and UL52 (see section 1.6.3).
The deoxyribonuclease encoded by the UL12 gene has an 
unknown role in replication. Finally the gene UL2 encodes 
the DNA repair enzyme, uracil-DNA glycosylase (Worrad and 
Caradonna, 1988; Mullaney et al., 1989).
Other elements of the HSV genome which have specific 
roles in DNA replication are (1) the origins of DNA
9replication; on^, located between genes UL29 and UL30 and
two copies of ori in R between genes IE3 and IE4 in IR
S S
and IE3 and IE5 in TRg (see section 1.6.3) and (2) the 'a' 
sequence which contains elements involved in cleavage of 
concatameric DNA as part of the process of packaging of DNA 
into nascent virions (see section 1.4.2).
The third class of genes consists of those encoding 
structural proteins and proteins involved in assembly of 
virions. Herpes virus particles are complex assemblies 
containing at least 30 different species of protein (Dargan,
1986). Twenty two genes have been identified as specifying 
structural or assembly proteins. The major capsid protein 
(MCP) is encoded by gene UL19 (Costa et al., 1984; Davison 
and Scott, 1986), although the capsid contains at least 
other proteins whose genes have not been identified 
(McGeoch, 1989). The major tegument protein is encoded by 
the UL48 gene (Campbell et al., 1984) and other tegument 
proteins are encoded by the UL36, US9 and US10 genes 
(Batterson et al., 1983; Frame et al., 1986a; Rixon and 
McGeoch, 1984) .
Seven viral glycoproteins have been identified (see 
section 1.8.4.d) and these are gH (encoded by gene UL22), gB 
(UL27), gC (UL44), gG (US4), gD (US6), gl (US7) and gE 
encoded by the US8 gene (McGeoch, 1989).
1.3.3 Relationship between HSV-1 and HSV-2 genomes
HSV-1 and HSV-2 are closely related viruses and show 
many serological cross reactions. DNA hybridisation studies 
have shown that most of the genome sequences are highly 
related (Davison and Wilkie, 1983). It is likely that the 
genetic organisation of HSV-2 is indistinguishable from that
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of HSV-1. Around 33 kb of the HSV-2 genome has been
sequenced. This includes the 'a1 sequence, ori , ori , the
L S
equivalents of the HSV-1 genes, UL2, UL11, UL12, UL23, UL27, 
UL39, UL40, UL44, UL45, US2, US7, US12 and parts of the 
□L30, UL54, US1, US8, US10 and IE3 genes (McGeoch, .1989). 
Direct comparison of the coding sequences of corresponding 
genes has shown 70-80% identities (McGeoch et al., 1987).
The greatest differences were shown in the non-coding 
sequences which are highly divergent especially in parts of 
the major repeats (Davison and Wilkie, 1981; Whitton and
Clements, 1984). A difference was found between the two
genomes in their US4 genes, encoding gG (McGeoch et al.,
1987). HSV-1 has a deletion of 1460 bp in its US4 coding 
sequence relative to HSV-2, therefore gG of HSV-1 is of 
smaller Mr than that of HSV-2.
1.4 The HSV 'a' sequence
1.4.1 General properties of the 'a1 sequence
The HSV genome contains a 200-500 bp sequence called the
'a' sequence, situated at the junction between the L and S
components and repeated in an inverted orientation at the 
termini of the genome (Wadsworth et al., 1975). Multiple 
copies of the 'a' sequence can be present at the L terminus
and the L-S junction, but only one copy is present at the S
terminus (Wagner and Summers, 1978; Locker and Frenkel,
1979; Davison and Wilkie, 1981; Mocarski and Roizman, 1981). 
The size variation of the 'a' sequence between different
strains has been shown by DNA sequencing of the 'a' sequence
(Davison and Wilkie, 1981; Mocarski and Roizman, 1981, 1982; 
Mocarski et al., 1985; Varmuza and Smiley, 1985).
The 'a' sequence of HSV—1 strain F is shown in Figure
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1.5 (Mocarski and Roizman, 1982). it is arranged as a 
head-to-tai1 dimer which has one copy of the direct repeat 
(DRl) at the point of fusion. The 'a' sequence consists of
(1) a 20 bp terminal repeat designated DRl (2) a 64 bp 
unique sequence designated Ub (3) 22 repeats of a 12 bp 
sequence designated DR2 (4) three repeats of a 37 bp
sequence designated DR4 and containing 11 of the 12
nucleotides of DR2 (5) a unique 58 bp sequence designated Uc 
and (6) a second copy of DRl. Variability of the copy 
number of DR elements accounts for most of the observed 'a' 
sequence polymorphism in different strains. For example, 
HSV-2 strain HG52 has only one copy of DR2 (Davison and 
Wilkie, 1981) while HSV-1 strain F has 22 copies (Mocarski 
and Roizman, 1982). Similarly HSV-1 strain 17 and HSV-2 
strain HG52 contain one copy of DR4 homology, which is a
part of Uc (Davison and Wilkie, 1981). Some strains of
HSV-1 like Justin contain an extra direct repeat called DR3 
which is present in two copies (Mocarski and Roizman, 1981, 
1982; Mocarski et al., 1985). Although there is variation 
in the copy number of the DR2 and DR4 elements, some regions 
of the 'a' sequence are highly conserved in different 
strains. These are within Ub and Uc and are represented by 
a short well conserved sequence about 20 bp in length 
located approximately 40 bp and 35 bp respectively from the 
ends of the 'a' sequence (Davison and Wilkie, 1981; Deiss et 
al., 1986).
1.4.2 Functions of the 'a' sequence
The 'a' sequence has a number of functions associated 
with genome organisation and viral DNA replication. These 
functions are described in the following section.
Figure 1.5
The structure of the HSV-1 strain F 'a' sequence 
(Mocarski and Roizman, 1982). The top line shows the 
prototype virus genome. An expansion of the 'a' 
sequence in the orientation found at the L/S junction is 
shown below the top line.
DRl = 20 bp elements present as a direct repeat at
the ends of tKe'a' sequence.
Ub = a unique sequence of 64 bp located towards the
b' sequence.
DR2 = a 12 bp repeat element present in 22 copies.
DR4 = a 37 bp repeat element present in 3 copies.
Uc = a unique sequence of 58 bp located towards the
c' sequence.
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(1) Circularisation of the genome
Circularisation of the HSV genome soon after infection 
is believed to be controlled by the 'a* sequence (Davison 
and Wilkie, 1983; Poffenberger et al., 1983).
Circularisation of the genome occurs by ligation of the two 
termini which posses a single base overhang on the opposite 
strands (Mocarski and Roizman, 1982).
(2) Isomerisation of the genome
HSV DNA contains equimolar amount of four isomers
differing in the orientation of U and U (see section
Li O
1.3.1). Inversion of the genome at the L-S junction occurs 
by site specific recombination mediated by the 'a' sequence 
(Mocarski et al., 1980; Mocarski and Roizman, 1981; Smiley 
et al., 1981). The role of the 'a' sequence in inversion 
and isomerisation of the genome has been demonstrated by 
Chou and Roizman (1985) who carried out detailed deletion 
analysis of the 'a' sequence. They found that deletion of 
the DR4 sequence results in impairment of genomic inversion, 
while deletion of DR2 and DR4 sequences abolished inversion. 
This demonstrates the presence of a cis-acting signal for 
site specific recombination and inversion in the DR2 and DR4 
elements. The authors however did not exclude the role of 
DRl In inversion, since deletion of both DRl elements 
resulted in an extremely low frequency of inversion (Varmuza 
and Smiley, 1985).
(3) Cleavage and packaging of the genome
Linear viral DNA molecules circularise soon after 
infection and newly replicated viral DNA molecules consist
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of large head-to-tail concatamers (Ben-Porat et al., 1976; 
Jacob et al., 1979) which are subsequently cleaved and 
packaged into capsids (Vlazney et al., 1982). The HSV 'a' 
sequence has been shown to contain cis-acting signals for 
cleavage/packaging of viral genomes and plasmid constructs 
containing an HSV DNA origin of replication can replicate 
but are only packaged if they contain an 'a' sequence (Stow 
et al. , 1983; Deiss and Frenkel, 1986). Two separate 
signals designated Pa d  and Pac2, located in the Ub and Uc 
regions respectively of the 'a' sequence, were essential for 
cleavage/packaging of viral genomes (Vcwrmuza and Smiley, 
1985; Deiss et al., 1986). Recently Nasseri and Mocarski 
(1988), using a transient cleavage assay, have shown that a 
179 bp fragment (containing Uc - DRl - Ub) from the junction 
of two tandem 'a' sequence carries all the sequence elements 
necessary for cleavage recognition and encapsidation.
(4) Promoter activity
It has been reported that the Ub region of the 'a' 
sequence of HSV-1 strain F contains the promoter of a gene 
encoding a polypeptide ICP34.5 whose coding region is in the 
long repeat in the same orientation as the IEl gene 
(Ackermann et al., 1986; Chou and Roizman, 1986). The gene 
encoding ICP34.5 lacks TATA consensus and instead there is 
TATA homology (TTTAAA). The 5' terminus of the transcript 
maps to DRl. The function of this gene is not clear and its 
sensitivity to phosphonoacetate suggests that it belongs to 
the late category genes. DNA sequence analysis of the 
corresponding region of HSV-1 strain 17 has not identified a 
similar ORF (Perry and McGeoch, 1988).
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(5) Protein binding
The HSV 'a' sequence encodes several cis-acting sites 
involved in circularisation, inversion, cleavage and 
packaging of DNA and expression of mRNA. It would be 
expected that specific viral or host proteins or both 
interact with the DNA at the specific cis sites to mediate 
such functions. Wu et al. (1979) using the electron
microscope, have shown that a small polypeptide binds to 
both termini and to L-S junctions of DNA extracted from 
virions. Similarly Dalziel and Marsden (1984) have shown 
that the late polypeptides (21K and 22K) encoded by gene 
US11 (Rixon and McGeoch, 1984) interact with the 'a' 
sequence of HSV-1 in vitro. These polypeptides were shown 
to be strong binding proteins (MacLean et al., 1987). The 
function of the interaction with the 'a' sequence is still 
not clear, since viruses lacking the USll gene are viable in 
tissue culture (Longnecker and Roizman, 1986; Umene, 1986; 
Brown and Harland, 1987).
Recently Chou and Roizman (1989) have reported that, the 
virus-specific DNAase as well as two proteins with Mr of 
>250K and 140K, form complexes with both P a d  and DRl 
regions of the 'a' sequence.
1.5 HSV transcription
Transcription of viral DNA takes place in the nucleus by 
the host cell polymerase II (Costanzo et al., 1977) . Viral 
RNAs are capped at their 5' ends, methylated at A residues 
and polyadenylated although non-polyadenylated RNA can be 
isolated (Bachenheimer and Roizman, 1972; Bartoski and 
Roizman, 1976; Moss et al., 1977; Stringer et_al., 1977). A 
relatively small proportion of HSV mRNAs are spliced; these
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include mRNAs of IEl, IE4, IE5 (Rixon and Clements, 1982; 
Watson et al., 1981; Perry et al., 1986), UL15 (McGeoch et 
al., 1988) and the mRNA of gC (Frink et al., 1983). The 
abundance and the stability of the various HSV-1 mRNAsvary 
and generally mRNAs of IE genes appear more stable than 
those of late genes (Wolf and Roizman, 1978). Following 
transcription, HSV mRNAs are transported to the cytoplasm, 
bind to ribosomes and are translated into proteins (Wagner 
and Roizman, 1969).
1.5.1 HSV temporal regulation
HSV encodes 70 predicted genes (McGeoch et al., 1988) 
which are expressed as three temporally regulated classes of 
proteins, immediate early (IE or alpha), early (E or beta) 
and late CL or gamma) according to their order of synthesis 
(Honess and Roizman, 1974; Clements et al., 1977; Jones and 
Roizman, 1979). Synthesis of these proteins is sequentially 
ordered in a cascade fashion. IE proteins induce E proteins 
and the latter shut off the expression of IE proteins and 
induce the expression of L proteins. The L proteins in turn 
shut off the expression of E proteins, and immediately after 
the next round of infection, induce the expression of IE 
proteins. Regulation of viral gene expression would appear 
to be predominantly at the level of transcription.
1.5.2 Immediate early (IE) gene expression
IE genes are the first to be expressed during viral 
infection and are first detected very early (1 h post 
infection), reach peak rates at approximately 2 to 4 h 
following infection and then decrease. Their corresponding 
RNAs are produced in the absence of viral protein synthesis
16
(Honess and Roizman, 1974). There are five IE genes in 
HSV-1, their transcript locations and orientations on the 
viral genome are shown in Figure 1.6. These are IEl, IE2,
IE3, IE4 and IE5 coding for polypeptide products VmwIEllO 
(ICPO), VmwIE63 (ICP27), VmwIEl75 (ICP4), VmwIE68 (ICP22) 
and VmwIE12 (ICP47) respectively (Clements et al., 1979; 
Preston, 1979a; Easton and Clements, 1980; Wagner, 1985; 
Everett, 1987).
Three of the five IE transcripts are spliced. The IE4 
and IE5 transcripts are derived from identical promoters 
located in the repeated sequences of the S region of the 
viral genome. The splice sites of their RNAs are also in 
the repeated sequences while their coding regions are 
different (Watson et al., 1981; Rixon and Clements, 1982). 
The transcript of the IEl gene is also spliced and lies 
totally within the repeated sequences of the L region and is 
therefore diploid (Perry et al♦, 1986). The transcript of 
the IE3 gene is unspliced, diploid and transcribed entirely 
within TR„ (Rixon et al., 1982). The only IE gene that is 
not associated with the repeated sequences is IE2 whose 
unspliced RNA lies in U (WKitton et al., 1983 ).
Li
Most of the IE polypeptides are phosphorylated and found 
predominantly in the nucleus of infected cells. The 
exceptional IE polypeptide is VmwIEl2 which is not 
phosphorylated and is found in the cytoplasm (Preston,
1979a; Hay and Hay, 1980; Marsden et al., 1982; Ackermann et 
al., 1984). The IEl and IE3 gene products have been shown 
to be potent transactivators of early and late gene 
promoters in transient expression assays (Everett, 1984, 
1987; O'Hare and Goding, 1988). The IE2 gene product 
(VmwIE63) has also been implicated m  the regulation of
Figure 1.6
The genome structure of HSV-1 (prototype) showing the 
map locations and orientations of the immediate early 
(IE) mRNAs (numbered 1 to 5). The spliced mRNAs are 
indicated.
0.1 
0.7
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viral promoters (Everett, 1986; Rice and Knipe, 1988; 
Sekulovich et al., 1988).
Analysis of ts mutants demonstrated that the gene 
products of both IE2 (VmwIE63) and IE3 (VmwIE175) are 
essential for productive infection and that VmwIEl75 is 
required for early and late gene expression while VmwIE63 
appears to be required after the onset of early gene 
expression and DNA replication (Preston, 1979b; Dixon and 
Schaffer, 1980; Watson and Clements, 1980; Sacks et al.,
1985). Viable mutants with deletions in IEl show growth 
restriction in certain cell types at low multiplicity of 
infection (moi) and normal growth at high moi (Stow and 
Stow, 1986; Sacks and Schaffer, 1987). Deletion mutants in 
IE4 confer a host range phenotype to the virus (Post and 
Roizman, 1981; Sears et al., 1985). The IE5 gene has been 
shown to be non essential for the growth of HSV in tissue 
culture (Longnecker and Roizman, 1986; Umene, 1986; Brown 
and Harland, 1987).
All the IE genes contain a characteristic cis-actinq 
element, TAATGARAT, which interacts with the major tegument 
protein (Vmw65 TIF) resulting in stimulation of IE gene 
expression (Mackem and Roizman, 1982; Batterson and Roizman, 
1983; Cordingley et al., 1983; Campbell et al., 1984;
Preston et al., 1984). Mutations within the gene coding for 
Vmw65 TIF abolish its ability to stimulate IE gene 
expression (Ace et al., 1989).
1.5.3 Early (E) gene expression
The early or beta genes are distributed in both the L 
and S regions of the HSV genome. Their transcription begins 
following the synthesis of functional IE polypeptides
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(Honess and Roizman, 1974) . The synthesis of the E gene 
products starts at 3 h post infection, reaches peak rates of 
synthesis about 5 to 7 h post infection after which it 
declines with time (Honess and Roizman, 1974).
The E genes have been subdivided into beta 1 and beta 2 
on the basis of their requirement of IE polypeptides 
(Pereira et_al. , 1977; Roizman and Batterson, 1985). The 
functions of several E polypeptides appear to be related to 
the synthesis of viral DNA. The beta 1 polypeptides are 
exemplified by the major DNA binding protein (DBP) and the 
large subunit of ribonucleotide reductase (RRl).
The beta 2 polypeptides include the 
viral TK and the DNA polymerase. Some early polpeptides 
require DNA synthesis for maximal expression and gD is an 
example of such a protein (Gibson and Spear, 1983; Johnson 
et al., 1986 ) .
1.5.4 Late (L) gene expression
The late or gamma gene products can be detected by 2 to 
3 h post infection and reach their maximum peaks by 10 to 16 
h post infection parallel to DNA synthesis which starts 
about 2 h post infection and reaches its maximum peak by 8 h 
post infection (Wilkie, 1973; Roizman, 1979).
The late genes can be subdivided into two classes, the 
gamma 1 (leaky late) and gamma 2 (true late), depending on 
their DNA replication requirement (Roizman and Batterson, 
1985; Wagner, 1985). In the absence of DNA synthesis, the 
expression of gamma 1 genes is reduced but still detectable, 
while those of gamma 2 is reduced to barely detectable 
levels (Powell e t a l . , 1975; Johnson et al., 1986; Godowski
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and Knipe, 1985). Examples of the leaky late genes are 
UL19, UL.27 encoding the MCP and gB respectively, while UL44 
and USll encoding gC and 21K/22K proteins are examples of 
true late genes.
The regulation of late gene expression is not fully 
understood. Some have been shown to require IE products for 
maximum trans-acti'vation of their promoters (Everett, 1987).
1.6 The HSV replicative cycle
The replicative cycle of HSV starts with the initiation 
of infection in which the virus envelope attaches to cell 
receptors resulting in fusion with plasma membranes and 
release of the capsid which is then transported to the 
nuclear pore where DNA is released into the nucleus. 
Transcription, DNA replication and assembly of capsids 
takes place in the nucleus. The steps of the replicative 
cycle are discussed below.
1.6.1 Attachment, penetration and uncoating
Attachment of the virus to the host cell surface takes 
place through specific receptors on the cell surface (Vahlne 
et al. , 1978). The nature of these receptors has not been 
identified. It appears that HSV-1 and HSV-2 have different 
receptors. Infection of cells with one virus strain causes 
interference with the attachment of a second virus strain of 
homologous but not heterologous serotype (Vahlne et al., 
1979). Following attachment, the virus enters the cells 
either by endocytosis (Hummeler et al., 1969) or by fusion 
of the viral envelope and plasma membrane (Morgan et al., 
1969). The latter is more likely to be the case since it 
has been demonstrated that the viral envelope fragment
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crystalisable (Fc) receptors can be detected on the cell 
surface following penetration (Para et al., 1980). The 
identification of virus-encoded gB (Manservigi et al., 1977) 
which is involved in membrane fusion supports the fusion 
mode of entry of HSV into cells. Temperature-sensitive 
mutants (t£>) which are defective in the gB gene can attach 
but are unable to penetrate the cells (Sarmiento et al., 
1979) .
Following penetration, the naked viral particle is 
transported via the cytoplasm (Batterson and Roizman, 1983) 
to the nuclear membrane where the capsid is degraded and the 
viral DNA released. The DNA enters the nucleus through the 
nuclear pores (Hummeler et al., 1969) where transcription 
occurs using the cellular polymerase II (see section 1.5).
1.6.2 Suppression of cellular macromolecular synthesis
Infection with HSV results in a decrease in the host 
cell DNA, RNA and protein synthesis. An immediate 
consequence of infection is the disaggregation of 
polyribosomes which is mediated by a component of the 
infecting virion. This process results in inhibition of 
host protein synthesis (Sydiskis and Roizman, 1966; Fenwick 
and Walker, 1978; Nishioka and Silverstein, 1978). The 
virion component is also involved in inhibition of host 
mRNA. These events called early shut off of protein 
synthesis, are more rapid in HSV-2 infected cells than in 
HSV-1 infected cells (Fenwick and Clark, 1982; Fenwick and 
McMenamin, 1984). Delayed inhibition of host protein 
synthesis depends on virus gene expression which results in 
the degradation of host transcripts (Nishioka and 
Silverstein, 1978; Hill et al., 1983). The virion function
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involved in shut off of host protein synthesis has been 
mapped to the region between 0.52-0.59 map units (m.u.) on 
the HSV-2 strain HG52 genome (Morse et al., 1978; Fenwick et 
ad., 1979) and to 0.604-0.606 m.u. on the HSV-1 strain KOS 
genome (Kwong et al., 1988). In addition, transfer of the 
UL41 equivalent gene from HSV-2 strain G (strong shut off) 
into the HSV-1 strain 17 genome (naturally weak shut off) 
results in enhancement of the shut off function of strain 17 
(R.D. Everett, personal communication). The mechanism by 
which HSV decreases the rate of host cell DNA synthesis 
remains unclear.
1.6.3 DNA replication
Replication of HSV is a complex process which is not 
fully understood. Soon after infection, viral DNA 
circularises by ligation of the termini in the nucleus 
(Davison and Wilkie, 1983). DNA synthesis starts at 3 h 
post infection, reaches a maximum between 9-11 h and is 
completed by 16 h post infection (Rixon, 1977).
Electron microscope analysis of viral DNA molecules 
before the onset and during the first round of DNA 
replication showed the presence of single stranded ends and 
circular molecules (Jean and Ben-Porat, 1976; Jacob and 
Roizman, 1977). At later times in infection, DNA molecules 
with internal eyes and forks, circular molecules with linear 
tails and large tangles of DNA are seen (Ben-Porat et al., 
1976; Hirsch et al., 1977; Jacob and Roizman, 1977; Jean et 
al. , 1977; Ben-Porat and Rixon, 1979). It has been shown 
that the number of terminal fragments detectable in 
replicating viral DNA was reduced compared to virion DNA 
(Jongeneel and Bachenheimer, 1981). This data suggested
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that circular DNA molecules replicate by a rolling circle 
mechanism yielding head-to-tail concatameric DNA (Jacob et 
al., 1979).
Two approaches have indicated that the products of seven 
genes (UL5, UL8, UL9, UL29, UL30, UL42 and UL52) are 
involved in viral D N A  replication. The first approach, 
using genetic analysis of HSV-1 mutants, has shown that 
seven complementation groups containing mutants with defects 
in D N A  synthesis map to these genes (Chartrand et al., 1979; 
Conley et al., 1981; Purifoy and Powell, 1981; Matz et al., 
1983; Weller et al., 1983, 1987; Carmichael et al., 1988; 
Goldstein and Weller, 1988; Marchetti et al., 1988). The 
second approach, using a plasmid amplification assay for 
HSV-1 origin-dependent D N A  replication, has demonstrated 
that the products of these seven genes are both necessary 
and sufficient for D N A  synthesis (Challberg, 1986; McGeoch 
et al. , 1988; Wu et al., 1988). Three of these seven D N A  
replication genes are UL29 which encodes for the major 
single strand D N A  binding protein (Conley et al., 1981;
Quinn and McGeoch, 1985), UL30 which encodes the viral DNA 
polymerase (Gibbs et al., 1985; Quinn and McGeoch, 1985) and 
UL42 which encodes a 65K double stranded DNA binding 
protein, DBP, (Marsden et al., 1987; Parris et al., 1988). 
Recently Weir et al. (1989), using a gel retardation assay,
showed that the UL9 gene product binds specifically to a 
viral origin of replication. These results are consistent 
with the findings of Olivo et al. (1988) who showed that the
UL9 gene specifies an origin binding protein. The UL5 gene 
product is a part of the DNA helicase in infected cells (Zhu 
and Weller, 1988). The DNA helicase has been shown to 
consist of three polypeptides with Mr of 120.000, 97.000 and
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70.000 which are the products of genes UL52, UL5 and UL8 
required for replication of a plasmid containing HSV-1 ori s
(Crute et al., 1989). Furthermore, the DNA primase (Holmes 
et al., 1988) has been found to be tightly associated with 
the DNA helicase forming a helicase-primase complex (Crute 
et__a_l. , 1989). The relationship between the two enzymes 
remains unclear.
The cis-actinq elements needed for replication (viral 
origins of DNA replication) are specified by two distinct
but related sequences. One (ori ) lies close to the centre
Li
of the U region while the other (ori ) is present within
J-J O
the short repeats, TRg and IRg (Vlazney and Frenkel, 1981; 
Spaete and Frenkel, 1982; Stow, 1982; Weller et al., 1985). 
It has been shown that a DNA fragment of 90 bp specifies a 
functional orig (Stow and McMonagle, 1983; Deb and Doelberg, 
1988; Lockshon and Galloway, 1988) and includes a 45 bp near 
perfect palindrome with a central A+T rich region. Elias 
and Lehman ( 1988) have demonstrated the presence of two 
specific binding sites within ori .O
The ori is located in U between 0.360 and 0.419 m.u.Ij L
However, when fragments spanning these sequences were cloned
into plasmid vectors, between 100-650 bp were deleted. The
deleted fragments have no origin activity (Spaete and
Frenkel, 1982). Successful cloning of ori in an undeleted
Li
form was achieved in yeast plasmid vectors (Weller et al.,
1985). Sequence analysis of ori from HSV-1 KOS (Weller et
Li
al., 1985 ), HSV-1 ANG (Gray and Kaerner, 1984) and HSV-1 
strain 17 (Quinn and McGeoch, 1985) has shown that oriL 
contains a large palindrome (144 bp) which is responsible 
for the deletion and cloning instability. The palindrome 
constitutes the minimum requirement of ori (McGeoch, 1987)
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with a high degree of homology to ori . Sequence analysis
O
of HSV-2 ori-L showed a strong degree of homology to the
HSV-1 sequence especially its palindrome (Lockshon and
Galloway, 1986). The significance of why the HSV genome has
three origins of replication and their contribution to DNA
replication is unknown. Mutant viruses lacking either one
copy of orig (Longnecker and Roizman, 1986; Brown and
Harland, 1987) or oriT (Polvino-Bodnar et al., 1987), qrow
Li
normally in vitro.
1.6.4 Assembly and maturation
Replicating viral DNA forms a pool of concatameric 
molecules which are cleaved into unit lengths and packaged 
into empty capsids in the nucleus (see section 1.4..2). The 
nuclear capsid containing the DNA attaches to the inner 
nuclear membrane and acquires an envelope by budding into 
the perinuclear space (Dargan, 1986; Roizman and Batterson,
1986). It has been reported that herpesviruses can acquire 
their envelopes by budding into the cytoplasmic vacuoles or 
Golgi membranes (Nii, 1971; Haguenau and Michelson-Fiske, 
1975). Virus particles maturing from different sites may 
exhibit morphological differences in their envelopes. It 
has been noted that HSV particles derived from nuclear 
membranes are circular and electron-dense, while those 
derived from cytoplasmic membranes have projections or 
globular structures on the surface (Nii, 1971).
Viruses egress from infected cells by a reverse 
phagocytosis process which is thought to happen when virus 
particles acquire envelopes from the cytoplasmic membrane. 
These particles bud into cytoplasmic vacuoles and are 
transported via the cytoplasm to the plasma membrane.
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Fusion of the vacuolar membrane with the plasma membrane 
extrude the enveloped viruses into the extracellular space 
(Nii, 1971; Katsumoto et al., 1981). Those virus particles 
that acquire envelopes from the inner nuclear membrane move 
along the reticulo-endothelial system and then either pass 
directly into the extracellular space or extrude by vacuole 
formation and reverse phagocytosis (Nii, 1971; Fong et al., 
1973) .
1.7 HSV-induced polypeptides
Following HSV infection, approximately 50 HSV-induced 
polypeptides have been identified on SDS-PAGE (Powell and 
Courtney, 1975; Marsden et al., 1976). Over 230 distinct 
polypeptides have been recognised using two dimensional PAGE 
(Haarr and Marsden, 1981). This greater number may be due 
in part to the resolution of families of peptide species 
related through post translational modification. The 
occurrence of post translational modification is reflected 
by the failure of some in vitro synthesised viral 
polypeptides to comigrate with their in vivo synthesised 
counterparts on SDS-PAGE (Preston, 1977). Four main post 
translational events occur comprising glycosylation (Haarr 
and Marsden, 1981; Palfreyman et al., 1983; Hope and 
Marsden, 1983), phosphorylation (Marsden et al., 1978;
Wilcox et al., 1980), sulphation (Hope et al., 1982; Hope 
and Marsden, 1983) and cleavage (Eisenberg et al., 1984; 
Balachandran and Hutt-Fletcher,1985). However, other forms 
of HSV polypeptide modification have been reported e.g fatty 
acylation which includes palmitylation of several surface 
glycoproteins (Schmidt, 1982) and myristylation of the HSV-1 
ULll gene product (Maclean et al., 1989).
26
1.7.1 HSV-induced enzymes
During the course of infection, many viral enzymes are 
expressed by HSV. Most of them are involved in nucleic acid 
metabolism and some of them are associated with virus 
particles. These enzymes are briefly described below.
The HSV-induced DNA polymerase, which is distinguishable 
from the host cell polymerase (Keir and Gold, 1963; Keir et 
al. , 1966 ), has a Mr of 136. 272 in HSV-1 strain 17 as 
deduced from DNA sequence data (Quinn and McGeoch, 1985).
It has been mapped to the UL30 gene between 0.40-0.42 m.u. 
of the genome and been shown to be essential for virus DNA 
replication (Hay and Subak-Sharpe, 1976; Chartrand et al., 
1979, 1980). The HSV DNA polymerase has an associated 3' to 
5' exonuclease activity (Knopf, 1979).
The thymidine kinase (TK) encoded by HSV has been mapped 
to the UL23 gene between 0.300-0.309 m.u. and sequenced 
(McKnight, 1980, Wagner et al., 1981). This enzyme 
phosphorylates thymidine and deoxycytidine (Jamieson and 
Subak-Sharpe, 1974). TK-negative viruses have been shown to 
have reduced pathogenicity (see section 1.8.4.a).
The alkaline exonuclease induced by HSV has been mapped
to 0.145-0.185 m.u. (Moss et al., 1979; Preston and 
Cordingley, 1982) and shown to be essential for DNA 
synthesis (Francke et al., 1978; Moss et al., 1979). This
enzyme possesses an associated endonuclease activity 
(Hoffmann and Cheng, 1979).
DNA topoisomerases have been described in HSV virions 
(Muller et al., 1985). These enzymes catalyse the breakage 
and rejoining of phosphodiester bonds in DNA and may be 
involved in DNA replication, transcription and recombination
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(Gellert, 1981).
Uracil-DNA glycosylase, a class of enzyme involved in 
DNA repair (Lindahl, 1979), is responsible for removing 
uracil residues in the DNA. The pathways which result in 
the presence of uracil in DNA are the incorporation of dUMP 
into it during replication (Bessman et al., 1958) and 
deamination of cytosine (Shapiro et al., 1973). The 
induction of viral DNA-uracil glycosylase activity has been 
reported in cells infected with HSV-1 and HSV-2 (Caradonna 
and Cheng, 1981). Isolation of an HSV-2 cDNA which encodes 
this enzyme has been described (Caradonna et al. , 1987).
The latter authors concluded that uracil-DNA glycosylase
created
acts in removing uracil residuesAby deamination of cytosine 
rather than by misincorporation of dUMP residues. Recently 
the HSV-1 UL2 gene, has been shown to encode uracil-DNA 
glycosylase and is dispensible for virus growth in tissue 
culture (Mullaney et al., 1989). Moreover, viruses with 
double insertion mutations in deoxyuridine triphosphatase 
(dUTPase) and uracil-DNA glycosylase grow normally in vitro 
(J. Mullaney, personal communication).
The HSV-induced ribonucleotide reductase (see section
1.8.4.a) has been described in both HSV-1 (Cohen, 1972) and 
HSV-2 (Cohen et al., 1974). This enzyme has been mapped to 
genes UL39 and UL40 between 0.580-0.585 m.u. (Preston et 
al., 1984) and consists of two subunits, large (RRl) and 
small (RR2) which form a complex that is essential for its 
activity (Frame et al., 1985; Bacchetti et al., 1986). 
Synthetic oligopeptides corresponding to the carboxy 
terminus of RR2 inhibit ribonucleotide reductase activity in 
vitro (Frame et al., 1985). This lack of enzyme activity is 
believed to be due to inhibition of the complex formation
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between RRl and RR2 (Cohen et al.f 1986; Dutia et al.,
1986) .
Deoxyuridine triphosphatase (dUTPase) catalyses the 
conversion of dUTP to dUMP and pyrophosphate and has been 
mapped to gene UL50 between 0.69-0.70 m.u. (Wohlrab et al., 
1982; Preston and Fisher, 1984). Virus mutants lacking 
dUTPase activity have been shown to grow normally in vitro 
(Fisher and Preston, 1986).
HSV-1 and HSV-2 have been shown to encode protein 
kinases by US3^genes (McGeoch, 1987) which are homologous 
with the members of the protein kinase family of eukaryotes 
(McGeoch and Davison, 1986). The role of protein kinase in 
HSV infection has not been determined although it is not 
essential for virus growth in tissue culture (Longnecker and 
Roizman, 1987 ) .
1.7.2 HSV DNA binding proteins
Approximately 16 HSV-1 induced polypeptides and 12 HSV-2 
induced polypeptides have DNA binding properties (Bayliss et 
al., 1975; Powell and Purifoy, 1976). Some of these like 
the major DBP (Powell et al., 1981) and the 65K DBP (Vaughan 
et al. , 1985) bind to DNA directly. VmwIEl75 has been shown 
to be a DNA binding protein (Hay and Hay, 1980; Faber and 
Wilcox, 1986). In contrast, Freeman and Powell (1982) 
showed that VmwIEl75 binds to DNA indirectly by association 
with the host cell DNA binding protein.
Several HSV-1 DNA binding proteins have enzymatic 
activities including DNA polymerase and alkaline exonuclease 
(see section 1.7.1) and have been shown to interact directly 
with DNA (Powell and Purifoy, 1977; Banks et al., 1983).
The 21K protein has been shown to bind to the 'a1 sequence
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(see section 1.4.2). The functions of the other DNA binding 
proteins are not yet known.
1.8 Virulence of Herpes simplex virus
1.8.1 Introduction
Herpes simplex virus (HSV) is a neurotropic human 
herpesvirus responsible for a variety of clinical conditions 
ranging from mild cutaneous lesions (cold sores) to the 
very rare fatal encephalitis. In many cases shedding may be 
asymptomatic. After acute infection, the virus travels via 
the axons of sensory neurons and establishes a latent 
infection in the dorsal root ganglia of the peripheral 
nervous system (Stevens and Cook, 1971). There is also 
evidence for latency in the central nervous system (Knotts 
et al. , 1973). Following reactivation and travel down the 
axons infectious virus is produced at the periphery which in 
some cases may result in disease that can range in severity 
from benign cutaneous lesions to acute fatal encephalitis 
(Baringer and Swoveland, 1973; Johnson, 1982). A variety of 
animal models e.g rabbits, mice, guinea pigs and tree shrews 
have been used to study HSV pathogenesis. Laboratory 
strains and clinical isolates with differing virulence for 
animal hosts exist (Dix et al., 1983) and strain specific 
differences within a given virus type may in part account 
for the variability of the resulting disease patterns 
(Wander et al., 1980).
Two types of HSV have been identified and classified on 
the basis of neutralisation (Nahmias and Dowdle, 1968) and 
restriction endonuclease patterns (Lonsdale et al., 1979; 
Buchinan et al., 1981). In addition to these differences, 
functional difference such as variation in tissue culture
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cytopathic effect (cpe) has been demonstrated (Ejercito et 
al., 1968).
1.8.2 Neurovirulence and neuroinvasiveness
Although neurovirulence and neuroinvasiveness are in
part related, they can be distinguished. The molecular
events that determine the neurovirulence and
neuroinvasiveness of HSV are largely unknown.
Neurovirulence of a virus can be defined as the capacity to
replicate following direct inoculation and to cause disease
in the nervous system. Neuroinvasiveness relates to the
capacity of virus to enter and move through the nervous
system following inoculation at the peripheral site. All
neuroinvasive viruses are also neurovirulent; the converse,
however, is not true (Stevens, 1987).
Virulence is determined by calculating the 50% lethal
dose (LDcn) for example using the formula of Reed and Muench 
5U
(1938), following inoculation of experimental animals. The 
LDj.q value for a given virus in a particular inbred strain 
of animal is also dependent on the age of the animal (Kohl 
and Loo, 1980; Zawatsky et al., 1982; Ben-Hur et al., 1983) 
and the route of inoculation (Caspary et al., 1980; Dix et 
al., 1983).
1.8.3 Extrinsic factors influencing the virulence of HSV 
The interaction between HSV and the host is complex and
heavily influenced by the genotype of both virus and host. 
The outcome of HSV infection, which ranges from subclinical 
to fatal, depends on many factors acting in concert. The 
factors determining the outcome of HSV infection are not 
fully understood and the relationship between them is
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unclear. These factors are listed in Table 1.1.
The in vivo roles of specific immunological processes 
(humoral and cell—mediated) in modulating the coarse of 
primary and recurrent HSV infection have not been fully 
elucidated. It is apparent that both processes are 
effective defence mechanisms which may act together to clear 
acute HSV infection at peripheral sites. HSV infection 
stimulates the production of antibodies which participate in 
virus neutralisation, antibody-dependent complement mediated 
cytotoxicity and antibody-dependent cell-mediated 
cytotoxicity (Norrild, 1985). Humoral immunity has been 
reported to play a role in restriction and spread of virus 
from peripheral sites to sites within the nervous system 
(McKendall et al., 1979). Knowledge regarding cell-mediated 
immunity has been derived from murine models of experimental 
herpesvirus infection. During HSV infection of mice a 
number of cell-mediated immune responses are stimulated 
which result in virus clearance from tissue. These include 
macrophages, natural killer cells (Lopez, 1985) and a 
variety of T-lymphocyte subpopulations which mediate 
cytotoxicity, delayed type hypersensitivity and helper or 
suppressor functions (Nash and Wildy, 1983; Nash et al.,
1985) .
Interferons (IFN) a group of proteins with a wide range 
of biological activities (Lengyel, 1982) play a central role 
in determining resistance to HSV infection (Lopez, 1985). 
There is increasing evidence that the antiviral activity of 
IFN is based on a number of different antiviral mechanisms 
which may operate independently of each other and may affect 
different stages of the virus growth cycle (Friedman, 1977; 
Jacobsen, 1986). Recent work on HSV infection in IFN
Table 1.1 Factors involved in determining the outcome of HSV 
infection
I. Host factors II. Viral factors
A. Immunological 1. Interference
1. Antigen specific 2. Strain of virus
a. T-lymphocytes
b. Antibodies
2. Antigen non-specific
a. Interferon
b. Macrophages
c. Natural killer cells
B. Non-immunological
1. Barrier (skin, mucous membrane)
2. Age of the host
3. Route of inoculation
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treated cells shows that IFN inhibits the onset of HSV IE 
transcription (Mittnacht et al. , 1988 ).
Non-immunological host factors such as the integrity of 
the skin and mucous membranes are also involved in 
resistance to HSV infection. Recent work on Langerhan s 
cells, which are present in the epidermis of the skin, 
suggests that in mice these cells play an important role in 
defence against HSV infection and an increase in their 
density in the skin was correlated with increased resistance 
to infection with HSV (Sprecher and Becker, 1986, 1987). 
Langerhan s cells have also been shown to be highly 
efficient as antigen presenting cells (Braathen et al.,
1980) and to be able to interact with T-lymphocytes in local 
lymph nodes (Silverberg et al., 1976).
Many studies have demonstrated that virus strain, route 
of inoculation, age of host, all have effects on virulence 
of HSV (Lopez, 1975; Caspary et al., 1980; Kohl and Loo, 
1980; Zawatsky et al., 1982; Ben-Hur et al., 1983; Dix et 
al., 1983; Sprecher and Becker, 1987). It has also been 
reported that serial passage of virus in vivo (Kaerner et 
al., 1983), in vitro (Goodman and Stevens, 1986 ) and at body 
temperature i.e 37.5°C (Thompson and Stevens, 1983a) could 
increase the virulence of HSV.
Viral interference is a very important determinant of 
viral infection and is defined as a phenomenon in which the 
presence of an initial or primary virus infection prevents 
the infection or replication by a secondary (superinfecting 
or challenge) virus. The mechanism by which this occurs is 
not well understood. Stow (1985) suggested that the block 
may result from either the presence of defective viral 
particles or competiton for host proteins necessary for
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viral DNA replication.
1.8.4 Viral genes determining virulence of HSV
HSV may rarely induce a life threatening encephalitis in 
humans (Rawls, 1985) and there is a continuing interest in 
understanding the properties of the virus relating to this 
syndrome. To define various aspects of the disease, 
experimental animals such as mice, rabbits, guinea pigs and 
rats have been used as models. Genetic analysis designed to 
identify specific neurovirulence and neuroinvasiveness 
associated genes is limited by the availability of suitable 
mutant viruses. Many laboratories are studying HSV genes 
and gene products associated with virulence using deletion 
mutants, monoclonal antibody resistance (mar) mutants, 
temperature sensistive (ts) mutants, drug resistance mutants 
and intertypic recombinants. Genes and loci modifying 
virulence of HSV are shown in Figure 1.7.A and B and 
described in the following sections.
1.8.4.a Viral enzymes
HSV encodes a thymidine kinase (TK) which is distinct 
from mammalian TK (Kit, 1979) and facilitates HSV 
replication in non-dividing cells (Jamieson et al., 1974). 
Virus mutants (TK ) deficient in the production of this 
enzyme replicate well in actively growing cell cultures and 
poorly in serum starved c e l l s (Jamieson et al., 1974; Field 
and Wildy, 1978). This led to the speculation that such 
mutants might be less virulent in vivo and it has been 
reported that TK~ mutants of HSV-2 are less virulent than 
wild type (TK+ ) HSV-2 (Marcialis et al., 1975; Field and 
Wildy, 1978; Stanberry et al., 1985). Similarly TK- mutants
Figure 1.7
A. Genes and loci in U , TR and IR involved in
Li Li Li
virulence of HSV. The top line shows the fraction map 
units (m.u.) of the genome from 0 to 0.83. The 
locations of different genes and loci are indicated on 
the viral genome.
B. Genes in IR , U and TR involved in virulence of
o o o
HSV. The top line shows the fraction m.u. of the viral
genome from 0.83 to 1.0. The locations and orientations 
of the genes are indicated on the viral genome.
0.32-0.42 
0.71-0.83
I
ll
o
CO
£
o
6
£
I
o
-s i-p^
o00
CO
0 
ho01
o
cn
co
I cno
co
co
I
o
CO
o
fe
o
CO
o
b>■P-
33
CO
CD
3
J3J3
co
O
<
05Ol
33
m
r o
_ o
o
k>
o
co
o
cn
o
cn
o
'"vj
o
00
CD
0.83 
0.9 
0.95
34
of HSV-1 have been shown to have reduced pathogenicity in 
animal models of herpes encephalitis (Field and Wildy,
1978), herpes keratitis (Marcialis et al., 1975; Price and 
Khan, 1981) and herpes labialis (Klein et al., 1981). 
Therefore viral TK would appear to influence HSV virulence, 
although the possibility that there are additional defects 
in these virus stocks arising from unrecognised mutations 
can not be excluded. The mechanism by which virus coded TK 
influences the pathogenicity of HSV may relate to reduced 
virus replication in neural tissue (Field and Wildy, 1978; 
Tenser et al., 1979; Klein et al., 1981; Price and Khan, 
1981; McDermott et al., 1984). During maturation, nerve 
cells stop expressing cellular TK and it is likely that TK+ 
viruses are able to replicate in such cells since these 
viruses are able to produce enough of their own TK to 
multiply in the central nervous system (Gordon et al.,
1983) .
The TK enzyme is required for DNA synthesis through 
phosphorylation of thymidine to thymidine monophosphate.
This function makes a good target for antiviral drugs. The 
common anti-HSV drug used for prophylaxis and therapy of HSV 
infections is acyclovir (ACV). It was initially feared that 
ACV resistant HSV strains might become a serious problem, 
analogous to penicillin resistant bacteria. ACV behaves as 
a nucleoside analogue which is selectively phosphorylated by 
HSV specific TK. The monophosphate form of ACV is then 
converted to the diphosphate and subsequently by cellular 
kinases to the triphosphate which is a potent inhibitor of 
HSV DNA polymerase. Three mechanisms of resistance to ACV 
have been described (i) loss of TK activity, (ii) alteration 
in TK substrate specificity and (iii) alteration of DNA
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polymerase (Coen and Schaffer, 1980; Crumpacker et. al.,
1980; Schippersand Crumpacker, 1980; Darby et al., 1981; 
Field et al., 1982; Larder et al., 1983; Schinazi et al., 
1986; Ellis et al., 1987; Kit et al., 1987). Mutants with 
an altered TK which are resistant to ACV may have reduced 
virulence (Darby et al., 1981; Klein et al., 1981; Sibrack 
e_t_aj.. , 1982). In one case, an ACV resistant mutant with an 
alteration in TK was shown to be highly virulent for mice 
(Sakuma et al., 1988). Mutants containing a drug resistance 
mutation in the viral DNA polymerase gene were attenuated 
for pathogenicity after intracranial inoculation and 
cataracts were reported as a common sequel (Field and Coen,
1986). Modulation of pathogenicity was also seen using 
flank and ear inoculation (Larder et al., 1986).
Ribonucleotide reductase (RR) catalyses the reduction 
of ribonucleotides to deoxyribonucleotides 
(Thelander and Reichard, 1979). The HSV enzyme consists of 
two subunits named large (RRl) and small (RR2-) (Cohen, 1972; 
Dutia, 1983; Preston et al., 1984; Cohen et al., 1985; Frame 
et al., 1985). It has been shown that RR is essential for 
virus growth in tissue culture (Preston et al., 1984).
Recent findings by Goldstein and Weller (1988) utilising 
viral RR mutants have substantiated the theory that the HSV 
enzyme is non-essential for virus growth in vitro. It has 
been shown that the HSV-1 ts mutants in RR, ts 1207 and ts 
1222 (Preston et al., 1988) have reduced pathogenicity for 
mice following intracranial and intraperitoneal inoculation 
(Cameron et al., 1988). Jacobson et al. (1989) showed that 
a mutant containing a deletion in the RRl gene is severely 
impaired in growth during acute infection of the eye and 
trigeminal ganglia in mice. In contrast, Turk et al. (1989)
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showed that two mutants containing a deletion in HSV-1 RRl 
produce lesions in guinea pigs as severe as those of wild 
type strains following intradermal inoculation.
1.8.4.b Vmw65 trans-inducinq factor (TIF)
A distinguishing feature of the IE genes is the presence 
of the cis-actinq element, TAATGARAT, in their 5' regulatory 
regions. This element responds to the HSV-1 virion 
polypeptide Vmw65 TIF resulting in stimulation of 
transcription from the IE promotors (Mackem and Roizman, 
1982; Batterson and Roizman, 1983; Cordingley et al., 1983; 
Campell et al., 1984; Kristie and Roizman, 1984; Gaff ney et 
al., 1985; Pellett et al., 1985; O'Hare and Hayward, 1987). 
Recent work by Ace et al. (1989) has shown that a HSV-1 
mutant unable to transinduce IE gene expression has reduced 
virulence for mice following intracranial and 
intraperitoneal inoculation.
1.8.4.C Temperature sensisitive (ts) mutants
Most of the tj5 mutants of HSV have been generated using 
a variety of mutagens (Schaffer et al., 1970, 1974; Timbury, 
1971; Brown et al., 1973; Esparza et al., 1974; Manservigi,
1974). It has been shown that some ts mutants of HSV have 
reduced virulence for guinea pigs (Anderson et al., 1980) 
and for mice (Lofgren et al., 1977). Temperature-sensitive 
mutants have been valuable in understanding the molecular 
events of the virus replication cycle in vitro.
1.8.4.d Glycoproteins
The genome of HSV—1 encodes at least seven antigenically
distinct glycoproteins; gB, gC, gD (Spear, 1976), gE (Baucke
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and Spear, 1976), gG (Marsden et al., 1984; Roizman et al.,
1984), gH (Buckmaster et al., 1984) and gl (Longnecker et 
al., 1987). HSV-2 counterparts for gB, gC, gD, gE and gG 
have also been described based on biochemical or 
immunological criteria or analysis of DNA sequence data 
(Pereira et al. , 1981; Balachandram et al., 1982; Eisenberg 
et_al., 1982; Hope et al., 1982; Para et al., 1982; Zezulak 
and Spear, 1983; Zweig et al.., 1983; Dowbenko and Lasky, 
1984; Swain et al., 1985; McGeoch et al., 1987). No HSV-2 
counterpart of gH has yet been identified. Virus-specific 
glycoproteins are structural components of the virion 
envelope and are expressed on the surface of infected cells 
where they may serve as targets for immune surveillance 
(Norrild, 1985; Dix, 1987). The known HSV-1 glycoproteins 
and their biological and immunological functions are 
summarised in Table 1.2 and their map locations is indicated 
in Figure 1.8.
Studies with ts and deletion mutants in various 
glycoproteins indicated that gC, gE, gG and gl are 
dispensible for growth of virus in tissue culture (Hoggan 
and Roizman, 1959; Heine et al., 1974; Cassai et al., 1975; 
Holland et al., 1984; Zezulak and Spear, 1984; Longnecker 
and Roizman, 1986, 1987; Longnecker et al., 1987; Weber et 
al., 1987; Harland and Brown, 1988; Schranz et al., 1989) 
whereas gB,/land gH have been shown to be essential 
(Manservigi et al., 1977; Little et al., 1981; Gompels and 
Minson, 1986 ) . Studies involving HSV—1 ts mutants in gB 
have suggested a role for gB in the entry of virus into 
cells (Sarmiento et al., 1979; Little et al., 1981) and 
cell-cell fusion (Manservigi et al., 1977; Haffey and Spear, 
1980). Furthermore evidence supporting the role of gB and
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Figure 1.8
Locations of the genes encoding HSV-1 glycoproteins.
The HSV-1 genome is represented in the prototype 
orientation with fractional genomic length (m.u.) above 
the genome. The approximate map locations of the 
glycoproteins are indicated by shaded boxes.
(Adapted from Marsden, 1987).
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to a lesser extent gD in virus attachment to the cell and 
cell-cell fusion has come from experiments with 
reconstituted viral glycoproteins (Johnson et al.f 1984) and 
monoclonal antibodies (Nobel et al., 1983; Fuller and Spear,
1985). Similar experiments have implicated gH in cell 
fusion (Gompels and Minson, 1986). Two antigenic sites in 
gB have been identified and shown to be linked with the 
ability of gB to contribute to virus infectivity (Highlander 
et al., 1989).
The role of gH in egress of virus from infected cells 
has been shown using a monoclonal antibody against gH which 
inhibits plaque formation suggesting the involvement of gH 
in cell-cell spread of infectious virus (Buckmaster et al., 
1984). It has been reported recently that monoclonal 
antibodies specific to gH of HSV block viral penetration 
without inhibiting adsorption of virus to cells (Fuller et. 
al. , 1989) .
HSV-1 gE (Bauke and Spear, 1979; Para et al., 1982) and 
gl (Johnson and Feenstra, 1987) have been associated with 
virus specific binding activity for the Fc component of 
immunoglobulin G (IgG). Evidence that binding of non-immune 
IgG to infected cell membranes can protect the cells from 
immune cytolysis (Adler et al., 1978) suggests that such 
binding may modify immune recognition of virus infected 
cells in vivo.
Glycoprotein C plays a role in the induction of humoral 
and cell-mediated immune responses during infection (Oakes 
et al. , 1980; Glorioso et al., 1985; Kumel et al., 1985; 
Marlin et al., 1985; Nash et al., 1985; Rosenthal et al.,
1987) and has the unique property of functioning as a 
receptor for the C3b component of complement (Friedman et
39
a_l. , 1984). This activity has been shown to interfere with 
activation of the alternative complement pathway (Fries et 
al., 1986).
Glycoproteins have been identified as virulence factors 
in studies of other viruses such as rabies (Dietzschold et 
al., 1983) and murine corona virus (Fleming et a1., 1986). 
Among herpesviruses gl and gill, pseudorabies virus 
structural components have been reported to influence viral 
neurovirulence (Mettenleiter et al., 1987, 1988). Although 
HSV encodes at least seven glycoproteins, their roles in 
neurovirulence remain largely unexplored.
The ability of gC to interfere with activation of the 
complement pathway suggested that gC may act as an important 
virulence determinant by protecting the virus from 
complement-mediated antiviral host defence mechanisms. 
Intravaginal inoculation of mice with a gC-2 negative (gC 2) 
mutant produced local inflammation followed by lethal spread 
of virus infection into the nervous system in an identical 
manner to that produced by the parental HSV-2 strain 333 
(Johnson et al., 1986). Similarly direct inoculation of a 
gC 2 mutant into the central nervous system produced lethal 
neurological disease. These results support the impression 
that gC-2 is not involved in virulence. On the other hand, 
HSV-2 marC mutants were found to be reduced in pathogenicity 
for the nervous system (Kumel et al., 1985). HSV-1 strain 
MP which is gC~l (Hoggan and Roizman, 1959; Holland et al.,
1984) was found to be highly virulent for mice following 
intracranial or footpad inoculation (Dix et al., 1983). 
Recently Sunstrum et al. (1988) have tested eight additional 
gC~l mutants derived from HSV-1 strain KOS 321 and shown 
that these mutants differ widely in their ability to induce
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lethal encephalitis in mice following intracranial 
inoculation. It was concluded that gC-1 is not a virulence 
determinant in the mouse model of HSV-1 induced 
encephalitis. It has been suggested that it is unlikely 
that either gC-1 or gC-2 play an essential role in the entry 
of virus into epithelial or neural cells, either in mice or 
humans (Johnson et al., 1986).
MarB or marD mutants with single epitope changes have no 
effect on pathogenicity, while multi-marB mutants show 
significantly reduced pathogenicity. This difference may be 
due to an unrecognised mutation other than the t_s phenotype 
of multi-marB mutants which alters pathogenicity (Kumel e_t 
al., 1985).
The involvement of gE and gG in virulence has been shown 
using genetically engineered deletion mutants of HSV-1
4strain F (Meignier et al., 1988 ). The LD,.^  of a gG was 10--------------  5 U
fold higher than the wild type, while that of a gE mutant 
was <100 fold higher following intracranial inoculation of 
mice. These results indicated that gG and to a lesser 
extent gE have important roles in virulence. In addition 
Weber et al. (1987) have shown that a HSV-1 mutant carrying
a chain terminating Tn5 insertion in the gene encoding gG 
has reduced neurovirulence in mice. It has been shown 
recently that mutants of HSV-2 strain HG52 in the US4 gene 
encoding gG were reduced in virulence for mice following 
intracranial inoculation (see section 3.2.2).
The role of gB in pathogenicity was demonstrated by 
transfer of the gB gene from HSV-1 strain KOS, which has 
been shown to be apathogenic for mice following 
intraperitoneal inoculation (Schroder et al., 1983), to 
HSV-1 strain ANG path, which is pathogenic for mice when
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inoculated by the same route (Kaerner et al.f 1983), 
resulting in recombinant virus which was apathogenic for 
mice (Weise et al., 1987).
1.8.4.e Other loci
Many groups have identified regions in the HSV genome 
involved in virulence using different animal model systems. 
Thompson and Stevens (1983b) used the HSV-1 intertypic 
recombinant RE6 which was generated by marker rescue of ts E 
syn with wild type HG52 fragments (Marsden et al., 1978). 
They showed that RE6 was completely avirulent for mice 
following intracranial inoculation and concluded that RE6 
was at least 10 million fold less neurovirulent than the 
parental wild type viruses. In an other study, Thompson et 
al. (1983) confirmed the avirulent phenotype of RE6 and
localised the HSV-1 region which restored neurovirulence to 
between 0.71-0.83 m.u. Cleavage of the wild type Hindlll c 
fragment (0.64-0.87 m.u.) with EcoRI eliminated its capacity 
to rescue RE6 and neurovirulence was restored by the 
addition of the HSV-1 BamHI _1 fragment (0.71-0.74 m.u.) that 
spans an EcoRI site at 0.72 m.u. (Thompson et al., 1985). 
Similarly Ben-Hur et al. (1987) following intracranial 
inoculation of mice concluded that a neurovirulence function 
resided in the BamHI 1 fragment (0.7-0.738 m.u.) of HSV-1 
strain F and that the function was closely linked to the 
viral gene for cell fusion. The latter correlated with the 
report by Yamada et al. (1986), who examined several HSV-1 
variants (all derived from the Miyama strain) and concluded 
that viral pathogenicity correlated with a higher cell 
fusion index and large plaque size.
Another intertypic recombinant RS6, which was generated
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by cotransfection of unit length ts; S of 17 syn+ DNA and
Xbal generated DNA fragments derived from HG52 (Stow and
Wilkie, 1978 ), was also studied in pathogenicity
experiments. Javier et al. (1987) have shown that the HSV-1
intertypic recombinant RS6 was approximately 10^ times less
neurovirulent for mice following intracranial inoculation
than either of its wild type parental viruses. The
avirulent phenotype of RS6 was due to failure to replicate
in mouse brain. Cotransfection experiments of RS6 DNA with
EcoRI e + k fragments (0.72-0.87 m.u.) of 17 syn+ generated
recombinant viruses with variable degrees of neurovirulence.
The relevant region between 0.72-0.87 m.u. was tentatively
delimited to 0.79-0.83 m.u. DNA analysis of the recombinant
viruses showed that the highly neurovirulent recombinants
had type 2 DNA replaced with type 1 DNA in the two regions
between 0.11-0.14 m.u. and 0.79-0.83 m.u. One exceptional
recombinant designated R13-1 was avirulent and had type 2
DNA replaced by type 1 DNA in the region between 0.79-0.83
m.u. These results suggested that there was at least
another region (0.11-0.14 m.u.) involved in HSV
neurovirulence. The same group (Javier et al., 1988a) have
3
shown that the R13-1 recombinant was 10 fold less 
neurovirulent than either of the wild type parental viruses 
despite a comparable efficiency of replication in mouse 
brain to that of the parental viruses. Marker rescue of 
unit lengh R13-1 DNA and cloned type 1 EcoRI d fragments 
(0.079-0.192 m.u.) spanning the region from 0.11-0.14 m.u. 
generated viruses with the wild type neurovirulence 
phenotype.
Another region of the HSV genome has been implicated in 
neuroinvasiveness. Thompson et al. (1986) have shown that a
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cosmid clone containing the Hindlll a fragment (0.25-0.53 
m.u.) of strain 17 syn+ in contransfection with full lengh 
KOS DNA, known to be less neurovirulent than most other 
HSV-1 strains (Dix et al., 1983), yielded recombinants with 
enhanced neuroinvasiveness for mice following footpad 
inoculation. Javier et al. (1986) reported that 
simultaneous inoculation of mice on the rear footpad with 
two non-neuroinvasive viruses (HSV-1 strains ANG and KOS) 
resulted in the deaths of 62% of animals. Studying the 
events resposible for pathogenesis of this virus mixture 
Sedarati et al. (1988) investigated the replication capacity
and spread of virus within specific tissue and found that 
the amount of neuroinvasive virus mixture had increased 
within the spinal cords and brains of infected mice compared 
to ANG and KOS strains which are defective in this capacity. 
Their findings suggested that the neuroinvasiveness of the 
virus mixture was a consequences of complementation as well 
as the generation and selection of neuroinvasive 
recombinants in the spinal cords of mice.
Recent work by Goodman et al. (1989) has shown that
HSV-1 strain ANG DNA contains at least two distinct 
neuroinvasive regions designated INV-1 (0.49-0.64 m.u.) and 
INV-II (0.32-0.42 m.u.) containing functions which can be 
transferred by DNA cotransfection to confer mesodermal 
invasiveness and virulence to the avirulent HSV-1 17 syn+ on 
the chorioallantoic membrane (CAM) of chicken embryos. The 
genes in the region INV-1 (0.49-0.64 m.u.) include the 
virion function associated with shutoff of host cell 
protein synthesis (Morse et al., 1978). The 5' end of the 
gC gene also maps within this region and gC is highly type 
divergent in terms of both sequence and antigenicity (Spear,
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1985). In addition the genes encoding RR and ICP10 reside 
within this region (Schaffer et al., 1987). The region 
INV-II (0.32-0.42 m.u.) contains genes encoding gB (Bzik et 
a].., 1984) and its associated syn 3 mutation locus (Ruyechan 
et al., 1979).
Sedarati and Stevens (1987) have examined the biological 
properties of HSV-1 strains F, HF and HFEM compared to HSV-1 
17 syn+ . They found that the three strains of HSV (F, HF 
and HFEM) were defective in replication in mouse cells, had 
reduced neurovirulence for mice following intracranial 
inoculation and were completely avirulent following footpad 
inoculation. In coinfection experiments, strain F 
complemented strains HF and HFEM but the latter two strains 
did not complement each other. All three strains were found
nor'
to complement the'-neuroinvasive KOS emphasizing the 
multigenic nature of HSV virulence.
Centifanto-Fitzgerald et al. (1982), studying the
patterns of ocular disease produced by HSV using the rabbit
eye model system, identified a region of the HSV-1 genome
between 0.71-0.83 m.u. involved in stromal disease. In
addition a study by Oakes et al. (1986) using intertypic
recombinants, has shown that HSV-1 DNA sequences between
0.31-0.44 m.u. were necessary for recombinant viruses to
spread from the cornea to the central nervous system of mice
following ocular inoculation. Similarly Day et al. (1987)
showed that a region important in DNA replication between
0.4-0.44 m.u. of HSV-1 strain 17 syn* was involved in spread
of virus from the cornea to the central nervous system
following ocular inoculation of mice. This region contains
ori , DNA polymerase and a part of the major DBP (Quinn and 
L
McGeoch, 1985; Weller et al., 1985).
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The tree shrew has also been used as an animal model to 
define HSV genes involved in virulence. The HSV-1 strain 
HFEM, which has a deletion of about 4.1 kb between 0.76-0.79 
m.u., is apathogenic for tree shrews after intraperitoneal 
inoculation (Rosen and Darai, 1985). Pathogenicity of 
strain HFEM was restored by cotransfection of its DNA and 
the BamHI b fragment (0.733-0.809 m.u.) from the pathogenic 
HSV-1 strain F (Rosen et al., 1985). Similarly insertion of 
the Mlul DNA fragment (0.7615-0.789 m.u.) from HSV-1 strain 
F restored the intraperitoneal pathogenicity to strain HFEM 
(Rosen e t al. , 1986 ). A similar DNA fragment (Mlu.1 
0.761-0.786 m.u.), spanning the Hpal £ sequences of the 
pathogenic strain F, has been shown to restore the 
intraperitoneal pathogenicity of HFEM for mice (Becker et. 
al., 1986). Recent work on the neurovirulence of seven 
deletion mutants of HSV-1 showed that all were attenuated 
for virulence in mice following intracranial inoculation 
(Meignier et al., 1988). The genes deleted from six of 
these map in the S component of HSV-1 DNA and were IE4, US2, 
US3, gG, gE, US11 and IE5.
Recently Taha et al. (1989a; and this thesis), have 
shown that a variant (JH2604) of HSV-2 strain HG52, whose 
genome is deleted by approximately 1.5 kb within both copies 
of the BamHI v fragment between 0-0.02 and 0.81-0.83 m.u. 
(Harland and Brown, 1985), is completely non-neurovirulent 
for mice following intracranial inoculation. Correction of 
the deletion by wild type Xbal (e, f or g_) or BamHI c[ 
fragments resulted in recombinants with wild type 
neurovirulence. Introduction of the JH2604 deletion back 
into the wild type genome resulted in non—neurovirulent 
recombinants, demonstrating that the deleted sequences in
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the variant JH2604 determine neurovirulence. Sequence 
analysis has shown that the variant JH2604 is deleted by 
1488 bp in both the IR and TRt copy of BamHI v (Taha etU Li — --
ad., 1989b). A similar region has recently been identified 
in HSV-1 strain 17 as being important in the determination 
of virulence in mice (Thompson et al., 1989).
1.9 Latency of HSV
Unlike many other human viruses which are eliminated by 
host mediated defence mechanisms soon after primary 
infection, HSV has evolved a complex strategy of replication 
and survival whereby it may remain within neural or 
non-neural tissues for long periods of time in a latent 
state thereby evading the immune response. The latent phase 
of HSV infection is defined as isolation of infectious virus 
from explant cultures after a period of time but failure to
TH««-
detect infectious virus from cell homogenates of * tissues or 
organs immediately post explantation.
The focal point of most clinical disease arising from 
HSV is the ability of the virus to interact with components 
of the peripheral nervous system. Following primary 
infection and active replication at peripheral sites, virus 
attaches to the sensory nerve terminals (Vahlne et al., 
1978), enters them and travels centripetally via neural 
routes to sensory ganglia (Cook and Stevens, 1973). It is 
within the neurons of the sensory ganglia that virus becomes 
latent (Cook et al., 1974; Stevens, 1975). HSV has been 
recovered in humans and animals from explanted nervous 
tissue, and adrenal glands (Nesburn et al., 1972; Knotts et 
al. , 1973; Cook and Stevens, 1976; Price et al., 1975;
Warren et al., 1978). Evidence is accumulating which
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suggests that peripheral non-neural sites of herpesvirus 
latency in humans and experimentally infected animals also 
exist. HSV-1 has been isolated in the absence of detectable 
clinical lesions from the ear skin, which was the initial 
site of inoculation, in 8% of mice latently infected with 
the virus though this was initially interpreted as 
reactivation from dorsal root ganglia (Hill et al,. 1980). 
HSV-2 and HSV-1 have both been recovered independently from 
the footpad as well as from the dorsal root ganglia of 
latently infected mice (Al-Saadi et al., 1983; Clements and 
Subak-Sharpe, 1983, 1988; Subak-Sharpe et al., 1984a, 1984b; 
Al-Saadi et al., 1988). In the guinea pig both HSV-1 and 
HSV-2 have been isolated from the site of primary infection 
(footpad and vagina) long after inoculation (Scriba, 1976, 
1981; Donnenberg et al., 1980). However, in the guinea pig 
spontaneous reactivation is very common. HSV has been 
reactivated from cultured cells of explanted corneal tissue 
of rabbits (Cook et al., 1987) and mice (Openshaw, 1983).
In humans, attempts to recover latent HSV from peripheral 
sites have been unsucessful (Rustigian et al., 1966) apart 
from the isolation from human corneas removed prior to 
corneal transplantation, due to chronic stromal keratitis 
(Shimeld et al♦, 1982; Tullo et al. , 1985; Cook, 1988).
The mechanism of initiation, maintenance and 
reactivation of latent HSV has been extensively studied 
(Wildy et al., 1982; Hill, 1985) but is still not fully 
undestood. The molecular investigation of viral genes 
expressed during the latent state has been difficult since 
only a minority of cells in neural tissue harbour latent 
virus (Kennedy et al., 1983). During the latent phase, the 
viral genome appears to be present in circular or
48
concatameric forms rather than the linear molecules found in 
intact virions (Rock and Fraser, 1983). During the latent 
phase there have been no confirmed claims of the detection 
of any HSV gene expression. Recently HSV-specific 
transcripts have been detected during HSV-1 latency in 
ganglia of seropositive patients (Croen et al., 1987;
Steiner et al., 1988; Stevens et al., 1988) and in 
experimentally infected mice (Deatly et al., 1987; Puga and 
Notkins, 1987; Spivack and Fraser, 1987; Stevens et al.,
1987;Vagner et al., 1988) and rabbits (Rock et al., 1987; 
Wechsler et al., 1988).
The HSV-1 transcripts present in sensory ganglia of
latently infected animals and humans originate from the long
repeat region of the viral genome^WVv are present as two
copies per genome. At least three viral transcripts
(latency associated transcripts- LAT), 2.0, 1.5 and 1.45 kb
are present during HSV-1 latency in humans and
experimentally infected animals (mice and rabbits) and map
to a 3.0 kb region contained within the BamHI b and e
fragments in the R region. These RNAs partially overlap
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the 3' terminus of the IEl gene but are transcribed in the 
opposite direction (Rock et al. , 1987; Spivack and Fraser, 
1987; Stevens et al., 1987; Deatly et al., 1988; Steiner et 
al., 1988; Wagner et al., 1988; Wechsler et al., 1988).
The DNA of the region from which transcription occurs 
during latency has been sequenced and, apart from IEl, does 
not contain any convincing protein-coding sequences (Perry 
and McGeoch, 1988). Moreover, most of the transcripts 
present during latency are not polyadenylated (Wagner 61 
al., 1988). The LATs might modulate latency via control of 
IEl gene expression, possibly by interacting with the DNA
49
sequence of the gene or with IElmRNA (Croen et al., 1987; 
Rock et al., 1987; Stevens et al., 198 7). However, HSV 
deletion variants that lack all or part of the LATs are 
latency competent in laboratory animals (Javier et al.,
1988b; Sedarati et al., 1989; Steiner et al., 1989). Thus 
these transcripts, the only HSV specified products so far 
detected in latently infected neurons, are not essential for 
the latency process in neurons, at least in animals.
Several studies have suggested that mutants of HSV-1
with defective TK have a reduced ability to establish latent
infections in vivo. Moreover, studies using genetically
engineered TK deletion mutants have shown that the mutants
can not establish either acute or latent ganglionic
infection in mice (McDermott et al., 1984; Tenser and Edris,
1987). Similarly, an HSV-1 TK mutant was shown to be
latency negative in mice but positive in rabbits suggesting
that the host cell may be a determinant in the establishment
of latent infection (Meignier et al., 1988). In contrast,
Efstathiou et al. (1989) have demonstrated by superinfection
mouse
of explanted/'ganglia with wild type HSV-1, that a TK
deletion mutant was able to establish latent ganglionic 
infection suggesting that the virus-encoded TK is not 
essential for establishment of latent infection. Recently 
Leist et al. (1989) have reported that an HSV-1 variant 
harboring a deletion in the TK gene can establish latent 
infections in mice spinal ganglia. That variant could not 
be reactivated when spinal ganglia were cultured J_n vitro 
suggesting that the expression of the viral TK gene plays no 
major role in establishment of the latent state but it has a 
role in reactivation from explanted ganglia. Similarly 
Tenser et al. (1989) concluded that although HSV-1 TK-
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mutants were able to establish latent infections in mouse 
ganglia, they failed to reactivate from explanted ganglia 
suggesting a role for TK in the reactivation process. Using 
an in vitro system to study latency, Russel and Preston 
(1986) have shown that infection of human foetal lung (HFL) 
cells with HSV-2 at the superoptimal temperature of 42°c 
results in a latent state which is stable on downshift of 
cultures to 37 C. The latent virus can be reactivated by 
superinfection with HSV or CMV but not with adenovirus.
Using this approach, Russel et al. (1987) have demonstrated
that the superinfection of HSV-1 dll403, which has a large 
deletion in the IEl gene coding for VmwIEllO (Stow and 
Stow,1986), can not reactivate latent HSV-2 suggesting a 
role for the IEl gene product in reactivation. Recently, 
Harris et al. (1989) using two mutants, have shown that
adenovirus recombinants expressing HSV-1 VmwIEllO reactivate 
latent HSV-2 in vitro. The HSV-1 mutant which possesses a 
deletion in the carboxy-terminal region of VmwIEllO 
reactivated latent HSV-2, whereas the other HSV-1 mutant 
which has a deletion in the second exon did not, suggesting 
that VmwIEllO alone is required for reactivation of latent 
HSV-2 in vitro. Contrary to this, Clements and Stow (1989) 
have shown that dll403, which has reduced virulence for 
mice, is able to establish a latent infection in mice 
sensory ganglia following footpad inoculation and the latent 
virus can reactivate from explanted ganglia suggesting that 
the gene product of the IEl gene (VmwIEllO) is dispensible 
for establishment and maintenance of latency and 
reactivation from the latent state.
1.10 HSV infection of the nervous system
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1.10.1 HSV-1 encephalitis
The most important neurological disease caused by HSV-1 
is an acute encephalitis which is the commonest type of 
fatal sporadic acute encephalitis occuring in man (Finelli,
1975). Beyond the fact that HSV-1 infection spreads within 
the brain causing progressive destruction of both neurons 
and glial cells, little is known of the pathogenesis of 
herpes encephalitis. The route of infection is likely to be 
an important factor in determining the topography of 
herpetic brain infection. HSV-1 can directly invade the 
brain of immunologically normal adults and produce an acute 
haemorrhagic necrotising encephalitis which is accompanied 
by high mortality and severe morbidity (Whitley et al., 
1982a) .
Two theories currently exist to explain the origin of 
the virus responsible for this devastating disease. Davis 
and Johnson (1979) speculated that HSV-1 encephalitis of 
adults represents reactivation of a latent endogenous virus 
from the trigeminal ganglia. Support for this hypothesis 
has been supplied by Whitley et al. (1982b) who demonstrated
that brain and oral isolates recovered from five of eight 
patients with simultaneous encephalitis and oral lesions 
were identical when compared by DNA restriction enzyme 
analysis. Alternatively the rather consistent striking 
localisation of tissue destruction to the subfrontal and 
medial temporal regions of the brain led Johnson and Mims 
(1968) to speculate that this disease is a primary infection 
caused by an exogenous virus which gains access to the 
central nervous system by the olfactory route. Evidence 
obtained from experimental animal models of focal HSV—1 
encephalitis produced by virus inoculation of the olfactory
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bulb or nasal mucosa would tend to support this hypothesis 
(Anderson and Field, 1983; Schlitt et al., 1986; Stroop and 
Schaefer, 1986 ) .
On the other hand, a number of animal studies have 
demonstrated that after inoculation of HSV—1 by a variety of 
routes there is a predilection for certain brain regions 
suggesting a selective vulnerability of these regions 
(Anderson and Field, 1983; Tomlinson and Esiri, 1983; 
McFarland and Hotchin, 1987).
1.10.2 HSV-2 encephalitis and meningitis
HSV-2 may produce severe neurological infections in 
infants infected at the time of birth who develop 
disseminated herpetic infection with hepatic and adrenal 
necrosis and diffuse encephalitis (Johnson, 1982). In 
adolescents and adults, primary infection is occasionally 
complicated by an acute self-limiting benign meningitis 
often associated with outbreaks of genital disease (Corey,
1984). The pathogenesis of HSV-2 meningitis is uncertain. 
Unlike HSV-1, HSV-2 can be recovered from both cerebrospinal 
fluid (CSF) and blood (Craig and Nahmias, 1973) of adults 
suffering from aseptic meningitis. Whether all cases of 
this illness are associated with viraemia remains to be 
determined. Nevertheless, it is generally accepted that 
HSV-2 meningitis is a consequence of reactivation from 
sacral ganglia of virus which subsequently seeds the CSF. 
Complications of HSV-2 meningitis include intermittent or 
permanent paralysis associated with transverse myelitis of
the spinal cord.
An exception to the more benign nature of HSV—2 in 
adults is seen in patients with immunodeficiency. Fatal
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disseminated herpesvirus infections, including encephalitis 
(Sutton et a1., 1974) and severe even fatal meningo­
encephalitis associated with HSV-2 as well as HSV-1 have 
been reported in patients undergoing intensive 
immunosuppressive therapy (Johnson, 1982).
1.11 Pathology of HSV encephalitis
There is marked necrosis in HSV encephalitis with 
petechial haemorrhage accounting for the earlier term, acute 
necrotising encephalitis. Microscopically, haemorrhagic 
necrosis with mononuclear inclusion bodies in the neurons 
and glial cells is seen (Drachman and Adams, 1962). Viral 
antigen distribution in human cases of herpes encephalitis 
was analysed using immunoperoxidase techniques (Esiri,
1982). The analysis showed that HSV-1 antigens were 
detected in the medial and inferior temporal lobes, 
hippocampus, amygdaloid nuclei, olfactory cortex, insula and 
cingulate gyrus. In a number of cases antigens were 
detected in glial cells of the olfactory tracts. The grey 
matter was predominantly affected, but antigens and 
inflammation extended also into the white matter. Viral 
antigens could be visualised early in the disease and by the 
fourth week, antigens were largely cleared and replaced by 
inflammatory cells. Using a combination of immunoperoxidase 
staining and in situ hybridisation it has been possible to 
show localisation of viral antigens and viral nucleic acid 
in the same cell allowing the distinction between productive 
and non-productive viral infections (Kennedy et al., 1988). 
Viral antigens and HSV RNA were detected in the same 
astrocytes, glial cells and macrophages.
In experimentally infected animals, viral antigen
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distribution in the central nervous system depends on the 
portal of virus entry (Anderson and Field, 1983; Chrisp et 
al., 1989) and the animal species (Stroop and Schaefer,
1986). Hayashi et al. (1986) have reported hydrocephalus in 
mice following intracranial inoculation with HSV-1. These 
brains showed dilation of the ventricles with irregular 
walls devoid of ependymal lining cells and proliferation of 
subependymal astrocytes. Mild mononuclear cell infiltration 
was also commonly seen in the subarachnoid space of 
hydrocephalic mice.
1.12 HSV and ocular diseases
HSV is endemic in the world with 60-70% of children aged 
5 years and 90% of adults having neutralising antibody 
against HSV (Smith et al., 1967). However, only 20-30% are 
estimated to manifest clinical disease and less than 1% 
exhibit ocular disease (Kaufman et al., 1983). The virus is 
the most common cause of corneal ulcer and corneal blindness 
in developing countries (Foster and Duncan, 1981). The two 
types of HSV are implicated in ocular disease.
Approximately 98% of non-neonatal ocular infection is caused 
by HSV-1 (Neumann-Haefelin et al., 1978) while 70-80% of 
neonatal ocular infection is from HSV-2 (Nahmias et al., 
1970) .
HSV ocular disease occurs as primary or recurrent 
infections. The most common manifestations of primary 
ocular disease are the infection of the eyelids and 
conjuctivi which are characterised by vesicle formation on 
the lid and acute follicular conjuctivitis respectively. 
Epithelial keratitis (involvement of the cornea) in the 
primary HSV infection, which is a self limiting disease,
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usually follows the onset of follicular conjuctivitis 
resulting in keratoconjuctivitis (Grayson, 1983). In 
neonates, HSV ocular manifestations include
keratoconjuctivitis and retinitis. Unilateral or bilateral 
cataracts associated with HSV neonatal infection is thought 
to develop secondary to uveitis or from direct viral 
invasion of the lens (Gibis and Burde, 1971).
The clinical manifestations of recurrent HSV ocular 
disease include blepharitis, conjuctivitis and keratitis.
The latter differs from that in primary HSV ocular infection 
in that keratitis extends to the stroma and endothelium 
resulting in permanent visual loss (Verdier and K^achmer, 
1984) .
Using animal model systems, such as rabbits, mice and 
guinea pigs for experimental HSV ocular infection, has 
provided valuable information on the pathogenesis of the 
disease (Nesburn et al., 1967; Hill et al., 1975; Wander et 
al., 1987) .
CHAPTER
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MATERIALS
Cells
Baby hamster kidney clone 13 (BHK-21 C13) cells 
(Macpherson and Stoker, 1962) and BALB/c mouse embryo 
fibroblast (3T3) cells (Flow Laboratories) were used.
Vi ruses
Herpes simplex virus type 2 (HSV-2) strain HG52 
(Timbury, 1971) and plaque purified stocks of HG52 (Taha et 
al., 1988) were used throughout this study. The HSV-2 
(HG52) deletion variants used were JH2603, JH2604, JH2605, 
JH2606, JH2607, JH2608, JH2609, JH2610 and JH2611 (Harland 
and Brown, 1988), characterised (Harland and Brown, 1985) 
under their previous designation of HG52XD86, HG52XD192, 
HG52XD8 5/5, HG52XD85/4, HG52X163X12 , HG52X163X14,
HG52XI63X21, HG52X163X3 and HG52X163X3X53 respectively. 
Herpes simplex virus type 1 (HSV-1) Glasgow strain 17 syn+ 
(Brown et al., 1973) and the HSV-2 thymidine kinase negative
- 7
mutant (TK ), obtained from D. Dargan, were also used.
Tissue culture media
BHK-21 C13 cells were cultured in Eagle's medium (Gibco 
Biocult.) containing twice the normal concentration of 
vitamins and amino acids, 100 units/ml penicillin, 100 ug/ml 
streptomycin, 5% (v/v) tryptose phosphate broth and 10%
(v/v) calf serum (ETC10). 3T3 cells were grown in
Dulbecco's Modified Eagle's medium (Flow Laboratories) 
containing 10% (v/v) newborn bovine serum and 2mM 
L-glutamine (DMEM10) . Other media used during this study
were;
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Emet/5C2 Eagle's medium containing 20% the normal
concentration of methionine plus 2% calf 
serum
PIC phosphate free Eagle's medium containing
1% calf serum
EHu5 Eagle's medium containing 5% human serum
EMC5 Eagle's medium containing 1.5% methyl
cellulose and 5% calf serum
Agar and bacterial growth media
2X YT broth 85mM NaCl, 1% (v/v) Difco bactotryptone,
1% yeast extract 
L-broth 170mM NaCl, 1% (v/v) Difco bactotryptone,
0.5% (w/v) yeast extract 
L-broth agar L-broth containing 1.5% (w/v) agar
Top agar 1% (w/v) agar in water
Plasmids
Plasmid pAT153 (Twigg and Sherratt, 1980) was used as 
the cloning vector and the pGZl plasmid containing the HG52 
BamHI c[ fragment (0.81-0.85 m.u.) was supplied by A.
Davi son.
Sera
Normal goat serum and biotinylated anti-rabbit IgG were 
supplied by Vector Laboratories (USA). Polyvalent rabbit 
antiserum to HSV was supplied by Dako Ltd.
Experimental animals
Three week old BALB/c mice, both sexes, (Bantin and
Kingman) were used in this study.
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Stains
Giemsa stain
1.5% (w/v) suspension of Giemsa in glycerol, heated at
56 C for 120 min and diluted with an equal volume of 
methanol.
Eo s i n
0.5% solution of eosin Y in distilled water.
Haematoxylin
lg haematoxylin, 50g potassium alum, 0.2g sodium iodate, 
lg citric acid and 50g chloral hydrate dissolved in lOOOrnl 
water with gentle heat.
Enzymes
Restriction endonucleases were obtained from Bethesda 
Research Laboratories (BRL). E. coli polymerase I (Klenow), 
T4 DNA ligase, calf intestinal phosphatase (CIP) were 
supplied by Boehringer Corporation Limited. Protein kinase 
and lysozyme were purchased from Sigma Chemicals Company.
Radiochemicals
All radiochemicals were obtained from Amersham 
International pic at indicated specific activity;
[oc-32p] dNTP'S 3000 Ci/mmol
33S-methionine 800 Ci/mmol
32p-orthophosphate 200 mCi/mmol
[Me-3H] thymidine 60 mCi/mmol
Solutions and buffers
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Phosphate buffered saline-A (PBS-A)
170mM NaCl, 3.4mM KCl, ImM Na2HP04, 2mM KH2P04, pH 7.2.
Phosphate buffered saline (PBS)
PBS-A supplemented with 6.8mM CaCl2 and 4.9mM MgCl2 .
PBS/calf serum
PBS containing 5% calf serum.
Tris-saline
140mM NaCl, 30mM KCl, 280mM Na2HP04, 1 mg/ml glucose, 
0.0015% (w/v) phenol red, 25mM Tris-HCl (pH 7.4), 100
units/ml penicillin, 100 ug/ml streptomycin.
10% Formal buffered saline
A stock solution of 40% formaldehyde to which 9% NaCl 
has been added. The working solution (10%) consists of one 
part of stock to nine parts water kept over marble chips for 
buffering.
Trypsin
0.25% (w/v) Difco trypsin dissolved in Tris-saline. 
Versene
0.6mM EDTA dissolved in PBS containing 0.002% (w/v) 
phenol red.
Trypsin-Versene
One volume of 0.25% trypsin plus four volumes versene.
Saturated phenol
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Phenol was saturated by mixing 2:1 with phenol 
saturation buffer (lOmM Tris-HCl pH 7.5, lOmM EDTA, lOOmM 
NaCl).
Phenol : chloroform (1 : 1)
This is a 1 : 1 mixture of phenol and chloroform.
Chloroform : isoamyl alcohol (24 : 1)
This is a 24 : 1 mixture of chloroform and isoamyl 
alcohol.
TBE
89mM Tris base, 89mM Boric acid, 2mM EDTA pH 8.3.
TE
lOmM Tris-HCl, O.lmM EDTA pH 8.0.
Restriction enzyme buffers
The buffers used were as recommended by BRL or Maniatis 
( 1982) .
Chemicals
M13 single strand primer, unlabelled nucleotides, 2', 31 
dideoxyribonucleoside triphosphates were supplied by 
Pharmacia Ltd. Wacker silicone was provided by 
Wacker-Chemical Company, Munich. Repelcote (2% solution of 
dimethyldichlorosilane in 1, 1, 1,- trichloroethane) was 
supplied by Hopkin and Williams, England. Avidin 
biotinylated horseradish peroxidase complex (ABC) was 
obtained from Vector Laboratories USA. DNA blotting 
membrane (Hybond^) was purchased from Amersham International
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pic. Other chemicals were supplied by BDH Chemicals UK or 
Sigma Chemicals Company and were of analytical grade.
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METHODS
2.1 Growth of cells
BHK-21 C13 cells were grown in 80 oz roller bottles 
containing 100ml ETC10 at 37°C in an atmosphere of 5% CO2 in 
air. Confluent cells were harvested by washing twice with 
versene and once with trypsin-versene and resuspended in 
20ml ETC10. The cells from one roller bottle (3xl08) are 
enough to seed 10 bottles (2x10^). 3T3 cells were grown in
a similar way using DMEM10 and were split 1 in 3.
2.2 Cell storage
Cells were harvested as described in section 2-1, 
pelleted and resuspended in ETC10 (for BHK-21 C13 cells) or
DMEM10 (for 3T3 cells) containing 10% (v/v) DMSO. Cells
were aliquoted into black cap vials at a concentration of 
10^/ml and frozen slowly to -140°C. Cells were recovered by 
thawing quickly and resuspended in ETC10 or DMEM10.
2.3 Growth of virus stocks
Virus stocks were propagated in BHK-21 C13 cells grown 
in 80 oz roller bottles. The growth medium was removed and 
the cells were infected at a multiplicity of infection (moi) 
of 0.003 plaque forming units (pfu) per cell, in 20ml ETC5. 
After 3-4 days incubation at 31°C, when extensive cytopathic 
effect (cpe) had developed, the cells were shaken into the 
medium and pelleted at 2000 rpm for 10 min at 4°C in a 
Fison's Coolspin centrifuge. The pellet was resuspended in 
5ml of supernatant medium, sonicated in a bath sonicator 
(50W at 4°C) and centrifuged as before. The cell debris 
pellet was discarded and the supernatant was the cell
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associated virus stock. The original supernatant from the 
2000 rpm spin was centrifuged at 12000 rpm for 2 h at 4°C in 
a Sorval GSA rotor and the pellet resuspended in 5ml of the 
supernatant was sonicated. This was termed supernatant 
virus. Virus stocks were aliquoted in 1ml volumes and 
stored at -70 C. Stocks were checked for sterility and 
titrated at 37°C or 31°C.
2.4 Sterility checks on virus and cell stocks
Cell or virus stocks were checked for bacterial 
contamination by streaking on blood agar plates in duplicate 
and incubating at 37°C and 31°C for 5 days. The cell and 
virus stocks were considered sterile if no contamination was 
detected on the plates.
2.5 Titration of virus stocks
Serial ten-fold dilutions of virus stocks were made in 
PBS/calf serum and 0.1ml of each dilution was added to 80% 
confluent BHK-21 C13 cells in 50mm petri-dishes from which 
the growth medium had been removed. After absorption at 
37°C for 1 h, monolayers were overlaid with 4ml of EHu5 or 
EMC5 and incubated at 37°C for 2 days or 31°C for 3 days. 
Monolayers were fixed and stained with Giemsa at room 
temperature (RT) for 30 min and plaques were counted using a 
dissecting microscope.
2.6 Preparation of virion DNA (HSV)
Virion DNA was prepared as described by Wilkie (1973) 
and Stow and Wilkie (1976). Virus infected BHK-21 C13 cells 
in 80 oz roller bottles (section 2.3) were harvested after 
exhibiting extensive cpe and pelleted at 2000 rpm for 10 min
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in a Fison s Coolspin centrifuge. The supernatant was kept 
on ice and the cell pellet resuspended in RSB (lOmM KCl, 
1.5mM MgC^* lOmM Tris-HCl pH 7.5) containing 0.5% (v/v) 
Nonidet P40 (NP40), was incubated on ice for 10 min and 
centrifuged at 2000 rpm for 3 min to remove the nuclei and 
cell debris. The pellet from this step was resuspended in 
RSB/NP40 and treated as above. The two cytoplasmic 
supernatants were pooled with the clarified virus infected 
cells medium and centrifuged at 12000 rpm in a Sorval GSA 
rotor for 2 h at 4°C. The virus pellet was resuspended by 
sonication in 8ml of NTE (lOmM Tris-HCl pH 7.5, lOmM NaCl, 
ImM EDTA) and lysed by addition of SDS and EDTA to a final 
concentration of 2% (w/v) and lOmM respectively. Virus DNA 
was gently extracted twice with an equal volume of saturated 
phenol and once with chloroform : isoamyl alcohol (24 : 1 
v/v) and precipitated by the addition of two volumes of 
ethanol. The DNA was pelleted at 2000 rpm for 10 min, dried 
in a vacuum desiccator and redissolved in water containing 
50 ug/ml RNase A. The DNA was quantitated by agarose gel 
electrophoresis using a standard DNA of known concentration.
2.7 Virus particle counts
An aliquot of a virus stock was mixed with an equal 
volume of latex beads and the same volume of phosphotungstic 
acid. A sample was spotted on a parlodium grid, air dried 
and visualised under the electron microscope. The number of 
virus particles and latex beads was counted and the 
concentration of particles in the virus stock calculated.
2.8 Purification of single plaque isolates
Virus stocks were titrated as described (section 2.5)
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and cell monolayers with the fewest plaques (5-10 plaques) 
were washed twice with PBS/calf serum. Individual separated 
plaques were picked into 500ul PBS/calf serum, sonicated and 
stored at -70°C. To grow a plate stock, a BHK-21 C13 
monolayer was infected with lOOul of the plaque solution and 
incubated at 37 C until the cpe was complete. The monolayer 
was harvested using rubber policemen, sonicated and stored 
at -70 C. Individual plaques were purified an additional 
three times prior to further analysis. To passage the 
plaque stocks, BHK-21 C13 monolayers in 50mm petri-dishes 
were inoculated at low moi and incubated at 37°C. Cells 
were harvested, sonicated and released virus stored at 
-70°C.
2.9 Virus growth properties in vitro
One step growth experiments were carried out as 
described by Brown and Harland (1987). Confluent 3T3 or 
BHK-21 C13 cells in 35mm petri-dishes were infected at a moi 
of 5 pfu/cell and incubated at 37°C or 38.5°C for 1 h.
Cells were washed twice with PBS/calf serum, overlaid with 
2ml of ETC5 and incubated at 37°C or 38.5°C. Samples were 
harvested at 0, 2, 4, 6, 8, 12, and 24 h post infection, 
sonicated and virus yields titrated on BHK-21 C13 cells at 
37°C.
In multi-step growth experiments, cells were infected at 
a moi of 0.002 pfu/cell. At 0, 24, 48, 72, and 96 h post 
Infection, cells were harvested, sonicated and titrated as 
before. Twenty four hour yield experiments were carried cut 
by infecting cells at a moi of 5 pfu/cell. Cells were 
harvested after 24 h and virus titrated as above.
66
j_yiP Virus growth properties in vivo
Virus growth experiments in vivo were carried out 
essentially as described by Thompson et al. (1983). Virus
stocks (10 pfu/mouse) were inoculated into the left 
cerebral hemisphere of 3 week old BALB/c mice of both sexes 
(section 2.11). At 0, 12, 24, 48, 72, 96, 120, and 144 h 
post infection, two surviving mice from each time point 
were sacrificed and their brains were removed aseptically 
and homogenised in 1ml PBS/calf serum using a Dounce 
homogeniser (Quick Fit, England). 0.2ml of the resulting
suspension was titrated for infectious virus on BHK-21 C13 
cells at 37°C as described (section 2.5).
2.11 Animal inoculation
Three week old BALB/c mice of both sexes were used.
Mice were anaesthetised with ether and 0.025ml of the
appropriate virus dilution in PBS/calf was inoculated into
the central region of the left cerebral hemisphere. Groups
of four to eight mice were inoculated with a single dilution
2 7of each virus stock (between 10 -10 pfu/animal). The virus
stocks were always retitrated on BHK-21 C13 cells on the day
of inoculation to determine the precise quantity of virus
inoculated. Mice were observed daily for 21 days after
inoculation and their clinical states recorded. The 50%
lethal dose value (LD,_q ) was calculated according to the
formula of Reed and Muench (1938) on the basis of deaths
between day 3 and 21. Using the intraperitoneal or footpad
routes, mice were inoculated with 0.1ml of appropriate virus
dilutions and the LDcr. calculated as before.
5U
2.12 Preparation and isolation of ^P-labelled virus DNA
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This method is a modification of that described by
Lonsdale (1979). BHK-21 C13 cells, in linbro wells in PIC
medium, were infected at a moi of 10 pfu/cell. After 1 h
absorption at 37°C, the virus was removed and the cells
washed with and maintained in PIC for 2 h at 31°C. Fifty 
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uCi of P-orthophosphate was added per well and incubation
continued for a further 48 h at 31°C. Cells were lysed by 
addition of SDS at a final concentration of 2.5% (v/v) and 
incubated at 37°C for 10 min. DNA was extracted once
with an equal volume of saturated phenol and precipitated 
with two volumes of ethanol. The DNA was dried at 37°C for 
10 min and redissolved in 200ul water. 20ul was digested 
with appropriate restriction enzymes and run on agarose gels 
(0.5%-1.2%) for 24 h at 40V. Gels were air dried and 
autoradiographed using Kodak XS-1 film.
2.13 Thymidine kinase assay
The method used was a modification of that of Jamieson 
and Subak-Sharpe (1974). BHK-21 C13 cells in 35mm 
petri-dishes were infected at a moi of 20 pfu/cell. After 
absorption for 1 h at 37°C, cells were overlaid with 2ml of 
ETC5 and incubated for 6 h at 37°C. Cells were washed twice 
with cold PBS, scraped into 1ml cold PBS and pelleted in a 
microfuge for 2 min. The pellet was resuspended in 150ul 
ice cold lysis buffer (20mM Tris-HCl pH 7.5, 2mM MgCl2, lOmM 
NaCl, 0.5% (v/v) NP40, 6.5mM 2-mercaptoethanol), maintained 
on ice for 5 min, mixed briefly and placed on ice for a 
further 5 min. The samples were centrifuged and the 
supernatant retained and stored at —70 C. 5ul of extract 
was mixed with the reaction buffer in a total volume of 50ul 
(0.5M Na2P04 pH 6.0, lOOmM MgCl2, 2mM dTTp, lOOmM ATP, 5ul
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aqueous [Me- H] thymidine 1 mCi/ml). After incubation for 1 
h at 30 C, the reaction was stopped by the addition of EDTA 
and thymidine at a final concentration of 20mM and ImM 
respectively. The samples were heated for 3 min at 100°C 
and placed on ice for 3 min. After centrifugation, 40ul of 
the supernatant was spotted onto DE81 discs and washed three 
times (10 min each at 37°C) with 4mM ammonium formate pH 6.0 
and lOuM thymidine. After a further two washes with 
ethanol, the discs were dried and radioactivity due to [ H] 
thymidine was determined using a scintillation counter.
2.14 Preparation and analysis of HSV infected cell 
polypeptides
The method was essentially that described by Marsden <et 
al. (1976). Confluent BHK-21 C13 cells in 35mm petri-dishes
were infected at a moi of 20 pfu/cell. After absorption for 
1 h at 37°C, the monolayers were washed twice with Eagle's 
medium containing 20% the normal concentration of methionine 
and 2% calf serum (Emet/5C2) and the same medium was used to 
overlay the monolayers. After 4 h incubation at 37°C, 100 
uCi/plate of S-methionine was added and incubation 
continued at 37°C for 24 h. Samples were washed twice with 
PBS, harvested into 500ul sample buffer (150mM Tris-HCl pH
6.7, 6.28% (w/v) SDS, 0.15% (v/v) 2-mercaptoethanol, 0.31% 
(v/v) glycerol, 0.1% (w/v) bromophenol blue) and after 
boiling for 5—10 min, were analysed by SDS—PAGE (described 
in section 2.15).
2.15 Sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE)
Two glass plates separated by a 1.5mm thickness perspex
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spacer, were cast vertically and sealed with teflon tape.
Two types of resolving gels were used (i) single 
concentration gels containing the appropriate amount of 
acrylamide cross-linked with 2.5% (w/w) N, N'-methylene 
bisacrylamide in resolving gel buffer (375mM Tris-HCl pH 
8.9, 0.1% (w/v) SDS) and (ii) gradient gels containing 
5%-12.5% gradient acrylamide cross-linked with 5% (w/w) N, 
N'-methylene bisacrylamide in resolving gel buffer. Ammonium 
persulphate (APS) and N, N, N', N '-tetramethylethylene- 
diamine (TEMED) were added to a final concentration of 
0.006% (w/v) and 0.004% (v/v) respectively prior to pouring. 
After polymerisation, gels were overlaid with butan-2-ol to 
get a smooth top surface which was then washed off with 
deionized water. The stacking gels contained 5% acrylamide 
(cross-linked with the same ratio of N, N'-methylene 
bisacrylamide used in resolving gel) in stacking gel buffer 
(O.llmM Tris-HCl pH 6.7, 0.1% (w/v) SDS). APS and TEMED 
were added to the stacking gel solutions as above and a 
teflon coated comb was inserted prior to pouring. Samples 
were boiled for 5-10 min in sample buffer, loaded and 
electrophoresed in tank buffer (52mM Tris, 53mM glycine,
0.1% (w/v) SDS) at 60mA for 3-4 h (Marsden et al., 1976, 
1978). Gels were fixed, stained for 1 h by shaking in 
methanol : water : acetic acid 50 : 43 : 7 in the presence 
of 0.2% (w/v) Coomassie Brilliant Blue R250. Gels were 
destained for 1—2 h in methanol : water : acetic acid 5 . 88 
: 7, dried under vacuum and exposed for autoradiography at
RT.
2.16 Agarose gel electrophoresis
Agarose gels tO.5%-1.2%) were prepared in 250ml IX TBE
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buffer (89mM Tris, 89mM boric acid, 2mM EDTA). The 
solutions were poured onto glass plates (125cm x 85cm) in 
which (12-15) tooth combs were placed. After setting, gels 
were transferred to horizontal tanks containing IX TBE. In 
the case of non-radioactive samples, TBE contained 5 ug/ml 
ethidium bromide. Gels were elecrophoresed at 50V 
overnight.
2.17 Restriction enzyme digestion
Viral DNA was digested with appropriate restriction 
enzymes (2-5 units/ug DNA), in the presence of IX 
recommended buffer, in a final volume of 40ul and incubated 
at 37°C for 2-16 h. The reaction was stopped by the 
addition of 20% restriction enzyme stop solution (RE stop)
(5X TBE, lOOmM EDTA, 10% (w/v) Ficoll, 0.1% (w/v) 
bromophenol blue) prior to electrophoresis (Maniatis et al., 
1982) .
2.18 Elution of DNA fragments from agarose gels
The DNA was digested with appropriate restriction 
enzymes and electrophoresed on agarose gels in the presence 
of 5 ug/ml ethidium bromide. The gel was visualised under 
long wave UV light and the appropriate fragment cut out 
using a sharp scalpel. The isolated gel slice was placed in 
an electrophoresis chamber containing 0.IX TBE. The DNA was 
electroeluted from the agarose gel onto the dialysis 
membrane of the electrophoresis chamber (preboiled in 0.IX 
TBE for 10 min) at 200V for 1 h. The DNA was collected, 
extracted with phenol : chloroform (1 : 1) and precipitated 
at -20°C with one volume isopropyl alcohol and 0.1 volume 
sodium acetate. DNA was washed with 70% ethanol, dried in a
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vacuum desiccator and redissolved in water.
2.19 Transfection of viral DNA by calcium phosphate 
precipi tation
Transfection was performed as described by Stow and 
Wilkie (1976). Calcium chloride (final concentration 130mM) 
was added to a solution containing 0.2-lug DNA and 10 ug/ml 
calf thymus carrier DNA in HEBS buffer pH 7.05 (130mM NaCl,
4 . 9mM KCl, 1.6mM Na2HP0^, 5.5mM D-glucosef 21mM Hepes). The 
samples were left for 5 min at RT to allow a fine suspension 
to develop. This suspension was added to drained 80% 
confluent BHK-21 C13 cells in 50mm petri-dishes. After 
incubation at 37°C for 45 min, cells were overlaid with 
ETC5. At 4 h post infection, cells were treated with 25% 
(v/v) DMSO in HEBS buffer for 4 min at RT. DMSO was then 
removed from monolayers by washing the cells twice with ETC5 
after which incubation was continued at 37°C for 3-4 days 
until extensive cpe had developped. The cells were scraped 
into the medium, disrupted by sonication and stored at 
-70°C. The transfected plate stocks were titrated and 
single plaques isolated for further analysis as described 
before (section 2.8). For correction of the genomic 
deletion in the variants, wild type fragments spanning the 
deletion were added to the transfection mixture at a 5, 10, 
and 20 fold molar excess over the intact deletion variant 
genomes. When the cpe was complete, cells were harvested as 
described above. To introduce the deletion into the HG52 
wild type genome, the fragments containing the deletion were 
added at 5, 10, and 20 fold molar excess with the intact 
wild type genomes.
72
2.20 Transfection and in vivo selection
The transfection procedure was described in section 2.19 
and the method of in vivo selection used was a modification 
of that described by Thompson et al. (1983). Serial ten 
fold dilutions of transfected plate stocks were made in 
PBS/calf serum, and 0.025ml of each dilution was inoculated 
intracranially into the left cerebral hemisphere of 3 week 
old BALB/c mice (usually two mice per dilution). Mice were 
observed daily and those which died from encephalitis were 
dissected and their brains removed and homogenised in 1ml 
PBS/calf serum. For virus isolation, 0.2ml of the brain 
homogenate was inoculated onto BHK-21 C13 cells in 50mm 
petri-dishes at 37°C. Cells were harvested after extensive 
cpe had developed and the virus isolates were plaque 
purified three times (section 2.8) prior to further 
analysi s.
2.21 Glycerol stocks of bacteria
Bacterial stocks were prepared from 10ml standing 
cultures grown overnight at 37°C in L-broth containing 
ampicillin (100 ug/ml). The bacterial stocks were pelleted
at 5000 rpm for 5 min at 4°C and pellets were resuspended in
L-broth containing 50% (v/v) glycerol.
2.22 Construction of recombinant plasmids
Linearised plasmid vector pATl53 (Twigg and Sherratt, 
1980) was treated with calf intestinal phosphatase at a 
concentration of 5 units/ug plasmid DNA. After incubation 
at 37°c for 1 h , the DNA was extracted twice with phenol :
chloroform (1 : 1), once with chloroform and precipitated
with two volumes of ethanol in the presence of 0.1 volume 3M
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sodium acetate. The DNA pellet was washed with 70% ethanol, 
dried and resuspended in an appropriate amount of water to 
give 40 ng/ul. A 3—4 times molar excess of the purified HSV 
DNA fragment relative to the phosophatase treated vector 
(40ng) was ligated overnight at 15°C in a 20ul ligation 
reaction containing 2 units of T4 DNA ligase and IX ligase 
buffer (lOmM Tris-HCl pH 7.5, lOmM MgCl2, lOmM DTT, ImM 
ATP) .
2.23 Transformation of bacterial cells with plasmid DNA
This procedure was based on the method described by
Cohen et al. (1972). Host bacterial cells, E. coli strain
DH5 (Hanahan, 1985) were grown to an optical density at 630 
(OD^ q ) of 0.3 and pelleted by centrifugation at 8000 rpm 
for 10 min at 4°C in a Sorval SS34 rotor. The pellet was 
resuspended in a half volume of ice cold 50mM CaCl^ and 
incubated on ice for 20 min. The cells were repelleted and 
resuspended in a tenth volume of ice cold 50mM CaCl2*
Plasmid DNA (20-100ng) was incubated with CaCl2 shocked 
cells on ice for 1 h. The cells were heat shocked at 42°C 
for 2 min and transferred to 1ml L-broth grown with shaking 
at 37°C in an orbital shaker for 1 h. lOOul of each sample 
were spread on L-broth agar plates containing 100 ug/ml 
ampicillin and incubated overnight at 37°C. Single 
bacterial colonies were picked from the plates and analysed 
(section 2.24) .
2.24 Small scale isolation of plasmid DNA
Bacteria from a single colony were grown overnight in an 
orbital shaker at 37°C in 1.5ml L-broth containing 100 ug/ml 
ampicillin. The cells were pelleted at 10000 rpm for 2 h in
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a microfuge and resuspended in 350ul STET buffer (8% (w/v) 
sucrose, 0.5% Triton X-100, 50mM EDTA pH 8.0, lOmM Tris-HCl 
pH 8.0) and 25ul of lysozyme (10 mg/ml) was added (Holmes 
and Quigley, 1981). This mixture was boiled for 1 min and 
centrifuged at 10000 rpm for 10 min. The supernatant 
containing the plasmid DNA was precipitated with an equal 
volume of isopropyl alcohol and 0.1 volume of 3M sodium 
acetate on ice for 15 min and subsequently pelleted at 10000 
rpm for 5 min. The DNA pellet was washed with 70% ethanol, 
dried in a vacuum desiccator and redissolved in water 
containing 10 ug/ml RNase A.
2.25 Large scale isolation of plasmid DNA
The method is basically that described by Birnboim and 
Doly (1979) as modified by Maniatis et al. (1982). Single
bacterial colonies from L-broth agar plates or 25ul from 
bacterial glycerol stocks were inoculated into 10ml L-broth 
containing 100 ug/ml ampicillin and incubated at 37°C 
overnight in an orbital shaker. 2ml of the overnight 
culture was inoculated into 350ml L-broth and shaken 
overnight at 37°C. The bacteria were pelleted at 5000 rpm 
for 15 min at 4°C in Sorval a GSA rotor. The culture 
pellet was resuspended in 6ml of freshly prepared (25mM 
Tris-HCl pH 8.0, lOmM EDTA, 15% (w/v) sucrose, 2 mg/ml 
lysozyme) and incubated on ice for 20 min. 12ml of freshly 
made 0.2M NaOH, 1% SDS (w/v) was added and incubation 
continued on ice for 10 min. Ice cold 3M sodium acetate pH
4.6 was added and incubation continued on ice for 20 min. 
The cell debris was pelleted at 15000 rpm for 15 min in a 
Sorval SS34 rotor at 4°C and RNase A was added to the 
supernatant at a final concentration of 50 ug/ml. After
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incubation at 37 C for 20 min, DNA was extracted twice with 
an equal volume of phenol : chloroform (1 : 1 v/v), once 
with an equal volume of chloroform and precipitated by the 
addition of 2 volumes of ethanol overnight at -20°C. The
DNA pellet was washed with 70% ethanol, dried in a vacuum
desiccator and resuspended in water. The DNA was
quantitated by comparing to a known standard.
2.26 Transfer of DNA fragments to nitrocellulose
The procedure followed was that of Southern (1975). The 
agarose gel containing the separated DNA fragments was 
placed in gel soak I (200mM NaOH, 600mM NaCl) for 1 h to 
denature the DNA and neutralised in gel soak II (1M Tris-HCl 
pH 8.0, 0.59M NaCl) for 1 h. The gel was then transferred 
onto sheets of Whatman 3mm filter paper presoaked in 10X SSC 
(IX SSC is 15mM trisodium citrate, 150mM NaCl). A sheet of 
Hybond blotting membrane, cut to the exact size of the gel, 
was placed on top of the gel followed by a similar sized 
sheet of Whatman 3mm filter paper wetted with blotting 
buffer. A stack of absorbant paper towels was placed onto 
the Whatman filter paper and finally a weight was placed on 
top. After 12-24 h, the Hybond blotting membrane was air 
dried and UV cross-linked for 2-5 min at a wave length of 
312nm (the DNA side down on a transilluminator).
2.27 Hybridisation procedure
The Hybond blotting membrane was prehybridised at 75 C 
for a minimum of 2 h in a sealed plastic bag containing 
hybridisation buffer [6X SSC, 6X Denhardt's bufferUX 
Denhardt's is 0.02% polyvinyl-pyrrolidone, 0.02% Ficoll),
0.1 mg/ml salmon sperm DNA, lOmM Tris-HCl pH 7.5]. The
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solution was replaced by fresh hybridisation buffer 
containing nick translated P-labelled DNA (see section 
2.28) and hybridisation was allowed to proceed for 48 h at 
75 C. The Hybond blotting membrane was removed and washed 3 
times, each for 45 min, at 60°C in washing buffer (2X SSC, 
0.1% (w/v) SDS, 5mM Na^HPO^ pH 7.0). The membrane was air 
dried and placed in contact with Kodak XS-1 film at RT.
3 22.28 In vitro ' P-labelling of DNA by nick translation
The method was as described by Rigby et al. (1977). DNA 
(0.5ug) to be used as a probe was labelled in a reaction 
containing 2 units of DNA polymerase I, 50mM Tris-HCl pH
7.8, 5mM MgC^r 10mM dTT, 10  ^ mg/ml DNase, 10 ug/ml BSA, 
2uCi [oc—32p ] dCTP, 2uCi [oc-32p ] dGTP , 0 . 2mM dATP and 0 . 2mM 
dTTP in a final volume of 30ul. Nick translation was
carried out at 15°C for 2 h. The DNA was precipitated on
dry ice for 15 min with 0.6 volume of isopropyl alcohol and
0.1 volume of 3M sodium acetate. The DNA pellet was
resuspended in 30ul water and reprecipitated with isopropyl 
alcohol and sodium acetate. The resultant pellet was 
redissolved in lOul water and 80% formamide and denatured by 
boiling at 100°C for 5 min.
2.29 Construction of recombinant Ml3
The double stranded replicative form (RE) of 
bacteriophage M13 mpl8 and mpl9 (Norrander 6t al., 1983) was 
prepared as for plasmids (section 2.25) . The fragments were 
prepared for insertion into M13 by digestion of pATl53 
containing the inserts with HincII-XhoI. The fragments were 
eluted from the gel as described (section 2.18). The vector 
was linearised with Smal-Sall and 40ng was incubated with a
77
120-160ng of the DNA insert with 2 units of T4 DNA ligase in 
ligase buffer (see section 2.22) for 24 h at 15°C (Sanger et 
al., 1980).
2.30 Transfection of bacterial cells with M13
E- coli strain JM101 (Messing, 1979) were grown in 2X YT 
broth to an OD^^q of 0.3 and calcium shocked as described 
(section 2.23). The ligation mixture was added to 0.2ml 
aliquots of the calcium shocked cells and incubated on ice 
for 1 h. The sample was heated to 42°C for 5 min and 0.2ml 
of an overnight standing culture of E. coli strain JM101 was 
added. 3ml of melted top agar at 42°C containing 20ul of 
2.5% isopropyl-D-thiogalactoside (IPTG) and 25ul of 2% 
5-chloro-4-bromo-3-indolyl-£-D-galactoside (BCIG) in 
dimethyl formamide was added to the sample and the mixture 
poured onto 90mm L-broth agar plates and incubated at 37°C 
overnight.
2.31 Growth and extraction of recombinant M13 clones
An overnight standing culture of E. coli strain JM101 
was used to inoculate 2X YT broth (1 : 100). This was 
dispensed in 1.5ml aliquots into 25ml universal bottles.
The recombinant M13 clones (colourless) plaques were tooth 
picked from the plates into the broth and incubated at 37°C 
for 5-6 h with shaking. The solution was then transferred 
to an eppendorf tube and centrifuged at 10000 rpm for 5 min 
in a microfuge to pellet the bacteria. The supernatant 
(0.8ml) was transferred to another eppendorf tube and the 
phage was precipitated by addition of 200ul of 20% 
polyethylene glycol (PEG Mr 6000) in 2.5M NaCl for 30 min at 
RT. After centrifugation at 10000 rpm for 5 min, the
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supernatant was removed. Following a brief centrifugation, 
any remaining supernatant was removed with a glass capillary 
tube. The phage pellet was resuspended in lOOul TE and 
extracted with 50ul phenol equilibrated with TE and 
precipitated by the addition of 2 volumes of ethanol and 0.1 
volume 3M sodium acetate. The phage DNA was pelleted by 
centrifugation at 10000 rpm for 5 min, washed with 70% 
ethanol, dried thoroughly in a vacuum desiccator, 
redissolved in 50ul TE and stored at -70°C (Sanger et al. , 
1980) .
2.32 Sequence analysis of recombinant M13 clones
Sequence analysis was carried out using the
dideoxynucleotide chain termination method of Sanger et al.
(1977) . The single stranded DNA template (2ul) was annealed
to 2.5ng of M13 single stranded primer in the presence of
annealing buffer (lOmM Tris-HCl pH 8.5, lOmM MgCl^) in a
volume of lOul at 37°C for 30 min. To the annealed DNA, 2
units of Klenow DNA polymerase I was added and the mixture
aliquoted in 2ul fractions into four wells of a U-bottomed
microtiter plate corresponding to the specific T, C, G and A
reactions of each clone. An equal volume of the nucleotide
mixture containing dNTP's and specific ddNTP's (see Table
322.1), lul of 11. 8uM dATP, 0.3uCi [°c- P] dATP was added to 
each well and the reaction allowed to proceed for 15 min at 
RT. The reaction was chased by the addition of 2ul chase 
solution (0.5mM uniform mixture of all four dNTP's) and
incubation was continued for 30 min at RT. The reaction was
stopped by the addition of 2ul formyl dye mixture (0.1% 
bromophenol blue (w/v), 0.1% xylene cyanol (w/v) in 
deionised formamide). The plate was heated for 1 min at
Table 2.1. Nucleotide concentration in DNA sequencing 
reaction
Sequencing solutions dG-0 dA-0 dT-0 dC-0
dNTP's concentration 
( 5mM)
dTTP 2 0 1 2 0 2 0
dCTP 2 0 2 0 1 2 0
7-deaza dGTP 20 20 20 1
10X TE 50 50 50 50
H20 540 370 370 370
Sequencing mix dN-0 mix ddNTP1s H20
T-sequence 250 250 (600uM ddTTP) 0
C-sequence 250 57.5 (140uM ddCTP) 197.5
G-sequence 250 77.5 (200uM ddGTP) 172.5
A-sequence 250 62.5 (140uM ddATP) 187.5
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100°C and electrophoresis was carried out through 
polyacrylamide gels.
 ^ ^^ Electrophoresis and autoradiography of sequencing gels
Vertical plates 40 x 20 x 0.03cm in size were used and 
spacer, gel combs were cut from plasticard. The notched 
plate was treated with repelcote. The plain plate was 
treated with 0.5% (v/v) Wacker silicone in 0.3% (v/v) acetic 
acid and ethanol (Garoff and Ansorge, 1981), which bonds the 
acrylamide to the plate. Generally, electrophoresis was 
carried out through 6% acrylamide gels. In this system the 
top mix used was 0.5X TBE, 6% acrylamide (electran grade),
9M urea (McGeoch et al., 1986). APS and TEMED were added to 
the top mix to a final concentration of 0.016% (w/v) and 
0.16% (w/v) respectively, the contents were poured, the gel 
comb was inserted and the gel rested in a nearly horizontal 
position until polymerisation was complete. The tape was 
removed from the bottom of the gel and the plates set with 
0.5X TBE in both the top and bottom tank of the gel kit. 
Before loading the DNA samples, gel wells were flushed with 
0. 5X TBE and the gel was run at a constant power of 40W for 
2 h. After electrophoresis, the plates were dismantled and 
the gel, bonded to the plain plate, immersed in a 10% acetic 
acid bath for 30 min to fix the DNA and remove the urea from 
the gel. The gel was dried down on the plate in an oven at 
125°C for 1-2 h and exposed against Kodak XS-1 film at RT.
2.3 4 Accumulation and handling of the sequence—data
DNA sequence data was handled and interpreted using the 
Institute oE Virology's VAX/VMS computer running the GCG 
soft ware (Devereux et al., 1984). The gel readings were
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read and typed into the account using the EDIT programme 
which stores data from gel readings under a chosen file 
name. The data was converted into GCG sequences using the 
FROMSTADEN programme. The gel readings were compared 
against each other using the programme BESTFIT to determine 
overlapping. The gel readings were aligned and compared 
against known sequences currently held using the BESTFIT and 
GAP programmes.
2.35 Tissue preparation for histopathology
Infected brains from dissected mice were removed and 
fixed in 10% formal buffered saline. The brain tissues were 
cut into blocks, dehydrated in a graded series of ethanol 
(50%, 70%, 90% and 100%) and embedded in paraffin wax. 
Several sections (6-7 microns thick) from each block were 
cut, mounted, baked for 24 h at 37°C followed by 30-60 min 
at 60°C and stained with either haematoxylin and eosin (H & 
E) or by immunoperoxidase staining.
2.36 Immunohistochemistry
The method used was essentially that described by 
Kennedy et al. (1985). Paraffin embedded sections were 
deparaffinised and dehydrated through xylene (two times, 30 
min each) and graded ethanol series (50%, 70%, 90% and 100%,
5 min each) respectively. Sections were washed for 10 min 
in PBS and incubated for 30 min with 0.3% hydrogen peroxide 
in methanol to stop the endogenous peroxidase activity. 
Following washing twice with PBS (10 min each), sections 
were incubated with blocking serum (3% normal goat serum in 
PBS) for 30 min. The excess of blocking serum was washed 
off and sections were incubated for 30 min with primary
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antibody (polyvalent rabbit antiserum to HSV) diluted 1:100 
in PBS. Sections were washed twice with PBS and incubated 
with secondary antibody (biotinylated anti-rabbit IgG) 
diluted 1:100 in PBS for 30 min. After washing twice with 
PBS, sections were incubated with avidin biotinylated 
horseradish peroxidase complex (ABC) for 30 min. 
Visualisation of the reaction was carried out using 3, 3'- 
diaminobenzidine tetrahydrochloride (0.5 mg/ml in PBS) 
containing 0.03% hydrogen peroxide for 5 min until the 
colour developed. Sections were washed with tap water, 
counterstained in haematoxylin for 30-60 seconds, dehydrated 
as before, mounted and examined under the light microscope.
CHAPTER
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RESULTS
— -^*---^ -enc:e variation within the elite laboratory stock of 
HSV-2 strain HG52
3.1.1 Introduction
HSV is a neurotropic virus that spreads centripetally in 
the nervous system from the primary site of infection (Cook 
and Stevens, 1973). In humans, invasion of the nervous 
system frequently leads to a latent infection in sensory 
ganglia, and in rare instances fatal encephalitis (Baringer 
and Swoveland, 1973; Fenner et al., 1974; Johnson, 1982).
The virus-host interaction is highly complex and influenced 
by the genotype of both virus and host. As direct study of 
HSV virulence in humans under experimental conditions is 
impossible, various animal model systems have been used. 
Previous work with animals has shown that most HSV strains, 
following different routes of inoculation, have the capacity 
to cause encephalitis and ultimately death. However, some 
isolates fail to kill the animals (Richards et al., 1981;
Dix et al., 1983; Sedarati and Stevens, 1987 ).
Heterogeneity of individual virus strains in functions 
required for replication of virus at the periphery and/or 
for spread to the central nervous system may be the cause of 
such differences. These functions might influence the 
pathogenesis of HSV at a variety of points; replication at 
the peripheral site, neural entry, spread within the nervous 
system and escape from immunological control. Though the 
intracranial route of inoculation may be criticised for 
being artificial, it has the clear advantage of bypassing 
many of the steps identified above as possibly subject to 
variation.
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HSV-2 strains are normally more virulent than those of 
HSV-1 when inoculated intragenitally, intraperitoneally or 
intracranially into experimental animals (Plummer et al., 
1968 f McKendall, 1980; Richards et al., 1981; Scriba and 
Tatzber, 1981). However the HSV-2 strain HG52 is less 
virulent than several other HSV-2 strains (Thompson and 
Stevens, 1983a). It has been shown that the elite stock of 
HG52 contains variants with detectable deletions in the 
genome at a fequency of 24% (Harland and Brown, 1985). It 
should be emphasised that HSV-2 strain HG52 is not unique in 
this respect, genomic variation having also been observed in 
other laboratory strains e.g HSV-2 strain 168 (Esparaza et 
al., 1974; J. Harland, personal communication).
3.1.2 Isolation of single plaque stocks
In order to determine the basis for variation in 
neurovirulence we have evaluated the neurovirulence of 
single plaque stocks picked from HG52. The elite stock of 
HG52 was derived from an initial single plaque from a 
patient isolate which was plaque purified three times before 
being inoculated into a 20 oz bottle and finally two rounds 
of growth in 20 burrlers - all in BHK-21 C13 cells (Timbury, 
1971). This elite laboratory stock of HSV-2 strain HG52 was 
plated out on BHK-21 C13 cells and twenty well separated 
plaques were picked at random from plates containing no more 
than 20 plaques. The virus had been grown in the presence 
of 5% human serum to neutralise released virus and to 
prevent the spread of plaques. The medium containing human 
serum was washed off thoroughly before picking plaques. The 
virus from each plaque was passaged twice at 37 C in BHK 21 
C13 cells (see method section 2.8), to increase the titre
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before immediately growing a large scale stock at 31°c (see 
method section 2.3) . All the plaque stocks were of a 
typical HSV-2 mixed syncytial/non-syncytial morphology. At 
each passage the DNA from each of the twenty virus stocks 
was subjected to restriction endonuclease digestion using 
the enzymes Xbal, Bglll, EcoRI, Hindlll, Hpal and BamHI (see 
method section 2.17). The results showed no apparent 
differences in the sizes of fragments and distribution of 
sites in the DNA of the twenty plaque stocks. The BamHI 
profiles of four independent plaque stocks are shown in 
Figure 3.1 as representative examples. The BamHI and z 
bands which differed in size in individual plaque stocks are 
located in the joint and repeat regions of the genome and 
are known variable fragments (Davison and Wilkie, 1981).
3.1.3 Neurovirulence of single plaque stocks
To determine the neurovirulence of the individual plaque
stocks, ten were selected at random for mice inoculation.
Groups of six to eight 3 week old BALB/c mice were
3 4 5inoculated with either 10 , 10 or 10 pfu/mouse of each of
the plaque stocks intracranially (0.025ml of virus) into the
left cerebral hemisphere after anaesthetising (see method
section 2.11). In this series of experiments no mice died
before day three following inoculation. The 50% lethal dose
(LDcn) was calculated on the basis of deaths between days 3 
5 0
and 21 according to the formula of Reed and Muench (1938).
The LDCn values of the plaque stocks are shown in Table 3.1. 
50
The stocks were assigned to one of three classes of
neurovirulence depending on the LD^q values. Claso I of
high virulence (LDj-q <10  ^ pfu/mouse) contains plaque stocks
3 4
17 and 14. Class II of intermediate virulence (LD5Q 10
Figure 3.1
Autoradiographs of BamHI digests of viral DNA
32 . .P-labelled m  vivo (1.2% agarose) of plaque purified
stocks of HG52 (from left to right, 8, 12, 11 and 14). 
Letters refere to specific fragments.
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Table 3.1. LD5q values after intracranial inoculation of 
plaque purified stocks of HG52
Plaque number Particle : pfu LD50 (pfu/mouse)
1 24 : 1
4
4x10
2 10 : 1
4
7x10
3 50 : 1
4
2x10
4 294 : 1 1.5x10
7 235 : 1 1 .5x10
8 14 : 1 3xl05
11 281 : 1 1.5x10
12 168 : 1
o■—i
14 9 : 1 < i o 3
17 6 : 1 <103
3 week old BALB/c mice were used (6 mice/dose). 
0.025ml of virus was inoculated.
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pfu/mouse) contains plaque stocks 1, 2, 3, 4, 7, 11 and 12 
and class III of low virulence (LD^q >10~* pfu/mouse) 
contains plaque stock 8 .
To determine whether the difference in the LD_. values
50
of the plaque stocks was related to the number of viral 
particles within the stocks, particle counts were performed 
(see method section 2.7) and the particle : pfu ratios are 
presented in Table 3.1. All the plaque stocks had particle 
: pfu ratios within the acceptable range for HSV-2. There 
is no correlation between the particle : pfu ratio and 
virulence of the plaque stocks 2, 8, 14 and 17 all having 
ratios of 14 : 1 or less.
Eleven separate virus isolates were recovered from the 
brains of individual mice immediately after death. The mice 
had been inoculated with different plaque stocks at a 
variety of doses. Brain tissue was homogenised and 0.2ml of 
the homogenate inoculated onto BHK-21 C13 cells (see method 
section 2.10) from which virus stocks were made. The DNA 
from each of the eleven virus isolates was subjected to 
restriction endonuclease analysis using the enzymes Xbal, 
Bglll, EcoRI, Hindlll, Hpal and BamHI. There were no 
apparent differences in the restriction enzyme patterns of 
each virus isolate compared to the initial infecting 
viruses. The BamHI profiles of the DNA of five independent 
virus isolates are shown as representative examples in 
Figure 3.2.
Two plaque stocks categorised as being of high virulence
(14 and 17), one of intermediate virulence (2) and one of
low virulence (8) were chosen for further study on the basis
of their values and particle : pfu ratios. To confirm
their L D ^  values and compare with that of the elite stock, 
50
Figure 3.2
Autoradiographs of BamHI digests of viral DNA 
32P-labelled in vivo (1.2% agarose) of viruses recovered 
from the brain tissue of dead mice (from left to right, 
12, 7, 7, 14 and 17). Letters refer to specific 
fragments.
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0.025ml of each of the above plaque stocks was inoculated
intracranially into the left cerebral hemisphere of 2-3 week
2 5old BALB/c mice at doses ranging from 10 -10 pfu/mouse and
the LDj-q values determined as before (see method section
2.11). The results are shown in Table 3.2 and are
comparable with the results obtained in the first experiment
(see Table 3.1). In addition the LD._A value of the elite
5 0
2
stock of HG52 was determined and found to be <10 pfu/mouse.
The clinical signs produced in mice following
intracranial inoculation were closely observed. Some mice
became hunched with ruffled fur and ceased to be active with
death following rapidly. These signs were seen within 2-3
days following inoculation with the high virulence stocks at 
4 5doses of 10 -10 pfu/mouse, but developed more slowly after
inoculation with high virulence stocks at lower doses of 
2 310 -10 pfu/mouse or with virus stocks of low or
2 5intermediate virulence at doses of 10 -10 pfu/mouse. The 
mice also showed a wide range of neurological signs, for 
example, fits and limb paralysis of varying severity. Some 
mice which showed severe neurological signs were killed 
according to the regulations for conducting animal 
experimentation.
3.1.4 Virulence analysis using the intraperitoneal route of 
infection
The LDj-q values of the plaque stocks 14, 17, 2 and 8
were also examined using the intraperitoneal route of
inoculation. Virus stocks were inoculated intraperitoneally
5 7at doses of 10 -10 pfu/mouse (0.1ml of virus) into 3 week 
old BALB/c mice (see method section 2.11). HSV-1 strain 17 
syn-f (Brown et al. , 1973) was also used in this experiment
Table 3.2. LD values after intracranial inoculation 
d U
selected plaque purified stocks and the elite stock of
Plaque number LD50 (Pfu/mouse)
2 2xl04
8 > 105
14 <102
17 5xl02
*
HG52 <10 2
* Non-plaque purified elite stock.
2-3 week old BALB/c mice were used (6 mice/dose). 
0.025ml of virus was inoculated.
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as a positive control with a known LD__ value. The results
50
shown in Table 3.3 demonstrate a clear difference between
the LDcr. value of the HSV-2 strain HG52 and the HSV-1 strain 5U
17 syn+ . The plaque stocks of HG52 (14, 17, 2 and 8 ) showed
differences in the LD,.- value which were comparable to the
5 0
differences in the LD^^ value following intracranial
5inoculation. Virus stocks 14 and 17 had LDrr. value of 10
5 0
pfu/mouse while stocks 2 and 8 were avirulent with LD
5 0
7
value of >10 pfu/mouse. An unexpected finding was
inversion of the dose response curves; though mice died at
5 6 7low dose (10 pfu/mouse) none died at higher doses (10 -10
pfu/mouse). These findings were seen only with the elite
stock of HG52 and the plaque purified stocks (14, 17, 2 and
8) .
3.1.5 Replication efficiency in vitro and in vivo
The replication efficiencies of the plaque stocks (14,
17, 2 and 8 ) and the elite stock of HG52 were tested in
vitro and in vivo. One step growth experiments were carried
out in BHK-21 C13 cells at 37°C (see method section 2.9) and
the results are shown in Figure 3-3. Each stock grew well
and there was no difference in the timing of the growth
cycle or the yield from any of the plaque stocks compared to
the elite stock of HG52.
The possibility that the observed differences in the
LDcn value of the individual plaque stocks was due to 
5 0
differential abilities to replicate in mouse brain was 
tested. The plaque stocks (14, 17, 2 and 8 ) and the elite 
stock of HG52 were inoculated at doses of 10 pfu/mouse into 
the left cerebral hemisphere of 3 week old BALB/c mice. At 
daily intervals post inoculation, mice were sacrificed
Table 3.3. LD5q values after intraperitoneal inoculation of 
selected plaque purified stocks of HG52, elite stock of HG52 
and HSV-1 strain 17 syn+
Plaque number TjD50 (Pfu/mouse)
17 105
14 105
8 > 107
2 > 107
HG52 >106
HSV-1 (17 syn +) 105
3 week old BALB/c mice were used (
0.1ml of virus was inoculated.
mice/dose).
Figure 3.3
One step growth curves of plaque stocks 14, 17, 2, 8 and 
the elite stock of HG52 in BHK-21 C13 cells (50mm 
monolayers 4x10^ cells) at 37°C. The cells were 
infected at a moi of 5 pfu/cell. After 45 min
absorption, cells were washed, overlaid with ETC5 and
incubated at 37°C. Cultures were harvested at the times 
indicated and the virus titre measured by plaque assay 
on BHK-21 C13 cells is given per ml (10^ cells). O HG52 
; □ plaque stock 14 ; ■ plaque stock 17 ; a  plaque stock
2 ; • plaque stock 8.
Time post inlection (h)
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(usually 2 mice/time point), their brains removed, 
homogenised and assayed for virus by titration on BHK-21 C13 
cells at 37°C. The in vivo growth curves are presented in 
Figure 3.4. Plaque stocks 14, 17 and the elite stock of 
HG52 replicated while plaque stocks 2 and 8 replicated
poorly. To determine whether the inefficient brain 
replication of plaque stocks 2 and 8 was specific to the 
brain cells or generalised to all mouse cells at the 
accepted body temperature of mice i.e 38.5°C, comparative 
one step growth experiments of plaque stocks (14, 17, 2 and 
8 ) were carried out in BALB/c mouse embryo fibroblast (3T3) 
cells at 38.5°C, and the virus yield titrated on BHK-21 C13 
cells at 37°C (see method section 2.9). The results are 
given in Figure 3.5. The plaque stocks (14, 17, 2 and 8 ) 
showed no replication and the virus titre diminished with 
time. The 3T3 cells appear to be non-permissive for HG52 at 
38.5°C. The plaque stocks (14, 17, 2 and 8 ) were not 
temperature sensitive. Twenty four hour yield experiments
\rv. B M K
(see method section 2.9) of plaque stocks 14, 17, 2 and 8yi
1 1 1  1 
gave titres of 4x10 , 6x10 , 6.5x10 and 5x10 pfu/ml at
31°C and 3x10^, 4x10^, 3.5x10^ and 3x10^ pfu/ml respectively
at 38.5°C.
3.1.6 Effect of passage on neurovirulence of individual 
stocks
To determine whether the plaque stocks (14, 17, 2 and 8 ) 
which had been categorised for virulence retained their 
virulence category following passage in BHK-21 C13 cells, 
they were passaged five times at low moi (see method section 
2.8) and ten plaques were picked from each stock. Virus 
stocks were made from each of these ten plaques and their
Figure 3.4
Replication kinetics of plaque stocks 14, 17, 2, 8 and
the elite stock of HG52 in mouse brain in vivo. Three
week old BALB/c mice were inoculated intracranially into
. . 5the left cerebral hemisphere with 0.025ml containing 10 
pfu of virus. At the time indicated post infection, 
surviving mice were sacrificed (2 mice/time point), 
their brains were removed, homogenised and the resulting 
homogenate was titrated for virus on BHK-21 C13 cells at 
37°C. O HG52 ? □ plaque stock 14 ; ■ plaque stock 17 ; a
plaque stock 2 ; • plaque stock 8.
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Figure 3.5
One step growth curves of the plaque stocks 14, 17, 2
and 8 in 3T3 cells at 38.5°C. Cells were infected at a
moi of 5 pfu/cell. After absorption for 45 min at 37°C,
the monolayers were washed, overlaid with ETC5 and
incubated at 38.5°C. Cultures were harvested at the 
times indicated and the virus titre, measured by plaque 
assay on BHK-21 C13 cells, is given per ml (10^ cells). □ 
plaque stock 14 ; ■ plaque stock 17 ? A plaque stock 2 ;•
plaque stock 8.
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DNAs analysed using six different restriction enzymes. The
results showed no apparent differences in the pattern of
each DNA stock and the BamHI profiles of four independent
plaque stocks and the elite stock of HG52 are shown as
representative examples in Figure 3.6. Two stocks each from
the plaque stocks 2, 8 and 14 and four from the plaque stock
17 at the 5th passage were chosen at random and inoculated
intracranially into the left cerebral hemisphere of 3 week
old BALB/c mice at doses of 10^-10^ pfu/mouse (0.025ml of
virus) and the LD.__ values were determined as before (see5U
method section 2.11). The results are presented in Table
3.4. The virus stocks derived from the intermediate (plaque
stock 2 ) and low (plaque stock 8 ) virulence stocks remained
stably of intermediate or low virulence. The virus stocks
derived from the high (plaque stocks 14 and 17) virulence
stocks were more heterogeneous. Some demonstrated
3 4intermediate levels of virulenece (10 -10 pfu/mouse) e.g 
virus stocks 14/3, 14/4 and 17/1 while others retained their 
levels of virulence. These results clearly demonstrated the 
virulence heterogeneity within the stock of HSV-2 strain 
HG52 and reemphesised the necessity of working with well 
characterised plaque purified stocks when assessing 
virulence. The high virulence plaque stock 17 was chosen as 
the baseline to study the effect of defined deletions in 
HG52 on virulence.
3.2 Virulence of deletion variants of HSV-2 strain HG52
3.2.1 Introduction
The identification of viral genes that control 
pathogenic properties in vivo, and the elucidation of their 
functions are of fundamental importance to an understanding
Figure 3.6
Autoradiographs of BamHI digests of viral DNA 
32
P-labelled in vivo (1.2% agarose) of the 5th passage 
plaque purified stocks and the elite stock of HG52 (from 
left to right), HG52, 8/10, 14/4, 17/1, and 17/3.
Letters refer to specific fragments.
a b
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Table 3.4. ^ 5 0  values after intracranial inoculation of
the 5th passage of the selected plaque purified stocks of 
HG52
Plaque number LD50 (Pfu/mouse)
2/7 >105
2/8 >105
8/4 >105
8/10 2 .1x10
14/3 3.9x10
14/4 2xl03
17/1 3xl03
17/3 5.5x10
17/8 <102
17/9 <102
3 week old BALB/c mice were used (6 mice/dose). 
0.025ml of virus was inoculated.
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of the basic molecular mechanism of HSV pathogenesis. Over
the past several years, many laboratories have been involved
in studies of HSV genes and gene products specifically
related to neurovirulence. Most of these studies were
carried out on HSV-1 using deletion mutants, temperature
sensitive (ts) mutants, monoclonal antibody resistant (mar)
mutants, drug resistant mutants and intertypic recombinants.
Very little is known about HSV-2 genes or gene products
associated with neurovirulence.
A series of HG52 variants with deletions in the internal
long repeat (IR ) or short unique/terminal short repeat 
Li
(Ug/TRg) regions of the genomes were studied to define the
role of the deleted genes in HSV neurovirulence using the
mouse model system. The size and location of the deletions
and growth characteristics of the variants have been
reported by Harland and Brown (1985) and Brown and Harland
(1987). The fact that the variants were not impaired in
their lytic growth cycle demonstrated that the deleted genes
were not essential for growth in vitro. Figure 3.7 shows a
schematic map of the HG52 genome with the location of the
IR deletions in the variants under study. The variants 
Li
used were as follows: their nomenclature when first 
published is given in brackets.
JH2603 (HG52XD86): has a 3.75 kb deletion which includes the
BamHI p/f site at 0.775 m.u. Most or all of the deleted 
sequences are within IR^ and probably span the UL/IRL 
junction. The deletion must remove at least part of the 
coding region of the immediate early gene 1 (IEl)
(0.785-0.81 m.u.) which codes for the immediate early 
polypeptide VmwIEllS (Preston et al., 19 78; Easton and 
Clements, 1980).
Figure 3.7
Structure of the HG52 genome (top line) showing U andL
Uc flanked by TR /IR and IR /TR respectively. The 
13 Li Li O O
second line shows an expansion of the Xbal £ fragment
(0.7-0.83 m.u.). The positions of the 'a' sequence and
the transcripts for IEl and IE2 genes are indicated.
The third line shows the positions of the BamHI sites
within Xbal £. The location and the extent of the
deletions in the variants is indicated. JH2604 is the
only variant which contains a deletion in both copies of
the R .
Li
T R l U l ir l  iRs u s  t r s
u IRL
0.70
X bal g
0.72
i
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JH2604 (HG52XD192): has a 1.5 kb deletion in TR and IR
L L
within both copies of the BamHI v fragment (0-0.02 and 
0.81-0.83 m.u.).
JH2605 (HG52XD85/5): has a deletion of 5.5 kb within IR
Li
including the BamHI p/f site and probably the (J /IRT
Li L i
junction.
JH2606 (HG52XD85/4) : has 9 kb deletion encompassing the 
BamHI p/f site, and the BamHI p> and v fragments excluding 
the 'a1 sequences. The deletion extends from approximately 
0.76 to 0.83 m.u. including the total coding region of the 
IE1 gene and the U /IR junction.
Li Li
A diagrammatic representation of the location and extent 
of the deletions in the U and TR components of the genomeO b
in the altered variants is shown in Figure 3.8. All have 
lost the Xbal site at 0.7 m.u. The variants analysed are as 
follows: their nomenclature when first published is given in 
brackets.
JH2607 (HG52XD163X12): has a deletion of 7.75 kb extending 
from approximately 0.94-0.994 m.u. The genes deleted are 
US10, US11 and US12 coding for polypeptides of Mr 33K, 
21K/22K, and VmwIEl2 respectively (Watson et al., 1979; 
Marsden et al., 1982; Dalziel and Marsden, 1984; Lee et al., 
1982), one copy of IE3 coding for VmwIEl82 (Morse et al., 
1978) and one copy of the short origin of replication (orig ) 
(Stow and McMonagle, 1983).
JH2608 (HG52X163X14): has a deletion of 7.5 kb including the
genes US10, US11 and US12. The deleted sequences have been 
replaced by inverted duplication of Ug/IRg sequences between 
0.83-0.91 and 0.94-1.2 m.u. such that the short repeat 
region is extended by 6 kb on either side. This means that 
this variant has two copies of the genes USl, US2, US3, US4
Figure 3.8
Xbal map for the DNA of HSV-2 strain HG52 (top line) 
from Cortini and Wilkie (1978), showing the position of 
Xbal sites. The location of the deletion in the 
variants is indicated and the positions of the lost Xbal 
sites (X) are also shown in each genome below the top 
line.
The origin of the joint fragments is as follows; a^ 
b =c+_i, e =£+h/ f. =2+A«
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coding for VmwIE68, a protein of unknown function, protein 
kinase and glycoprotein G respectively (McGeoch et al., 1985 
and 1987; McGeoch and Davison, 1986; Frame et al., 1986b) 
and the coding region of US5 (McGeoch et al., 1985).
JH2609 (HG52X163X21): is the same as JH2608 except that it 
contains additional Hindlll and EcoRI sites at 0.94 m.u. and 
has lost the Xbal site at 0.91 m.u.
JH2610 (HG52X163X3); has lost the Xbal site at 0.91 m.u. 
resulting in fusion of Xbal h and j.
JH2611 (HG52X163X53): has lost all the Xbal sites (0.45,
0.7, 0.91 and 0.94 m.u.).
3.2.2 Neurovirulence of the deletion variants
Neurovirulence of the HG52 deletion variants was assayed
by intracranial inoculation of 3 week old BALB/c mice at
3 7doses ranging from 10 -10 pfu/mouse (5-6 mice/dose). The
mice were monitored for 3 weeks following inoculation and
the LDcr. values calculated (see method section 2.11). The
5 0
results are shown in Table 3.5. The °f the wild type
elite stock of HG52 is shown for comparison. Most of the 
deletion variants exhibited reduced neurovirulence and can 
be segregated into three groups. The first group with an
7
LD^q value of >10 pfu/mouse, classified as avirulent 
includes JH2604. The second group with an L D ^  value of 
10^-10^ pfu/mouse classified as of reduced virulence 
includes JH2610, JH2608, JH2609, JH2605 and JH2606. The
4
third group with an L D ^  value of 10 pfu/mouse classified 
as attenuated includes JH2611, JH2607 and JH2603. These 
results indicate that the capacity of all the variants to 
kill mice following intracranial inoculation was reduced 
with LD50 values ranging between 104->107 pfu/rnouse compared
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2
to <10 pfu/mouse for the HG52 elite stock. Comparing these
results with the range of neurovirulence results obtained
for individual plaque stocks of HG52 indicated that the LDrri5U
values of all the deletion variants except JH2604 and JH2610 
fell within the range of the parental HG52.
It had previously been shown that although not 
temperature sensitive the deletion variants in U /TR wereO O
temperature restricted at 38.5°C (Brown and Harland, 1987) 
the ambient body temperature of mice. As any impairment in 
neurovirulence may have been attributed to this restriction 
it was decided to concentrate on the variants with deletions 
in IR i.e JH2603, JH2604, JH2605 and JH2606. These
-Lj
variants displayed reduced neurovirulence.
~3VA2-605 was chosen as a model in cotransfection
experiments and to test whether the deletion in the variant
JH2603 has any effect on neurovirulence. The deletion in
the variant JH2603 was shown to be 3.75 kb in IR within theJL
Xbal fragment. In order to introduce the deletion into 
the genome of plaque 17 stock of HG52, purified DNA from the 
the variant JH2603 was digested and the Xbal fragment 
(0.7-0.83 m.u.) containing the deletion was excised, eluted 
and cotransfected with intact plaque 17 stock genome (see 
method section 2.19) . The fragment was used at a 5, 10 and 
20 fold molar excess over the intact plaque 17 stock DNA. 
Fifty plaques were picked, grown into plate stocks and the 
DNAs of twenty five were digested with Xbal (see method 
section 2.17) and their restriction profiles studied. One 
designated R17XD86 showed a profile indicating that the 
fragment containing the deletion had recombined into the 
wild type genome. After three rounds of plaque 
purification, Xbal digestion confirmed that recombination
94
had occurred and that the deletion in JH2603 had been
inserted. The results are shown in Figure 3.9. The
recombinant R17XD8 6 (lane 2) shows that the Xbal g_ and the
Xbal containing joint fragments (e and f_) were now running
at the positions of the equivalent bands in JH2603 (lane 3)
and not in their normal wild type position (lane 1). The
recombinant was inoculated intracranially into 3 week old
2 5BALB/c mice at doses ranging from 10 to 10 pfu/mouse (see 
method section 2.11). As controls, the highly neurovirulent
plaque 17 stock of HG52 and JH2603 were used at doses
2 3 2 5ranging from 10 -10 and from 10 -10 pfu/mouse
respectively. The results given in Table 3.6 showed that
4
the recombinant had an LD__A value of 3.5x10 pfu/mouse which5 0
is the same as the variant JH2603 indicating that the
sequences deleted in JH2603 had an effect on neurovirulence.
In conclusion, the results indicate that all the
deletion variants of HG52 analysed had reduced
neurovirulence following intracranial inoculation of 3 week
old BALB/c mice with LD_n values ranging 10^->10^ pfu/mouse
5 0
2compared to <10 pfu/mouse for the wild type elite stock of 
HG5 2.
3.3 Analysis of the deletion variant JH2604
3.3.1 Neurovirulence of JH2604
The DNA structure of the deletion variant JH2604 has
been described in detail by Harland and Brown (1985).
Essentially the genome has a deletion of approximately 1.5
kb in both copies of BamHI v located between 0-0.02 and
0.81-0.83 m.u. in TRt and IR respectively. The relevant
L Li
restriction maps for HG52 are shown in Figure 3.10 (Cortini 
and Wilkie, 1978). To determine the neurovirulence of
Figure 3.9
Autoradiographs of Xbal digests of viral DNA 
32P-labelled in vivo (0.5% agarose) of HG52 (lane 1), 
R17XD86 (lane 2) and JH2603 (lane 3). Letters refer to 
specific fragments, arrowheads indicate the positions 
where fragments are missing and stars indicate novel 
fragments.
1 2 3
f
Table 3.6. LD5q values after intracranial inoculation of 
plaque 17 stock of HG52, JH2603 and the recombinant R17XD86
Virus Virus dose (pfu)/animal LDso (pfu/mouse)
2 3 4 510 10 10 10
Plaque 17 2/6 + 5/6
*
ND ND 3.5xl02
JH2603 0/6 0/6 3/6 5/6
oi—i
R17XD86 1/6 0/6 2/6 5/6 3.5xl04
+ Number of deaths/number of animals inoculated. 
* ND not determined.
3 week old BALB/c mice were used.
0.025ml of virus was inoculated.
Figure 3.10
Restriction endonuclease maps for the DNA of HSV-2 
strain HG52 from Cortini and Wilkie (1978). The origin 
of the joint fragments is as follows. Xbal : a =c+hf b 
=c+gr e =g_+h, f =g+_i. Hindi 11 : c =i.+k, d =g+k, f = i+ 
m, g = j+m. EcoRI : b = f+k, c =h+k r d =f+mr e =h+m. 
Bglll : a =d+k, b =d+m, e =h+k, f =h+m. Hpal : b 
=f+(S) , e =g+ (S ) . Kpnl : b =c+r, e = f+r. BamHI : g 
=v+u.
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JH2604 compared to the parental HG52 elite stock,
experiments were carried out to estimate the LDrn values in5 0
2 5mice. Twenty five ul aliquots of HG52 at doses of 10 -10
5 7pfu/mouse and JH2604 at doses of 10 -10 pfu/mouse were
inoculated into the left cerebral hemisphere of 3 week old
BALB/c mice of each sex. Deaths were scored between days 3
and 21 post inoculation and the LD,.,. values calculated (seeb 0
method section 2.11). The results are shown in Table 3.7.
The elite parental stock of HG52 showed an LDC. value ofb 0
2
<10 pfu/mouse which was comparable to that determined
3
previously and to the LD..- value of <10 ofu/mouseb 0
calculated for the plaque purified , plaque 17, stock of
HG52 (see results section 3.1). The LD..- value of JH2604b 0
7 7was greater than 10 pfu/mouse; at a dose of 10 pfu/animal,
only one animal out of nine died and no others showed signs
of encephalitis or any other symptoms of illness or
g
distress. Also, two mice each infected with 10 pfu/mouse 
of JH2604 remained healthy after inoculation. Thus the
g
deletion variant JH2604 was at least 10 fold less
neurovirulent than the parental stock of HG52. The particle
: pfu ratios of 54 : 1 for HG52 and 71 : 1 for JH2604 are
comparable and fall within the normal range of values for
HSV-2. Following footpad inoculation (see method section
2.11) the variant JH2604 failed to kill any of the mice (15
6 7 8mice) inoculated at doses of 10 , 10 and 10 pfu/mouse
g
giving an value of >10 pfu/mouse.
3.3.2 Growth of JH2604 in vivo
To determine whether the low neurovirulence of JH2604 
was due to failure of replication in the mouse brain, the 
growth of the virus in vivo was tested. Samples of HG52 and
Table 3.7. Neurovirulence of HG52 and JH2604 in BALB/c mice 
following intracranial inoculation
Virus Virus dose (pfu)/animal
102 103 104 105 106 107
HG52 * * 7/12+ 8/12 12/12 6/6 ND* ND
JH2604*** ND ND ND 0/4 0/4 1/9
+ Number of deaths/number of animals inoculated.
* ND not determined.
** Particle : pfu 54 : 1.
*** Particle : pfu 71 : 1.
3 week old BALB/c mice were used.
0.025ml of virus was inoculated.
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5
JH2604 (10 p£u/mouse) were inoculated into the left 
cerebral hemisphere of 3 week old BALB/c mice of both sexes. 
At 0, 24, 48, 72, 96, 120 and 144 h post infection, two mice 
were killed and their brains were removed, homogenised and 
the resulting suspension sonicated and assayed by plaque 
titration on BHK-21 C13 cells at 37°C (see method section 
2.5). The results plotted in Figure 3.11 show that the 
parental HG52 grew well in the mouse brain with the titre 
continuing to rise at 120 h post inoculation; by 144 h all 
the mice had died from encephalitis. In contrast, the 
variant JH2604 failed to show any replication and the titre 
diminished progressively with time. These results indicated 
that the variant JH2604 was specifically restricted in the 
nervous system due to a replication deficiency in mouse 
brain cells.
3.3.3 Growth of JH2604 in vitro
The deletion variant JH2604 grows like wild type in a 
single cycle growth experiment in BHK-21 C13 cells at 37°C 
(Harland and Brown, 1985); the parental elite stock of HG52 
is somewhat temperature restricted at 38.5°C in that, though 
displaying exponential growth, the highest titre of virus 
reached by 12 h post infection is not appreciably higher 
than the starting titre immediately post absorption (Brown 
and Harland, 1987). The variant JH2604 is not temperature 
sensitive but is impaired in single cycle growth experiments 
at 38.5°C to the same extent as the parental HG52. The
7
titre of the JH2604 stock used for all experiments was 4x10 
pfu/ml at 31°C and 3xl07pfu/ml at 38.5°C. HG52 stock 
generally gives a lower titre compared to HSV-1 strain 17 
syn+, due to the fact that HG52 is mainly cell associated.
Figure 3.11
In vivo growth kinetics of HG52 and JH2604. Three week
old BALB/c mice were inoculated into the left cerebral
5
hemisphere with 25ul of virus containing 10 pfu/mouse. 
At indicated times post infection, two surviving mice 
from each time point were sacrificed. The brain tissue 
was removed and homogenised; the resulting cell 
suspension was sonicated and released infectious virus 
titrated on BHK-21 C13 cells at 37°C. O HG52 ; • 
JH2604.
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To determine whether JH2604 was temperature sensitive 
in mouse cells at the accepted ambient body temperature of 
mice i.e 38.5°C, comparative one step growth experiments 
were carried out in BALB/c mouse embryo fibroblast (3T3) 
cells at 38.5°C (see method section 2.9), and the virus 
yield was titrated on BHK-21 C13 cells at 37°C. Results are 
given in Figure 3.12 and show that the parental HG52 
replicated poorly, reaching a titre comparable to the input 
titre by 8 h post infection and then diminished. The 
variant JH2604 showed little evidence of replication and the 
virus titre progressively fell by 2 logs with time. In one 
step growth experiments perfomed at 37°C in 3T3 cells 
(Figure 3.13), the parental HG52 demonstrated some 
replication by 24 h post infection while JH2604 failed to 
replicate. Since it was possible that HG52 grows more 
slowly in 3T3 cells, multistep growth experiments were 
performed at 37°C in 3T3 cells. The results are shown in 
Figure 3.14 and again the parental HG52 showed some 
replication and reached its highest titre by 24 h post 
infection. The variant JH2604 failed to replicate and the 
titre dropped by 4 logs with time. It is concluded that 
BALB/c 3T3 cells are poor hosts for replication of HSV-2 
strain HG52 although some replication of wild type virus 
does occur; these cells are totally non-permissive for the 
deletion variant JH2604 both at 37°C and 38.5°C.
3.3.4 Infected cell polypeptide synthesis by JH2604
It has been shown previously that JH2604 synthesises 
normal amounts of HSV-induced immediate early polypeptides 
under immediate early conditions (Harland and Brown, 1985). 
To determine whether the deletion in JH2604 affected any
Figure 3.12
Single cycle growth kinetics of HG52 (O) and JH2604 (•) 
in 3T3 cells at 38.5°C. Cells were infected at a moi of 
5 pfu/cell. After absorption, cells were washed, 
overlaid with ETC5 and incubated at 38.5°C. At various 
times post infection, cells were harvested, virus was 
released by sonication and titrated on BHK-21 C13 cells 
at 37°C. The titre is given per ml (10** cells).
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Figure 3.13
One step growth curves of HG52 and JH2604 in 3T3 cells 
at 37°C. Cells were infected at a moi of 5 pfu/cell. 
Following absorption, cells were washed, overlaid with 
ETC5 and incubated at 37°C. Cells were harvested at 
times indicated and the virus titre measured by plaque 
assay on BHK-21 C13 cells at 37°C is given per ml (10** 
cells). O HG52 ; #JH2604.
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Figure 3.14
Multistep growth kinetics of HG52 and JH2604 in 3T3 
cells at 37°C. Cells were infected at a moi of 0.002 
pfu/cell. After absorption, cells were washed, overlaid 
with ETC5 and incubated at 37°C. At various times post 
infection, cells were harvested, virus released by 
sonication, titrated on BHK-21 C13 cells at 37°C and the 
titre is given per ml (10^ cells). O HG52 ; •JH2604.
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other detectable polypeptide synthesis, the infected cell
polypeptides of HG52 and JH2604 were labelled with 
35S-methionine and analysed by SDS-PAGE (see method section 
2.15). The results are shown in Figure 3.15. There were no 
detectable differences between the infected cell 
polypeptides synthesised by HG52 (lanes 1 and 6) and by 
JH2604 (lanes 2 and 5) compared to the mock infected cells 
(lanes 3 and 4) indicating that the deletion in JH2604 does 
not affect detectable general polypeptide synthesis.
3.3.5 Thymidine kinase synthesis by JH2604
It is widely accepted that the expression of
virus-encoded thymidine kinase (TK) enzyme activity is
necessary for the maximum demonstration of virulence
phenotype by HSV (Field and Wildy, 1978). To determine
whether the lack of neurovirulence of JH2604 was due to a
mutation in TK synthesis, TK assays were performed on HG52,
-7JH2604 and a known TK-negative mutant (TK ) using the
method described in section 2.13. The results of two
separate experiments are shown in Table 3.8. With the
-7 3TK-negative mutant (TK ) the H counts per minute (cpm) 
were marginally below the background (mock infected) levels 
in both experiments, while the wild type HG52 gave counts of
3.4 and 2.4 times the background levels and the variant 
JH2604 gave counts of 3.6 and 3.0 times the mock infected 
levels. Thus JH2604 is at least as efficient as HG52 in 
synthesizing the TK enzyme and thereforethe avirulent 
phenotype of JH2604 was not due to lack of expression of TK 
enzyme activity.
3.3.6 Correction of the deletion in JH2604
Figure 3.15
Autoradiographs of infected cell polypeptides induced in 
BHK-21 C13 cells, labelled with ^S-methionine from 4-24 
h post infection and separated on SDS-PAGE using single 
10% (lanes 1 and 3) and gradient 5-12.5% (lanes 4 and 6) 
concentrations of acrylamide gels. HG52 (lanes 1 and 6) 
; JH2604 (lanes 2 and 5) and mock infected (lanes 3 and 
4). Numbers refer to the apparent molecular weight
-3
(xlO ) of HSV-2 infected cell polypeptides.
10%
1 2 3
5-12-5%  
4 5 6
157 M  
138.134 ^ | 3 |
84
66 r
42-5 actin
38.37
36
29-5
* *
actin
157
138134
*r-
84
66
42-5
37
35
29-5
Table 3.8. TK assays on HG52, JH2604 and TK 7 viruses
Virus
Mock infected 
TK-7 (17)
HG52
JH2604
Radioactivity (cpm)/ug protein 
Experiment 1 Experiment 2
2573
2216
8713
9265
3460
2812
8424
10645
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The strategy employed to correct the deletion in the
genome of JH2 604 and subsequent isolation of recombinants is
shown in Figure 3.16. Essentially unit length JH2604
genomes and restriction endonuclease fragments spanning the
deletion from the HG52 genome were cotransfected onto
BHK-21 C13 cells. The progeny viruses were allowed to
amplify until the cpe was complete. Cultures were harvested
independently, titrated out and plaques were picked, grown
into plate stocks and their DNAs were analysed by
restriction endonucleases using the method of Lonsdale
(1979). Recombinant viruses were isolated, plaque purified,
their DNA profiles and LD.__ values determined (see methodb U
section 2.11). In this study purified DNA from the highly
3
neurovirulent plaque 17 stock of HG52 <10 pfu/mouse)
was digested with Xbal and the Xbal £ and £ containing joint 
fragments (e and £_) were excised and after purification by 
electroelution (see method section 2.18) were used 
independently in cotransfection experiments with the intact 
JH2604 DNA. The deletion in JH2604 was shown to be within 
Xbal £ and the £ joint f ragments (e and .f) . The Mr of 
fragment Xbal £ (0.7-0.83 rn.u.) is 13x10^; that of Xbal e 
(£+h 0.83-0.91 rn.u.) is 21x10^ and of f_ (£+£ 0.94-1.0 rn.u.) 
is 19x10^. In cotransfection experiments the fragments were 
used at a 5, 10 and 20 fold molar excess to the intact 
JH2604 DNA. Although the deletion in JH2604 is only 1x10^
Mr (1.5 kb) in both copies of BamHI v, these large Xbal 
fragments were used to facilitate recombination between the 
fragment and the intact genome (the larger the fragment, the 
greater the chance of recombination occurring) as no 
selection system was available. Two hundred plaques were 
picked, and the DNA of 46 of these was digested with Xbal;
Figure 3.16
Strategy employed to correct the deletion in the variant 
JH2604 in vitro.
Intact JH2604 
genomes
Xbal RE fragments 
from HG52
Amplification in culture (BHK-21 C13 cells)
i
Pick plaques
i
RE analysis
i
Isolation of the recombinants
i
Plaque purification
i
RE analysis
i
Neurovirulence of the recombinants 
( LD5q values)
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four of these digests showed profiles indicating that the
deletion in Xbal £ had been corrected, as the £, e and f_
bands ran in the normal wild type position. Three were from
cotransfections using a 20 fold molar excess of Xbal e and
the fourth from a plate in which Xbal £ had been
cotransfected at a 20 fold molar excess with JH2604 DNA.
After three rounds of plaque purification, Xbal digestion
confirmed that recombination had occurred and that the
deletion in JH2604 had been corrected. The recombinants
were designated R17(192)E pi. 8, Rl7(192)E pi. 14, R17(192)E
pi. 15 and R17(192)F pi. 10. Figure 3.17 shows Xbal
profiles of the four recombinants (lanes 2-5) compared to
HG52 (lane 1) and JH2604 (lane 6). Xbal digestion
demonstrated that the deletion had been corrected in IR i.e
Li
within Xbal £. The size of the other Xbal fragment
£
containing BamHI v (i.e c, 45x10 Mr) is such that an
alteration in size of Mr 1x10^ would not be detectable.
Therefore Hindlll and Hpal digestion was carried out. The
results are shown in Fiqure 3.18. BamHI v in TRt is located— L
within Hpal £, and BamHI v in IR is located within Hpal £_.
Jlj
The variant JH2604 shows if and £ deleted by approximately
1x10 Mr (lane 6) compared to jf and £ of HG52 (lane 1). The
size of the Hpal £ and f containing joint fragments (b and
c) are so large that a deletion of 1x10^ Mr would not be
detectable. In the recombinants Hpal _f and £ have returned
to their wild type positions (lanes 2-5). BamHI v in TR is
Li
located within Hindlll i, and in IR within Hindlll £^ _Li
Therefore with the variant JH2604, Hindlll i^ and £ and the £ 
and £ containing joint fragments i.e c, d, If and £ (lane 12) 
are deleted compared to the corresponding HG52 fragments 
(lane 7) . In the recombinants, i^, £, c, d, £_ and £ have all
Figure 3.17
Autoradiographs of restriction digests of viral DNA 
32P-labelled in vivo. Xbal digestion (0.5% agarose) of 
HG52 (lane 1), R17(192)E pi. 8 (lane 2), R17(192)E pi.
14 (lane 3), R17(192)E pi. 15 (lane 4), R17(192)F pi. 10 
(lane 5) and JH2604 (lane 6 ). Letters refer to specific 
fragments, arrowheads indicate the positions where 
fragments are missing and e', £', 3 ' indicate novel 
fragments.
h
Figure 3.18
Autoradiographs of restriction digests of viral DNA 
32P-labelled in vivo. Hpal (lanes 1 to 6) and Hindlll 
(lanes 7 to 12) digestion of HG52 (lanes 1 and 7),
JH2604 (lanes 6 and 12), R17(192)E pi. 8 (lanes 2 and 
8 ), R17(192)E pi. 14 (lanes 3 and 9), R17(192)E pi. 15 
(lanes 4 and 10) and R17(192)F pi. 10 (lanes 5 and 11). 
Letters refer to specific fragments, arrowheads indicate 
the positions where fragments are missing and _f', £' 
etc. indicate novel fragments.
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returned to their wild type positions (lanes 8-11). The
Hpal and Hindlll digests demonstrate that the deletion has
been corrected in both copies of BamHI v i.e in TR and IR .L L
The TK phenotype of the recombinants was tested by TK assays 
(see method section 2.13) to ensure that no secondary
mutation^affecting virulence had occured and the results are
shown in Table 3.9. The recombinants were as efficient as 
the wild type in synthesizing the TK enzyme.
3.3.7 Neurovirulence of the Rl7(192) recombinants
To determine their neurovirulence, the three times
plaque purified recombinants were inoculated intracranially
into the left cerebral hemisphere of 3 week old BALB/c mice
2 6at doses ranging from 10 to 10 pfu/mouse. As controls the
highly neurovirulent plaque 17 stock of HG52 and JH2604 were
2 5 5 7used at doses ranging from 10 -10 and 10 -10 pfu/mouse
respectively. The results are given in Table 3.10 show that
all four recombinants have regained neurovirulence with
3 5values ranging from 10 to 3x10 pfu/mouse. These
values are within the range of the values of the individual
2 5plaque stocks of HG52 (<10 -3x10 pfu/mouse) (see section
3.1). The avirulent phenotype of JH2604 has been confirmed
7
with an LD..- value of >10 pfu/mouse. The particle : pfu 
5 0
ratios of the recombinants are shown in Table 3.10 and are
within the acceptable range for HSV-2. The avirulent
phenotype of JH2604 has therefore been corrected by
insertion of wild type sequences replacing the deletion in
both copies of the BamHI v fragment.
The range of the LD,_„ values obtained with the
50
recombinants in which the deletion has been corrected 
suggest either (i) there are sequences apart from those
Table 3.9. TK assys on the R17(192) recombinants, R192(17)
_7
recombinants, HG52 and TK
Virus Radioactivity (cpm)/ug protein
Mock infected 2352
TK-7 2115
HG5 2 8220
Rl7(19 2)E pi. 8 7924
Rl7(19 2)E pi . 14 8140
Rl7(192)E pi. 15 8080
Rl7(19 2)F pi. 10 7982
R192(17)E pi. 2 9630
R19 2(17)E pi. 5 8356
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deleted in JH2604 which act either in conjunction with or
independently of those between 0-0.02 and 0.81-0.83 m.u. to
determine neurovirulence or (ii) the DNA stock of HG52
plaque 17 is heterogeneous, in that viruses arising from
individual genomes have different virulence potential. The
latter would mean that the virus population of HG52 plaque
17 despite its recent purification contains a genome mixture
with virulence values similar to those of the
individual plaque stocks of the elite HG52 laboratory stock 
3 5(<10 -3x10 pfu/mouse). To determine whether this was the
case, a DNA stock of HG52 plaque 17 was transfected and five
well separated progeny plaques were isolated. Virus stocks
from the five plaques were inoculated into 3 week old BALB/c
2 4mice at doses ranging from 10 -10 pfu/mouse and the LD^ -q
values were determined (see method section 2.11). The
results in Table 3.11 show that the LD values of these
5 0
plaque stocks were <10^ to >10^ pfu/mouse confirming the 
virulence heterogeneity within the stock of HG52 plaque 17.
3.3.8 Introduction of the JH2604 deletion into the HG52 
genome
Having confirmed that the avirulent phenotype of JH2604 
could be corrected by insertion of wild type fragments to 
correct the deletion, reciprocal experiments were carried 
out to determine whether removal of the relevant sequences 
from HG52 resulted in an avirulent phenotype. In order to 
insert the deletion in JH2604 into the wild type genome, 
purified DNA from JH2604 was digested with Xbal and the 
three fragments £, e and f were excised and purified from 
the gel (see method section 2.18). The three fragments were 
independently used in cotransfection experiments with intact
Table 3.11. LDcri values after intracranial inoculation of5 u
the plaque stocks picked from transfected HG52 plaque 17 DNA
Plaque number Virus dose(pfu)/animal LDso (pfu/mouse)
2 3 410 10 10
17/1 0 / 5 + 3/5 5/5 8.5x10 2
17/2 3/5 5/5 5/5 <102
17/3 0/5 0/5 2/5 >104
17/4 0/5 0/5 1/5 >io4
17/5 1/5 3/5 5/5 7xl02
+ Number of deaths/number of animals inoculated.
3 week old BALB/c mice were used.
0.025ml of virus was inoculated.
10 3
DNA from HG52 plaque 17 stock (high neurovirulence) at a 5, 
10 and 20 fold molar ratio. No selection system was used to 
isolate recombinants when 200 plaques were picked. Of the 
DNA of 40 of these digested with Xbal, two showed Xbal 
profiles indicating that the fragment containing the 
deletion had recombined into the wild type genome (Figure 
3.19 lanes 2 and 3) in that the <g, e and _f bands were now 
running at the positions of the equivalent bands in JH2604 
(lane 4) and not in their normal wild type positions (lane 
1). Hpal and Hindlll digestion (Figure 3.20) confirmed that 
the deletion was in both copies of R in that Hpal and f 
(lanes 2 and 3) and Hindlll i_rir c, d, and (lanes 6 and
7) were running below their normal wild type positions 
(lanes 1 and 5). The recombinants were plaque purified 
three times, their restriction profiles confirmed and virus 
stocks were grown. The recombinants were as efficient as 
wild type in synthesizing TK enzyme (Table 3.9). The 
recombinants were designated R192(17)E pi. 2 and R192(17)E 
pi. 5 .
3.3.9 Neurovirulence of the R192(17) recombinants
To determine their neurovirulence, the two recombinants
R192(17) were independently inoculated intracranially into
the left cerebral hemisphere of 3 week old BALB/c mice at 
S 7doses of 10-10 pfu/mouse. Control infections with the 
HG52 plaque 17 stock and JH2604 were performed at the same 
time. The results are shown in Table 3.12. It can be seen
7
that each of the recombinants had an LD_n value of >10b U
pfu/mouse i.e the same as that of the non-neurovirulent 
deletion variant JH2604. The particle : pfu ratios of the 
recombinants are shown in Table 3.12 and were comparable to
Figure 3.19
Autoradiographs of restriction digests of viral DNA 
32P-labelled in vivo. Xbal digestion (0.5% agarose) of 
HG52 (lane 1), R192(17)E pi. 2 (lane 2), R192(17)E pi. 5 
(lane 3) and JH2604 (lane 4). Letters refer to specific 
fragments, arrowheads indicate the positions where the 
fragments are missing and , £_' etc. indicate novel 
fragments.

Figure 3.20
Autoradiographs of restriction digests of viral DNA 
32P-labelled in vivo. Hpal (lanes 1 to 4) and Hindlll 
(lanes 5 to 8) digestion of HG52 (lanes 1 and 5),
Rl92(17)E pi. 2 (lanes 2 and 6), Rl92(17)E pi. 5 (lanes 
3 and 7) and JH2604 (lanes 4 and 8). Letters refer to 
specific fragments, arrowheads indicate the positions 
where fragments are missing and c', d 1 etc. indicate 
novel fragments.
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that of wild type. These results imply that the sequences
within the 3 kb terminal portion of R probably within BamHI
L
v are required for neurovirulence of HSV-2 strain HG52.
3.3.10 In vivo selection
The JH2604 deletion had been shown to be within the 
BamHI v fragment (0-0.02 and 0.81-0.83 m.u.) (Harland and 
Brown, 1985) but we chose to correct or insert the deletion 
using large Xbal fragments because of the small size of the 
relevant BamHI fragment and the lack of a selection system. 
The position of the relevant BamHI, Xbal, Hindlll and Hpal 
fragments is seen in Figure 3.21. Using the large Xbal 
fragments is open to the criticism that as well as replacing 
the deleted sequences, the recombinants could also have 
contained other sequences from the cotransfecting Xbal e or 
_f and that the observed effect on neurovirulence was not due 
to the deletion but to a secondary mutation. To counter 
this argument, correction of the deletion by a small 
fragment BamHI £ i.e v (0.81-0.83 m.u.) + u (0.83-0.85 m.u.) 
using an in vivo selection system in BALB/c mice was carried 
out. The strategy employed to correct the deletion using an 
in vivo selection system and isolation of recombinants was a 
modification of that described by Thompson et al. (1983) and
is summerised in Figure 3.22. Since the variant JH2604 does 
not kill mice due to *\ts lack of a biologically selectable 
marker i.e failure of replication in mouse brain, any deaths 
will be due to recombination of the JH2604 genome with a 
restriction endonuclease fragment of HG52 which displays the 
desired phenotype (neurovirulence) and the genotype of the 
recombinants can then be defined by restriction endonuclease 
analysis. In this study intact JH2604 genomes were
Figure 3.21
Structure of the HSV-2 strain HG52 genome (top line)
showing UT and U_ flanked by TR /IR and IR /TR 
Li S Li Lj O  O
respectively. The positions of the relevant BamHI, 
Xbal, Hpal and Hindlll fragments are indicated.
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Figure 3.22
Strategy employed for correction of the deletion in the 
variant JH2604 using in vivo selection in mice.
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cotransfected in BHK-21 C13 cells with different molar 
ratios (1, 5 and 10 fold) of the BamHI c[ fragment of the 
highly neurovirulent plaque 17 stock of HG52 (see section
3.1). When extensive cpe was apparent the cells were 
harvested, sonicated and the resulting virus suspension 
serially diluted. Twenty five ul was inoculated 
intracranially into the left cerebral hemisphere of 3 week 
old BALB/c mice (2 mice/dilution). By three days post 
infection, two mice had died, one inoculated with the virus 
from a transfection plate infected with a 10 fold molar 
excess of BamHI £ and the other from a transfection with a 5 
fold molar excess of BamHI g_. The brain of the mouse 
inoculated with the products of the 10 fold BamHI 
transfection plate was necrotic and could not be used. The 
brain of the other dead mouse was removed, homogenised and 
0.2ml of the resulting suspension inoculated onto BHK-21 C13 
cells in a 50mm petri-dish. The infected plate was 
harvested, the virus released by sonication and used to
reinfect mice intracranially to determine its LD.^ value.5 0
This stock gave a value of <10^ pfu/mouse. The DNA of
the plate stock was subjected to restriction enzyme analysis 
and the Hindlll and Hpal DNA profiles are shown in Figure 
3.23. The analysis showed that the virus recovered from the 
brain (lanes 3 and 6) was a mixture of JH2604 (lanes 2 and 
5) and HG52 (lanes 1 and 4). Therefore the plate stock of 
the virus recovered from the brain was titrated out on 
BHK-21 C13, separate plaques were picked, plate stocks from 
each were made and their DNA analysed by Hindlll and Hpal 
digestion. Two plaque stocks that showed a HG52 profile 
were subjected to three rounds of stringent plaque 
purification and a stock of virus was grown from each after
Figure 3.23
Autoradiographs of restriction digests of viral DNA 
32
P-labelled in vivo. Hpal (lanes 1 to 3) and Hindlll 
(lanes 4 to 6) digestion of HG52 (lanes 1 and 4), JH2604 
(lanes 2 and 5) and virus recovered from the brain 
(lanes 3 and 6). Letters refer to specific fragments 
and stars indicate novel fragments.
M
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the third round. The recombinants were designated
recombinant 1 and 2. Hindlll and Hpal DNA profiles of the
two virus stocks are shown in Figure 3.24 and it can be seen
that the two recombinant viruses (lanes 1, 2, 5 and 6) have
DNA structures equivalent to the wild type HG52 (lanes 4 and
8) and not the deletion variant JH2604 (lanes 3 and 7). The
two recombinant viruses were each inoculated intracranially
into the left cerebral hemisphere of 3 week old BAbB/mice at
doses of 102, 102 and 10^ pfu/mouse (5 mice/dose) and their
LD_n determined. The results are shown in Table 3.13. It 50s
can be seen that for both recombinants, all infected mice
2died at a dose of 10 pfu/mouse giving an LD^q value for 
2
each of <10 pfu/mouse. Using the approach of in vivo
recombinant selection HSV-2 function(s) associated with at a
least 10^ fold increase in neurovirulence have been
localised. The fact that the two recombinants isolated
contained the DNA region (BamHI g_ fragment) in both copies
of the R from the highly neurovirulent plaque 17 stock of 
Li
HG52 demonstrate unequivocally that the sequences within 
BamHI g_ are required for JH2604 to restore its 
neurovirulence to the level of wild type virus.
3.4 Sequence analysis of the fragment containing the 
deletion in the variant JH2604
3.4.1 Size variability of the BamHI g (v + u) joint fragment 
of the variant JH2604
JH2604 had been shown to contain a deletion of 
approximately 1.5 kb in each copy of BamHI v fragment 
between 0-0.02 and 0.81-0.83 m.u. (Harland and Brown, 1985). 
It was initially thought that the deletion in both copies of 
BamHI v may not have been identical but that the variant had
Figure 3.24
Autoradiographs of restriction digests of viral DNA 
32
P-labelled in vivo. Hpal (lanes 1 to 4) and Hindlll 
(lanes 5 to 8) digestion of recombinant viruses (lanes 
1, 2, 5 and 6), JH2604 (lanes 3 and 7) and HG52 (lanes 
and 8). Letters refer to specific fragments and stars 
indicate novel fragments.
Hpal Hindlll
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Table 3.13. LD.__ values after intracranial inoculation of
5 U
the _in vivo recombinants
Virus Virus dose (pfu)/animal LD50 (pfu/mouse)
2 3 410 10 10
Recombinant 1 5/5+ 5/5 5/5 <10^
2
Recombinant 2 5/5 5/5 5/5 <10
+ Number of deaths/number of animals inoculated. 
3 week old BALB/c mice were used.
0.025ml of virus was inoculated.
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lost at least 150 bp of equivalent sequences from both
copies of R . Therefore it was important to delimit the 
Li
deletion and sequence the fragment spanning the deletion to 
know its exact location. BamHI digestion of JH2604 DNA 
shows that the BamHI g fragment (v + u) is missing from its 
normal position and appears to run in two positions (1) just 
above the 1 fragment and (2) just above the m fragment 
(Figure 3.25). These two fragments were excised and 
purified from a 1.2% agarose gel (see method section 2.18), 
and cloned into the BamHI site of pATl53 plasmid (see method 
section 2.22). Two positive clones designated 22 and 28 
were isolated. Southern blot analysis of a BamHI digest 
using nick translated intact HG52 genomes as the probe (see 
method section 2.28) showed hybridization to one band in 
clone 22 running just above the BamHI 1 fragment and one 
band in clone 28 running just above the BamHI m fragment 
(Figure 3.26). When clone 22 DNA was nick translated
and used as a probe in Southern blots with BamHI digested 
DNA of HG52, JH2604, clone 22 and clone 28, it can be seen 
that; with HG52 there is positive hybridization to BamHI v, 
u and g; with JH2604 there is positive hybridization to u 
and to the two bands running coincidentally with BamHI 1 and 
m. It is assumed that the small size of the deleted v
fragment precludes its identification on this gel. With
clones 22 and 28 there is hybridization to two bands, the
lower one representing the pATl53 DNA and the upper one in
each case the deleted BamHI g fragment running 
coincidentally with BamHI 1 and m respectively. The 
variation in the mobility of the fragments in clones 22 and 
28 could be due to either (a) the deletion in each case 
being a different size or (b) variability in the copy number
Figure 3.25
Autoradiographs of restriction digests of viral DNA 
32P-labelled m  vivo. BamHI digestion (1.2% agarose) of 
JH2604 (lane 1) and HG52 (lane 2). Letters refer to 
specific fragments, arrowheads indicate the positions 
where the fragments are missing and stars indicate novel 
fragments.
1 2
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Figure 3.26
Autoradiographs of Southern blots containing BamHI 
restriction fragments of clone 28 (lanes 1 and 5), cl 
22 (lanes 2 and 6), JH2604 (lanes 3 and 7) and HG52 
(lanes 4 and 8) to which nick translated probes have 
been hybridised. The probes were the recombinant 
plasmid clone 22 (lanes 1 to 4) and HG52 DNA (lanes 5 
8). Letters refer to specific fragments.
Wt probe
Cl one 2 2 probe
1 2  3 4 5 6 7 8
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of the reiterated sets of sequences known to exist in this 
region of the genome (Davison and Wilkie, 1981).
3.4.2 Subcloning of BamHI g of the variant JH2604 into M13 
bacteriophage and nucleotide sequencing
The wild type HG52 BamHI c[ fragment has been shown to be
5815 bp in length extending from IR to IR (D. J. McGeoch,
S Li
unpublished results). There is a HincII site at nucleotide 
position 3053 within the 'a' sequence and a Xhol site at 
nucleotide position 5069 just upstream of the 5' end of the 
IEl gene (Figure 3.27). Plasmids containing the JH2604 
BamHI g_ inserts were cut with XhoI-HincII giving a fragment 
of 516 bp in size (2016 bp in the case of wild type BamHI 
fragment) in both cases and the remainder of the BamHI 
fragments were normal. This indicated that (1) the deletion 
in JH2604 was contained completely within the XhoI-HincII 
fragment, (2) the deletion as predicted from restriction 
endonuclease analysis was approximately 1.5 kb in size and 
(3) both copies of BamHI v contained a deletion with 
apparently identical end points and size.
These 516 bp fragments were ligated into the Smal-Sall 
sites of M13 mpl8 and mpl9 phage and the ligated DNA was 
transfected into E. coli strain JM101 (see method section 
2.30). The nucleotide sequence of the M13 clones was 
determined by the dideoxynucleotide chain termination method 
(see method section 2.32). Sequencing of clones 22 and 28 
showed homology to the wild type sequence, starting at the 
HincII site (3053) and continuing for 30 bp to nucleotide 
position 3083 (Figure 3.28). There is then a deletion of 
1488 bp and homology starts again at nucleotide position 
4571 and continues with no alteration to the Xhol site at
Figure 3.27
Structure of the HG52 genome (top line) showing U andL
LJ0 flanked by TR /IR and IR /TR respectively. TheS L L S o
second line shows an expansion of the BamHI £ fragment
(0.81-0.85 m.u.) which is 5815 bp. The position of the 
'a1 sequence and the transcript of the IEl gene is 
indicated. The bottom line shows the positions of
HincII and Xhol sites within BamHI £.
TR, U L IR, IRc Uc TR<
i r L IRS
5815
BamHI g I-----
0
; I :
IE 1 a seq
Xhol - HincII l
5069
l i l
3053 1769 1237
Figure 3.28
Portion of an autoradiograph of a 6% sequencing gel 
showing the cloning site (3053) within the 'a' sequence 
and the start (3083) and end (4571) of the deletion in 
JH2604. Sequencing products were separated on denatured 
polyacrylamide gels (Sanger et al., 1980) containing 9M 
urea (McGeoch et al., 1986).
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5069 (Figure 3.27) . The deletion includes one copy of the
17 bp direct repeat (DRl) element of the 'a' sequence,
AGTCCCCGTCCTGCCGC and four copies of a 19 bp sequence,
CCCCTCCGACCCCCTGACG starting at position 3 771 (D. McGeoch,
unpublished results). The deletion terminates 522 bases
upstream of the 5' end of the I El gene.
Sequence analysis showed that the nucleotide sequences
deleted, and hence the size of the deletion in both clones
22 and 28 were identical indicating that the difference in
the mobility of the remnant of BamHI g_ in each clone was due
to variable copy numbers of the reiterated sequences outwith
the deleted region.
HincII also cuts BamHI g_ at nucleotide position 1237
within BamHI u. Xhol in addition to cutting BamHI at 5069
cuts within BamHI u at nucleotide position 1769 (Figure
3.27). This 532 bp sequence within BamHI u was sequenced
and shown to be identical to that of HG52 with no point
mutations, deletions or insertion. In total 2548 bp of the
JH2 604 BamHI g_ fragment have been sequenced and shown to be
identical except for the deletion. However a point mutation
within the remaining 3267 bp can not be excluded.
It is concluded from the nucleotide sequence analysis
and the in vivo studies that the sequences within the 1488
bp fragment located between 0-0.02 in TR and 0.81-0.83 m.u.
Li
in IR of HSV-2 strain HG52 confer neurovirulence for BALB/c
]_J
mice. The analysis clearly demonstrates a function in vivo 
for the deleted sequences which may suggest that the region 
is protein coding.
3.5 Neuropathology
In order to study the morphological changes produced by
110
the elite stock of HG52 and the variant JH2604 and the 
distribution of the viral antigens in mice brains, 
experiments were carried out in 3 week old BALB/c mice.
Mice were inoculated intracranially into the left cerebral 
hemisphere (see method section 2.11) with virus stocks (10 
pfu/mouse) and at 0, 24, 48, 72, 96, 120, 144, and 168 h 
post infection, two surviving mice from each time point were 
sacrificed and their brains were removed and processed for 
histopathology and immunohistochemistry (see method sections 
2.35 and 2.36). Two mice were inoculated intracranially 
with PBS/calf serum as a control.
3.5.1. Macroscopic examination of brains infected with 
JH2604 and HG52
In 20% of the brains it was possible to identify the 
site of intracranial inoculation over the lateral aspect of 
the left cerebral hemisphere. There were no intracranial 
complications and in particular there was no evidence that 
the intracranial pressure had been high during life.
3.5.2 Microscopic examination of paraffin sections of brains 
infected with JH2604 and HG52
For the controls, they were normal and there was no 
evidence of inflammation, hydrocephalus or intracranial 
herniation (Figure 3.29). The nature and severity of 
neurohistological changes in the brains inoculated with 
either HG52 or JH2604 are shown in Table 3.14. At 24 h post 
infection, all the mice brains inoculated with either the 
elite stock of HG52 or JH2604, showed a mild degree of 
lymphocytic infiltration of the meninges. This infiltration 
was most conspicuous at the base of the brain. In all other
Figure 3.29
Paraffin embedded section of normal mouse brain, 
shows normal white matter H & E X430.
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aspects the brains looked normal and there was no evidence 
of hydrocephalus. At 48 h post infection, the brains 
inoculated with HG52 showed abnormality limited to a mild 
lymphocytic infiltration of the basal meninges. In 
contrast, the brains inoculated with the variant JH2604 
showed in addition to the basal meninges, focal infiltration 
of the walls of the third ventricle by lymphocytes and an 
associated mild enlargement of the ventricular system. By 
72 h post infection, the brains inoculated with HG52 showed 
small foci of necrotising encephalitis in the internal 
capsule and thalamus of the left cerebral hemisphere. Even 
though these lesions appeared to be associated with the site 
of inoculation, their absence in the earlier time points 
clearly indicated a response by the brain to the 
inoculation. By 96 h post infection, however, the lesions 
were larger and bilateral (Figure 3.30), affecting both grey 
and white matter. Within these areas there was focal 
necrosis of all neurons and glia, vacuolation of the white 
matter, swelling of the related astrocytes and a mild 
infiltration by neutrophil polymorphs. Some of the related 
blood vessels appeared to be highly cuffed by macrophages. 
There was also a moderate amount of lymphocytic infiltration 
of the basal meninges.
In contrast, the changes in the cerebral hemisphere of 
the brains infected with JH2604 at 72 h and 96 h post 
infection were different in that there was no evidence of 
necrotising encephalitis, even at the site of inoculation. 
There was, however, an encephalitis with mild cuffing of 
small vessels, largely by lymphocytes, but also with 
occasional macrophages (Figure 3.31). This perivascular 
cuffing was limited to the site of inoculation and was
Figure 3.30
Paraffin embedded section of mouse brain inoculated 
intracranially with HSV-2 strain HG52 96 h post 
infection. Figure shows focus of acute necrotising 
encephalitis in which there is a vacuolation of the 
neuropilei, necrosis and fragmentation of gliajwith mild 
infiltration by lymphocytesjand neutrophil polymorphs H 
& E X430 .
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Figure 3.31
Paraffin embedded section of mouse brain inoculated 
intracranially with the deletion variant JH2604 96 h
post infection. The figure shows localised infiltration
✓ *
of lymphocytes and macrophages*and perivascular cuffing /
of blood vessel. In contrast to Figure 3.30 notice the 
complete absence of necrosis H & E X430.
i
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associated with a mild basal lymphocytic meningitis and a 
marked focal infiltration of the ventricular walls by 
lymphocytes. There was evidence of mild hydrocephalus. At 
120 h and 144 post infection, the nature of histological 
changes in both HG52 and JH2604 infected brains remained 
unchanged though the amount increased over time. For 
example, in HG52 infected brains there were multiple foci of 
necrotising encephalitis widely scattered throughout the 
grey and white matter of both the cerebral hemispheres and 
hindbrains. By 122 h post infection, the changes were more 
easily seen with considerable proliferation of microglia, 
macrophage formation and a sprinking of neutrophil 
polymorphs. There was also both hypertrophy and hyperplasia 
of astrocytes. 01igodendroglia were difficult to recognise 
and there was vacuolation of myelinated fibers. There was a 
small amount of perivascular cuffing by lymphocytes, changes 
that were also seen in relation to the walls of the 
ventricular system. There was a mild degree of 
hydrocephalus and small numbers of lymphocytes were present 
in the basal meninges. Similar foci of necrosis were also 
seen in the brain stem and cortex of the cerebellum.
The changes in the brains infected with JH2604 at 120 h 
and 144 h post infection were different from HG52 though 
similar to those noted at earlier time points in this study. 
These changes consisted of widely distributed foci of 
perivascular cuffing by lymphocytes. In addition, there was 
a variable but moderate amount of lymphocytic infiltration 
of the basal meninges and an extension of this inflammatory 
process from the meninges along the intracortical vessels.
In this latter site there was also glial and astrocytic 
response, but no evidence of neuronal necrosis. There was
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also perivascular infiltration by lymphocytes and all brains 
had developed a moderate degree of hydrocephalus. By 168 h 
post infection, only the brains inoculated with JH2604 were 
available since no mice had survived at that time point with 
HG52. The changes were similar to those described earlier. 
The only possible quantitative change was an increased 
amount of perivascular infiltration by lymphocytes which 
resulted in a moderate degree of ventricular enlargement.
3.5.3 Immunohistochemistry of paraffin sections of brains 
infected with JH2604 and HG52
In control brains there was no evidence of staining in 
various cell types of the brain, its meningeal covering or 
the ependymal lining of the ventricles (Figure 3.32). In 
the brains infected with HG52 at 24 h and 48 h post 
infection, positive staining was seen in some astrocytes 
along the line of inoculation as well as in some of the 
ependymal cells of the third ventricle. Similar changes 
were seen in the JH2604 infected brains in which positive 
staining was limited to the immediate vicinity of the site 
of inoculation and one or two ependymal cells in the wall of 
the third ventricle. By 96 h post infection the HG52 
infected brains showed a positive staining of astrocytes not 
only to the site of inoculation, but also in and around the 
foci of necrotising encephalitis (Figure 3.33). Some of the 
staining appeared to be intranuclear and intracytoplasmic 
but where the cells had undergone necrosis, chromagen 
appeared to be extracellular. Prior treatment with trypsin 
removed much of the staining from the foci of necrosis but 
left positive staining in what appeared to be both 
astrocytes and nerve cells. Apart from staining of a few
Figure 3.32
Paraffin embedded section of normal mouse brain 
immunostained with avidin biotinylated horseradish 
peroxidase rabbit anti-HSV 1:100. Notice the complete 
absence of staining in the white matter X430.

Figure 3.33
Paraffin embedded section of mouse brain inoculated 
intracranially with HSV-2 strain HG52 96 h post 
infection and immunostained with avidin biotinylated 
horseradish peroxidase rabbit anti-HSV 1:100. Positive 
staining (brown) is seen in both viable/and necrotic/ 
nuclei and extracellularly in the neuropile X430.
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ependymal cells, there was no positive staining elsewhere in 
the forebrain. There was, however, positive staining of 
both Purkinji cells and related reactive Bergmann glia in 
foci of early necrosis within the cortex of the cerebellum.
The changes in JH2604 infected brains at 72 h and 96 h 
post infection were different, positive staining being 
limited to astrocytes in the immediate vicinity of the site 
of inoculation (Figure 3.34), a few ependymal cells in the 
wall of the third ventricle and related subependymal 
astrocytes. There was no evidence of staining of neuronal 
cells, either within the forebrain or hindbrain. The 
remainder of the brain appeared normal. The patterns of 
positive staining in the brains infected either with HG52 or 
JH2604 at 120 h and 144 h post infection were different but 
similar to those identified in the earlier time points. In 
the HG52 infected brains, it was possible to see positive 
staining in the astrocytes and nerve cells in the immediate 
vicinity of the foci of necrotising encephalitis in both 
forebrain and cerebellum.
These results clearly demonstrated that the variant 
JH2604 is restricted in its growth in brain cells especially 
in neuronal cells.
Figure 3.34
Paraffin embedded section of mouse brain inoculated with 
the deletion variant JH2604 96 h post infection and 
immunostained with avidin biotinylated horseradish 
peroxidase rabbit anti-HSV 1:100. Positive staining 
(brown) is limited to astrocytes along the line of 
inoculation X430.
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DISCUSSION
The aim of this thesis was to identify gene(s) involved
in neurovirulence of HSV-2 strain HG52 in the mouse model
system by analysis of the effect in vivo of deletion
variants of the virus. Before studying biological
properties such as latency and virulence of defined deletion
variants in an animal model system, it is essential to
determine the phenotype of the parental wild type virus in
the system under study. Therefore we have evaluated the
neurovirulence of individual plaque stocks isolated from the
elite laboratory stock of HG52 to determine the baseline
from which to evaluate the neurovirulence of the HG52
deletion variants.
The ten individual stocks isolated from the elite stock
of HG52 showed differences in their LD..- values following5U
intracranial inoculation of 3 week old BALB/c mice. On the
basis of the LD,_q values compared with that of the elite
stock of HG52, the plaque stocks were subdivided into three
classes of neurovirulence; low with a LDrr. value >10^b U
3 4pfu/mouse, intermediate with a value 10 -10 pfu/mouse
and high with a LD<-q value of <10^ pfu/mouse. None were
designated as avirulent. The difference between low and
high virulence stocks is over 3 logs. The same differences
in the LDrr. values between high and low virulence stocks
5 0
were seen using the intraperitoneal route of inoculation. 
Although HG52 showed a normal dose response curve following 
intracranial inoculation, the inversion of the dose response 
curve following intraperitoneal inoculation was unexpected. 
This inversion of the HG52 dose response curve is an 
observation which is specific for HSV-2 strain HG52, since
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HSV-1 strain 17 showed a normal dose response curve. The 
reason for the inversion is unclear and is possibly due to 
the intraperitoneal route of inoculation. It has been shown 
that intraperitoneal infection with HSV-2 is an excellent 
inducer of macrophage phagocytosis activity in mice 
(Armerding et al., 1981). The activated macrophages, 
possibly induced by the local IFN generated or by the virus 
infection alone, might be required for resistance to an 
intraperitoneal infection. Injecting a high dose of virus 
intraperitoneally could result in activation of more 
macrophages and production of high levels of IFN which may 
result in resistance to infection. Although this 
explanation might be correct for a high infectious dose, it 
does not fit with the lower dose of virus.
Passaging of the single plaque stocks in vitro at 37°C 
showed in some cases a shift from high to intermediate 
virulence whereas the phenotype of low virulence was 
generally retained after repeated passage at 37°C. The 
shift from high to intermediate virulence could result from 
the presence of a mixture of the three classes of virulence 
in the high virulence stocks, despite their plaque 
purification. Therefore, in an in vivo experiment, the 
score would be for high virulence. When the high virulence 
stocks were passaged in vitro i.e in the absence of in vivo 
selection pressure they segregated into the three virulence 
classes. This explanation has been supported by the 
virulence heterogeneity of high virulence stocks during 
cotransfection experiments which will be discussed later.
Thompson and Stevens (1983a), using 4-6 week old Swiss 
Webster mice, found the LD^q value of the elite stock of 
HG52 to be 104 pfu/mouse following intracranial inoculation.
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Five plaques were isolated and stocks from these passaged 
four times at 31°C or 37.5°C. Those passaged at 31°C 
retained their low virulence, however, after passage at 
37.5°C, virulence increased in four cases and in one case 
remained low. Similar findings have also been observed in 
HSV-2 strain Curtis (Thompson andStevens, 1983a). It is 
clear from these findings that there is virulence 
heterogeneity within HSV-2 stocks, a finding we have now 
clearly confirmed, quantitated and extended. As Thompson 
and Stevens (1983a), showed the effect of temperature on 
selection of virulent HSV-2 stocks, Goodman and Stevens
(1986) have demonstrated that passage of HSV-1 strain 17 in 
vitro in chick embryo fibroblast cells enhanced the 
virulence of the virus for chick embryos in vivo suggesting 
that in vitro passage of HSV potentiated, rather than 
attenuated virulence. In our hands, there was no such 
effect of temperature and passage in vitro on virulence of 
HSV-2 strain HG52. Our findings are similar to those 
reported in PRV by Lomniczi et al. (1984).
Restriction endonuclease analysis of the DNAs of the 
isolated plaque stocks was carried out at different passage 
numbers using a range of restriction enzymes and no 
differences were seen in the size and distribution of 
fragments. In addition, the DNAs of virus stocks reisolated 
from mice brains retained their original restriction 
endonuclease profiles. Restriction endonuclease analysis 
however can not detect point mutations or small changes 
(deletions/insertions <150 bp) in the viral genome which 
could be possible sources of variation in the biological 
behaviour of the virus in vivo. The particle : pfu ratios 
of the plaque stocks can not be evoked to explain the
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differences in biological behaviour. Using the two criteria 
of restriction endonuclease profile and particle : pfu 
ratio, all of the ten plaque stocks used to infect animals 
were classified as wild type.
The replication kinetics of the individual plaque stocks 
have shown that the observed difference in neurovirulence 
was due to inefficient replication in mouse brain in vivo as 
the plaque stocks 17 and 14 (high virulence) replicated 
with kinetics similar to the elite stock of HG52, while 
plaque stock 8 (low virulence) replicated poorly (see Figure 
3.4). The replication capacities of plaque stocks 17 and 14 
in mouse brain were specific for brain tissue as they did 
not show differential replication kinetics in vitro in 
BHK-21 C13 cells. Therefore, the restriction of the growth 
of the low virulence stock appeared to be specific and not 
generalised. The results obtained with individual plaque 
stocks clearly demonstrate that the laboratory strain HG52 
is heterogeneous with respect to neurovirulence in mice.
HG52 is not unique in this respect as it has been shown that 
both virulent and avirulent stocks of HSV-1 strain KOS exist 
(Dix et al., 1983). Although the elite stock of HG52 was 
initially derived by rigorous plaque purification of a 
patient isolate, it is heterogeneous not only in terms of 
neurovirulence, but also contains a proportion of viable 
virus with aberrant genomic structures comprising at least 
24% of the population (Harland and Brown, 1985; 1988; Brown 
and Harland, 1987).
The basis for the variation in an important biological 
property is unclear but one possible reason is the presence 
of point mutations, deletions and/or insertions in the 
genome which can not be detected by restriction endonuclease
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analysis. Such changes in the viral genome might affect any 
of the stages in the viral replication. Our results 
emphasise the importance of working with well characterised 
parental virus when assessing the biological behaviour of 
mu t a n t s .
Having confirmed the heterogeneity within HG52, the 
plaque stock 17 has been used as the prototype virus and its 
LDc„ value has been taken as the baseline from which toD U
evaluate the neurovirulence of the deletion variants.
The nervous system is a critical target for HSV 
infection. The relationship between HSV and the peripheral 
nervous system is usually benign in that the virus remains 
latent in the neurons of dorsal root ganglia from which it 
reactivates intermittently. However, when HSV invades the 
central nervous system the likely outcome is a fatal 
encephalitis. It is therefore important to determine those 
genes of HSV which predispose it to invade and destroy 
nervous tissue. Viral genes controlling neurovirulence have 
only been identified recently and various laboratories have 
predominantly implicated the viral sequences between 
0.7-0.83 m.u. (Thompson and Stevens, 1983b; Thompson et al., 
1985; Rosen et al., 1986; Javier et al., 1987). This region 
contains the whole of IRT and part of U and the genes
JLj Li
encoded therein are one copy of IEl and UL50 to UL56 
(Clements et al., 1979; Whitton et al., 1983; Perry et al., 
1986; McGeoch et al., 1988). The mapping of virulence genes 
has come from the analysis of intertypic HSV recombinants 
constructed between low an high virulence strains of HSV 
using cloned viral fragments (Thompson et al., 1983; 1985). 
Deletion variants more readily allow defined regions of the 
genome to be studied for their neurovirulence properties.
120
The deletion variants analysed in this study have 
deletions ranging from 1.5 kb to 9 kb in the TR /IR and
Li L i
U /TR regions of the genome. All the deletion variants had
reduced pathogenicity for mice following intracranial
inoculation and depending on their LDr„ values they fell50
into three classes of neurovirulence with LD..- values
5 0
ranging from 10^->10^ pfu/mouse. The variants deleted in 
the U /TR regions are JH2607, JH2608, JH2609, JH2610 andO O
JH261L. The size and extent of the deletion in these
variants relied mainly on restriction endonuclease and
Southern blot analysis (Brown and Harland, 1987). As no
sequence data was available at the time of their isolation,
the exact sequences deleted in each variant remains
unresolved at present making the interpretation of the
neurovirulence results slightly difficult.
The variants JH2607, JH2608 and JH2609 had LDcr. values
5 U
4 5 5 /of 10 , 2.5x10 and 10 pfu/mouse respectively and the
feature they have in common is the loss of the US10, US11
and US12 genes. These LD,_q values are at least 3 logs
2
higher than the HG52 plaque 17 value (<10 pfu/mouse)
implying a role for the US10, USll and US12 genes either 
individually or cummulatively in neurovirulence. In 
addition the variant JH2607 has lost one copy of the IE3
4gene and one copy of ori and comparing its LD50 value (10O
pfu/mouse) with those of JH2608 (2.5xl05 pfu/mouse) and
JH2609 (10 pfu/mouse) indicated that the deletion of one
copy of the IE3 gene and one copy of o^ig had no effect on
neurovirulence. The LDCA values of the variants JH2608 and
5 U
5 5JH2609 are comparable (2.5x10 and 10 pfu/mouse 
respectively). The additional changes in the genomes of 
JH26 0 8 and JH2609 compared to JH2607 are extension of the
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short repeat regions by 6 kb on either side as well as loss
of the Xbal site at 0.91 m.u. in the variant JH2609 (Brown
and Harland, 1987). The common features of the variants
JH2609, JH2610 and JH2611 are the loss of Xbal sites at 0.7
and 0.91 m.u. (Brown and Harland, 1987). In addition the
variant JH2611 has lost the Xbal sites at 0.45 and 0.94 m.u.
(Brown and Harland, 1987). The DNA sequences around the
Xbal sites at 0.45, 0.7 and 0.94 m.u. are not known for
HSV-2, but in HSV-1 these sites lie within UL33, between
UL49 and UL50 and in the intergenic region of US9 and US10
respectively (McGeoch et al., 1985: 1988). The DNA
sequences around 0.91 m.u. in HSV-1 lie within the US4 gene,
encoding gG (McGeoch et al., 1985). The glycoprotein gG in
HSV-2 strain HG52 is encoded by the US4 gene. The Xbal site
at 0.91 m.u. lies within the coding region of the gene
(McGeoch et al., 1987). It has been shown that in the
variants JH2610 and JH2611 neither gG-2 nor its precursor
were synthesised, but two polypeptides migrating above the
normal positions of gG-2 and its precursor were made, while
the variant JH2609 failed to synthesise gG-2 or its
precursor showing that gG-2 is not essential for virus
growth in vitro (Harland and Brown, 1988). The variants
JH2609, JH2610 and JH261.1 had reduced pathogenicity for mice
following intracranial inoculation having LD,_A values of50
10^, 4.2x10^ and 5x10^ pfu/mouse respectively. These LD__
5 0
values are much higher than the value of the elite
stock of HG52 (<10 pfu/mouse), indicating the importance of 
gG-2 in neurovirulence. These results are consistent with 
the findings of Meignier et al. (1988) which showed that a
gG~ mutant of HSV-1 strain F had reduced pathogenicity for 
mice.
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Generally, the variants deleted in the U /TR regionsO O
were shown to be temperature restricted at 38.5°C (Brown and
Harland, 1987), so we can not rule out this growth
disadvantage from contributing to reduced neurovirulence
although Javier et al. (1988a) have shown that
neurovirulence functions are independent of high titre virus
replication in mouse brain.
The variants with deletion in IR /TR were shown to grow
Li L i
normally in tissue culture in BHK-21 C13 cells (Harland and
Brown, 1985). It has been shown that the IR region of the
Li
HSV-1 strain 17 genome (Figure 4.1) contains the IEl gene
between 0.785-0.81 m.u. (Perry et al 1986) and the LAT
transcripts between 0.782-0.796 m.u. running in the opposite
orientation to the IEl gene (Wagner et al., 1988; Perry and
McGeoch, 1988). In HSV-1 strain F a gene has been proposed
which codes for a polypeptide designated ICP34.5 in the same
orientation as the IEl gene (Chou and Roizman, 1986).
Again, restriction endonuclease analysis and until recently
the lack of sequence data for this region in the HG52 genome
has not allowed precise determination of the extent of the
deletions. The IE polypeptide analysis of the variant
JH2603, whose genome is deleted by 3.75 kb in IR , showed a
Li
reduction in the amount of: VmwIEll8 synthesised in infected
cells, supporting the conclusion that only one copy of the
coding region of VmwIEll8 had been deleted (Harland and
Brown, 1985). Although the LAT transcripts have recently
been identified in HSV-1 (see section 1.9), their existence
in HG52 is under analysis. If they exist in the same
positions as those identified in HSV-1, theoretically the
deletion in JH2603 would remove one copy of the LAT
transcripts in IRT . The deletion in JH2605 is 5.5 kb, is
Li
Figure 4.1
Gene organization of IR in HSV-1 strain 17. The top
Li
line shows the UT (dotted line), IR (open box), 'a'
L  Lj
sequence (solid box) and IR (dotted open box).b
Locations of the coding regions of genes (open boxes) 
and orientations of transcripts (arrows) for IEl (Perry 
et al., 1986), LAT (Wagner et al., 1988) and proposed 
ICP34.5 in strain F (Chou and Roizman, 1986) are 
indicated.
The minnor LAT (Mitchell et al.. 1990) is indicated by dotted 
arrow.
c
r
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confined to IR and removes the BamHI f_/p site at 0.775 m.u.
(Harland and Brown, 1985). Whether the deletion affects
VmwIEll8 synthesis is unresolved. The deletions in the
variants JH2603 and JH2605 may involve the U /IRr junction.
L Li
The UT gene adjacent to the UT/IRr junction in HSV-1 strain
-Li L i 1j
17 is UL56 (McGeoch et al., 1988) and it has already been
implicated in intraperitoneal pathogenicity in tree shrews
(Rosen et al., 1986) and mice (Becker et al., 1986). The
deletion in the variant JH2606 is 9 kb in length and removes
the UjVIR^ junction, the BamHI f_/p site at 0. 775 m.u., the
total coding region for VmwIEll8 (Harland and Brown, 1985)
and possibly the LAT transcripts. As in JH2603 and JH2605,
there is also a possibility that UL56 is removed from the
variant JH2606. The variant JH2604 which is deleted by 1.5
kb in both the TR and IR copies of BamHI v between 0-0.02
J_i Li
and 0.81-0.83 m.u. is the only variant in which IE 
polypeptide synthesis is not affected (Harland and Brown, 
1985).
All the deletion variants in TR /IR had reduced
Li L i
pathogenicity for mice following intracranial inoculation
4 7with values ranging from 10 to >10 pfu/mouse compared
2
to <10 pfu/mouse for HG52. Therefore the variants were at
least 3 logs and at most 6 logs less neurovirulent than the
elite stock of HG52. These results imply that the genes in
the IR region of HG52 genome are important in the control 
Li
of neurovirulence. Although the variants JH2603 and JH2606 
had lost one copy of the IEl gene, they still produced 
disease in mice. Recently Clements and Stow (1989) have 
shown that the mutant dll403, which contains a 2 kb deletion
within both the TRL anci i r l copies of the IEl gene (Stow and 
Stow, 1986), had reduced virulence for mice following
124
intracranial and footpad inoculation.
The precise role of the L A T  transcripts in latency is 
unresolved but their deletion results in impairment of virus 
reactivation from explanted latently infected ganglia (see 
section 1.9). Their role in neurovirulence is not yet 
known. However, preliminary latency experiments of the 
IR^/TR^ deletion variants showed that all the variants were 
capable of establishing latent infection in dorsal root 
ganglia of mice, but they were impaired to a different 
extent in reactivation from latent infection (G.B. Clements, 
personal communication).
The variant JH2604, whose genome is deleted by 1.5 kb in
both copies of the BamHI v fragment, was avirulent for mice
7 2with a value >10 pfu/mouse compared to <10 pfu/mouse
for HG52 implicating the sequences between 0-0.02 and
0.81-0.83 m.u. in neurovirulence. As the DNA sequences
between 0-0.02 and 0.81-0.83 m.u. deleted in JH2604 appeared
to be important in neurovirulence and since no potential ORF
has been clearly identified in this region in HSV-1 strain
17 or in HSV-2 strain HG52, it was important to characterise
this variant in detail. It was calculated from restriction
endonuclease analysis and Southern blot data that the
variant JH2604 had a 1.5 kb deletion in both copies of the
BamHI v fragment between 0-0.02 and 0.81-0.83 m.u. in TR
and IR respectively (Harland and Brown, 1985). As no 
Li
sequence data for this region of HG52 was available at the 
time of its isolation, the size and location of the deletion 
relied on restriction endonuclease and Southern blot 
analysis. It was thought that the same sequences were 
deleted from each copy of the BamHI v fragment but the size 
of the deletion (1.5 kb) and the size of the BamHI v
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fragment (3 kb) did not preclude the deletion in each copy
n ° r \
being at least in part* contiguous (Harland and Brown, 1985).
We have demonstrated that the variant JH2604 is
avirulent for 3 week old BALB/c mice on intracranial
7inoculation with a value >10 pfu/mouse compared to
2
<10 pfu/mouse for plaque stock 17. It also failed to kill
any mice following footpad inoculation at doses of 10^, 10^
8 8 and 10 pfu/mouse giving a LD value >10 pfu/mouse. In
protection experiments, JH2604 failed to produce zosteriform
spread of disease in mice following flank inoculation and
those mice were protected following the inoculation of a
lethal challenge of the HG52 elite stock by the same route
of inoculation (B. Rouse, personal communication to S.M.
Brown). The variant JH2604 and its parental HG52 grew
equally well in BHK-21 C13 cells at 37°C and is no more
temperature restricted at 38.5°C than HG52 (J. Harland,
personal communication). However, JH2604 failed to grow in
mouse 3T3 cells at both 37°C and 38.5°C, but as the elite
stock of HG52 also showed poor replication in these cells,
the apparent lack of growth of JH2604 is not significant.
It has recently been shown that using mouse 3T6 cells,
JH2604 grew as well as the HG52 elite stock (A.R. MacLean,
personal communication) and that the restriction in 3T3
cells was specific for this particular clone of cells and
not for mouse cells per se.
Of significance is the finding that JH2604 does not
replicate in vivo in mouse brain. The elite stock of HG52
grows efficiently within the brain at the accepted ambient
mouse temperature of 38.5°C, reaching peak titres by 120 h
post infection with all the infected animals dying by 144 h
post infection. JH2604 showed some replication by 12 h and
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24 h post infection, but by 48 h post infection the amount 
of infectious virus recovered from brains was over 1 log 
unit lower than the input virus measurable immediately post 
absorption. The growth kinetics of JH2604 in vivo in mouse 
brain and in vitro in BHK-21 C13 and 3T6 cells imply that 
JH2604 is specifically restricted in neural tissue and not 
generaly restricted in murine or other cell types. These 
findings have been supported by neuropathological and 
immunohistochemical studies of brains infected with JH2604 
and the elite stock of HG52.
The results of neuropathological studies showed a 
fundamental difference in the histopathological appearence 
of the two types of lesion produced by JH2604 and the wild 
type virus. The wild type virus being characterised by 
disseminated widely distributed foci of necrosis throughout 
the brain with minimum associated inflammatory cell 
response. In contrast to these changes, the microscopy of 
the brains infected with JH2604 was strikingly different 
with complete absence of necrotising encephalitis even at 
the site of inoculation. However, the lesion was 
characterised by perivascular cuffing of small vessels by a 
combination of lymphocytes and macrophages, these changes 
being limited to the site of inoculation or the ependymal 
lining of the ventricles. A probable consequence of the 
ependymitis that characterised the variant JH2604 was the 
development of hydrocephalus, a feature that was more oliten 
and readily seen in the JH2604 infected brain compared with 
the parental HG52. The hydrocephalus was probably due to a 
narrowing of cerebrospinal fluid pathways due to a 
combination of desquamating debris and the marked 
inflammatory cell infiltration, an appearance described
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previously in HSV-1 infected mice (Hayashi et al., 1986).
The distribution of the virus in the brain was determined by 
immunohistochemical studies which reflected the histological 
identification of the pathological process in the brains of 
infected animals. In JH2604 infected brains there was a 
positive staining (viral antigens) limited to astrocytes in 
the immediate vicinity of the site of inoculation with a few 
ependymal cells in the wall of: the ventricular system. In 
contrast, HG52 infected brain showed a wide distribution of 
positive staining in neurons and astrocytes. These results 
confirmed that JH2604 has a blockage in its replication in 
neural cells. In the absence of JH2604 replication, the 
infiltrating lymphocytes and neutrophil polymorphs are 
hypothesised to clear the remaining input virus from the 
brain.
The mechanism by which a deletion of 1.5 kb in the 
JH2604 genome resulted in failure of replication in the 
central nervous system is not clear. The function of the 
deleted sequences is unlikely to be involved in attachment, 
penetration or uncoating because JH2604 is capable of 
establishing and reactivating from a latent infection in 
mice (G.B. Clements, personal communication), therefore 
JH2604 must be capable of entering neurons and expressing 
some of its genes despite the lack of growth in neural 
tissue. In this respect, Steiner et al . (1990) have
recently shown that HSV-1 mutant in Vmw65 TIF (Ace et al., 
1989) can establish latent infection in mice following eye 
infection in the absence of viral replication. Similar 
findings have also been observed in the avirulent RE6 
(Thompson et al., 1989). The possible functions of deleted
sequences might affect gene expression at one or more of
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several stages; transcription, translation, DNA synthesis,
packaging or encapsidation. Evidence of lower efficiency of
translation in an attenuated poliovirus, which contains a
mutation in the 5' non-coding region of its RNA that
resulted in attenuated virus which failed to replicate in
the mouse brain (LaMonica et al. , 1987), has been reported
(Svitkin et al., 1985).
It has been shown that viral encoded TK modulates
virulence, since HSV without this enzyme is relatively
non-neurovirulent. The TK phenotype of the variant JH2604
was indistinguishible from that of the parental HG52. The
non-neurovirulence and lack of growth in mouse brain is
therefore not a result of the virus lacking TK.
In order to determine the role of genomic information in
the regions between 0-0.02 and 0.81-0.83 m.u. in
neurovirulence, cotransfection experiments were carried out.
The intact JH2604 DNA was cotransfected with the Xbal
fragments of HG52 plaque stock 17 DNA containing sequences
deleted from JH2604. The isolation of the recombinants, in
which the deleted sequences had been replaced by equivalent
sequences from the Xbal fragments, enabled the determination
of whether the replaced sequences had a direct effect on
neurovirulence. From 28 mice infected with R17(192)E pi. 8,
5
the LD^ p. value of the recombinant was calculated to be 2x10 50
pfu/mouse; from 40 mice infected with R17(192)E pi. 14,
1x10^ pfu/mouse; from 28 infected with R17(192)E pi. 15, 
3xl05 pfu/mouse and from 46 infected with R17(192)F pi. 10,
c:
3x10 pfu/mouse. These values are within the range of LD50 
values for individual plaque stocks of HG52 (see Table 3.1). 
There are two possibilities to explain the range of ^ D ^  
values obtained with the recombinants, in which the deletion
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has been corrected, either (i) there is another mutation 
outside the regions between 0-0.02 and 0.81-0.83 m.u. which 
precludes successful rescue of neurovirulence functions or 
(ii) the DNA stock of plaque 17 used for cotransfection 
produced virus which was heterogeneous with respect to 
neurovirulence. The latter was shown to be the case when 
five plaques picked from transfected plaque stock 17 DNA, 
showed LD,_q values ranging from <10^ to >10^ pfu/mouse (see 
Table 3.11). However, the deaths of 10/33 animals infected
5
with Rl7(192) recombinants at a dose of 10 pfu/mouse and 
10/15 with 106 pfu/mouse compared to 0/12 with 10^ 
pfu/mouse, 0/12 with 10^ pfu/mouse and 2/18 with 10^ 
pfu/mouse of JH2604 point to the avirulent phenotype having 
been corrected by replacement of the deleted sequences 
within both copies of the BamHI v fragment or the exchange 
of sequences within the remainder of the Xbal e fragment
(this will be discussed later). It obviously would have
been more critical to correct the deletion in JH2604 by 
cotransfection with the BamHI joint fragment (v + u) of
HG52 plaque 17 DNA, but because this fragment is so small
(4x10 Mr) and no selection system was available, we 
initially chose, to facilitate recombination by using large 
Xbal fragments.
The isolation of two recombinants in which the deletion 
in JH2604 has been introduced back into the HG52 plaque 
stock 17 genomes allowed the determination of how the 
reciprocal recombinants behaved following inoculation of 
mice. Intracranial inoculation of 18 mice with each 
recombinant produced an LD5Q value of >10 pfu/mouse in each 
case. This is identical to the LD,-^  value determined from 
42 animals infected at the same time with JH2604. These
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results provided substantive evidence that the sequences 
deleted in JH2604 are involved in the determination of 
neurovirulence of HSV-2 strain HG52.
The possibility that Rl7(192) recombinants might contain
other sequences from the contransfecting Xbal fragment of
the plaque 17 stock of HG52 and the implication that besides
the deleted sequences, the sequences within Xbal e and f_
were not equivalent in HG52 plaque 17 and JH2604 and that
the observed effect on neurovirulence was not due to the
deletion but to some other mutation, was tested. The
deletion in the variant JH2604 has been corrected by the
small BamHI (v + u) joint fragment from plaque 17 DNA
using in vivo selection in mice. The isolation of two
recombinants that displayed plaque 17 neurovirulence with
2
LD,_q values of <10 pfu/mouse, demonstrated that the 
sequences within the BamHI fragment and probably within 
the BamHI v fragment are required to restore the 
neurovirulence of JH2604 to the level of HG52 plaque 17.
The BamHI v fragment o l  HG52 co-maps with the BamHI j3 
fragment of HSV-1. The nucleotide sequence of the BamHI v 
fragment was not known at the time of animal experiments, 
but in HSV-1 strain 17 no complete genes had been identified 
in BamHI s (Perry and McGeoch, 1988). The 5' end and 500 bp 
from the end of the IEl gene are located within the BamHI s 
fragment. It has been shown previously that JH2604 makes 
VmwIEll8 (equivalent to VmwIEllO in HSV-1) of normal size 
and in normal amounts compared to the parental HG52 (Harland 
and Brown, 1985), indicating that the deletion within the 
BamHI v fragment in both copies of R^ does not extend into 
the reading frame for the IEl gene. It has also been shown 
that the general infected cell poypeptides synthesised by
131
JH2604 are not identiflably different from those of HG52.
In HSV-1 strain F, Chou and Roizman (1986) have reported a 
gene in R coding for a polypeptide ICP3 4.5 whose promoterLi
is in the terminal 'a' sequence. The same putative gene has
not been identified in the sequences of HSV-1 strain 17
(Perry and McGeoch, 1988) and it is now known that its
equivalent is not present in HG52 (D.J. McGeoch, personal
communication). The in vivo analysis of the HG52 deletion
variant JH2604 has demonstrated that at least 500 bp of the
BamHI v fragment within or spanning 1500 bp of the terminal
sequences of R are required to confer neurovirulence for 
Li
JH2604.
Towards the end of: the experimental work described in 
this thesis, the BamHI joint fragment of HG52 was 
sequenced and the sequence made available by Dr. D.J.
McGeoch. It therefore became important to delimit the 
deletion in JH2604 by sequencing the fragment in which the 
deletion was located and to clarify the possibility of the 
presence of other mutations.
The isolation of two positive pATl53 clones containing 
the deleted JH2604 fragment and their restriction 
endonuclease analysis and subcloning, demonstrated that the 
deletion in each clone was approximately 1.5 kb and was 
contained within the HincII-XhoI (between nucleotide 
position 3053 to 5069) subfragment and had apparently 
identical end points and size. Sequence analysis confirmed 
that the sequences deleted in both clones were identical and 
were 1488 bp in length. The deletion included a complete 
copy of the 17 bp DRl element (AGTCCCCGTCCTGCCGC) of the fa' 
sequence, four copies of a 19 bp reiterated sequence 
(CCCCTCCGACCCCCTGACG) and stopped 522 bp upstream from the
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5' end of: IEl gene. The variability in the mobility of the 
joint fragment spanning the deletion in both clones was 
confirmed as not being due to variation in the size of: the 
deletion in each copy of the BamHI v fragment but possibly 
to variation in copy numbers of: reiterated sets of sequences 
located in the repeats (see section 1.3.1). Such variation 
has been shown previously in HSV-2 strain HG52 (Davison and 
Wilkie, 1981) and in HSV-1 strain KOS (Wagner and Summers, 
1978) .
Whether the deleted sequences contain an ORE is under 
analysis. Chou and Roizman (1986) presented sequencing data 
and proposed that the region between the IEl gene and the
'a' sequence in HSV-1 strain F contains a gene in the same
orientation as the IEl gene (see Figure 4.1). An 
antipeptide serum based on this predicted ORF identified a 
protein ICP34.5, in extracts of infected cells (Ackermann et. 
al. , 1986). When comparisons were made between the 
published sequence for this region in strain F and the 
equivalent region in HSV-1 strain 17, Perry and McGeoch 
(1988) found a number of differences including a difference
in the copy number of a 9 bp tandem repeat family (10
complete copies in strain F and five in strain 17) and 20 
points in HSV-1 strain 17 at which an addition or deletion 
breaks the proposed coding ORF. This led to the conclusion 
that the entire ORF proposed by Chou and Roizman (1986) was 
not genuinely protein coding. The data presented by Perry 
and McGeoch (1988) were thought to be consistent with their 
being protein coding sequences in this locality but they did 
not consider the analysis satisfactory enough to propose any 
gene layout.
The BamHI joint fragment of HSV-2 strain HG52 has been
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found to be 5815 bp in length (D .J . McGeoch, personal 
communication). The sequences deleted in the variant JH2604 
are shown in Figure 4.2. When comparisons were made between 
these sequences and the published sequences for this region 
in HSV-1 strain 17, there is a degree of homology between 
the two sequences (D.J. McGeoch, personal communication).
The sequence arrangement in this region of HG52 is at 
present under critical analysis and it is thought that there 
is a potential ORF, but its precise end points have not been 
identified (D.J. McGeoch, personal communication).
The data presented in this thesis on correction and 
introduction of the deletion by a variety of methods 
suggests that the region deleted in the HSV-2 variant JH2604 
must be protein coding. Support for the work in this thesis 
has recently come from Thompson et al. (1989) who showed
that an HSV intertypic recombinant (REG) was avirulent for 
mice and cotransfection followed by in vivo selection in 
mouse brain of RE6 DNA with a 1.6 kb cloned fragment mapping 
between 0.82-0.832 m.u. from the pathogenic HSV-1 strain 17 
restored the neurovirulence phenotype of RE6.
FUTURE PROSPECTS
The information gained from this thesis is important 
both for further study of the molecular events controlling 
pathogenicity of HSV as well as the potential of the variant 
JH2604 for a prototype live vaccine.
As all the deletion variants analysed in this study had 
reduced pathogenicity for mice, it would be important to 
delimit the deletions by sequence analysis. The exact 
sequences deleted would be determined and marker rescue 
experiments correcting the deletions and analysis of
Figure 4.2
The sequences deleted in the variant JH2604. These
sequences are a part of the BamHI g_ joint fragment of
HG52 running from IR to IR (D.J. McGeoch, personal
S Li
communication). The start (3083) and end (4571) of the 
deletion are indicated by stars. The 17 bp DRl element 
is also indicated by the dotted box. The four copies of 
a 19 bp reiterated sequence are underlined.
2801
2851
2901
2951
3001
3051
3101
3151
3201
3251
3301
3351
3401
3451
3501
3551
3601
3651
3701
3751
3801
3851
3901
3951
4001
4051
4101
4151
4201
4251
4301
4351
4401
4451
4501
4551
GTGTGGTGGT CTGCGGCACA I .............. m i l ........... m u ........... ..................... ..GCCTGCT&GT CCCCGTCCTG i i i i a i i a i i i i i gCCGC33CGGGG
GCGGGCGCGG GAAAAAAGCC GCGCGGGGGC GCCCGCGGGA AGGCCAGCCC
CGCGGCGCGC GGGGGGAGGG GCGGCGCCCG CGGGGGAGCG GCCGGCTCCG
GGGGAGGGAC GGGGAAGGGG GCGCGCGGGG CTGCCCTGCC GCCCGCCCGC
CCGCCGCCGC CCGCCTTCGC GCCCCCCCCC AAAAAACACC CCCCCCGGGG
GTTGACTCCC CGGGGGAAAA GAGGCGGGGC
★
j i i i i a i i a i i i i i i i m i a i i iGGCJAGTCCCC it l a n  a i i i  i i a u a t i a  i i  a i m  i i  i i  i i fGTCCTGCCGC:
CGCCCCCTTA AGAGGGCCCG CAACACGGCC CGGGCTGCGC ACGCCAGCCG
GGACGGGTGA GTTCGCTAGG CAAGCACGGA CTGGCGGTTA CACGTGCATG
CGTGCCGAGT GAACTCTCCC GCCCCGACGC GCTCCGGCTC CGGGCCTACG
CCGAGCCCCA GCCGCCCGCC ATGTCCCGCC GCCGGGGTCC CCGCCGCCGG
GGTCCCCGGC GCCGGCCGCG CCCCGGCGCT CCAGCCGTGC CGCGCCCGGC
GCTCCAGCCG TGCCGCGCCC CGGCGCGCTC CCAACCGCAG ACTCCCAAAT
GGTCCCTGCG TACGACTCGG GAACCGCGGT CGAGAGCGCG CCGGCCGCGT
CCTCGCTCCT GCGGCGCTGG CTGCTGGTGC CCCAGGCGGA CGACAGCGAC
GACGCGGACT ACGCCGGCAA CGACGACGCA GAGTGGGCGA ACAGCCCCCC
GAGCGAGGGC GGGGGGAAGG CGCCGGAGGC CCCGCACGCC GCGCCTGCCG
CCGCCTGCCC CCCGCCGCCG CCGCGCAAGG ACGCGGGCCG CAGCGCCCCC
TTCCGCCCCA CCTGGCGCTA CGGCTGCGCA CCACGACGGA GTACCTGGCG
CGCCTGAGCT GCGCCGGCGG CGGCCCCCCG CGTCCCCGCC CGGGAACGCG
CCGCGCGGGA AGGTACGCCT CCCCTCCGAC CCCCTGACGC CCCTCCGACC
CCCTGACGCC CCTCCGACCC CCTGACGCCC CTCCGACCCC CTGACGCCCC
TCCGACCCCC GTGTCTCCCC GCCCGCAGTG TGCTTCTCGC CGCGCGTGCA
GGTGCGCCAT CTGGTGGCCT GGGAGACGGC CGCGCGCCTG GCCCGACGGG
GGTCCTGGGC GCGCGAGGGG CCGACCGGGA CCGGTTCCGG CGCCGCGTGG
CGGCGGCCGA GGCGGTCATC GGACCGGTGC CTGGAGCCCG AGGCCCGAGC
TCGGGCCCGA GCCCGGAGCC CGGGCCCACG ACAGACGGCG GACCCGCGGA
GGAGGAGGAG GCGGCGGCGG CGGCGCGCGG GTCCTCCGCC GCCGCGGGCC
CGGGCCGTCG GGCGGTCTAG GGTTGAACCG GCGAGGGCGG CCTCGGCCGG
CGGAGCCCCG GAGCTCCGAA GTCTGCGCGA GGCCGCTCTC CGAAGAGACG
ATGGGAGCCC CGCGTATATA TCCGCGAGGG CCCGGCGCCG CCCCGCCGCT
CCGCCCGCCC CAGGGGGCGG CGCCGGCCAA CCGCGCGCCG CCGCGCGGGC
CCGGACT CCG CCCCGGCGAC CGCCCCGCGC CGGCTTCCCG GTATGGTAAT
TAGAAACTTT TAATAGGCGG TCCCGGCCGC CATCCCCGCG CATGGTAATT
AGCAACTTTT AATGGGCCGG CGTTCCCGCT CGCGGTAATT AGCAGCTTTT
AACGGGCCGC CATTCCCGCT TATGGTAATT AAAAACGTTC GGACGGCCCC
TCGCTCCCCG CGTAATTACT CCCTCGGGGT TCCGGGTTAT GCTGATTACT
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resulting recombinants in vivo would give a better
understanding of the precise role of the deleted sequences
in neurovirulence.
The variant JH2604 which is avirulent for mice and 
failed to replicate in mouse brain should be further 
investigated to determine the stage of blockage in viral 
replication in neural tissue. A combined immunohisto- 
chemical and transcriptional analysis of infected neuronal 
tissue should help in understanding where the blockage in 
viral replication occurs. In this respect it would be of 
great interest to determine the in vivo functions of the 
deleted sequences in latent and acute ganglionic infections 
and examine the gene expression, if any, in neural cells.
Finally the identification of an ORF in the region 
deleted in JH2604 which has homology to equivalent sequences 
in HSV-1 identifies the avirulent phenotype of JH2604 
probably being due to a functional protein. In this respect 
designing a variant in HSV-1 with a similar deletion as that 
in JH2604 as well as heterologous marker rescue would help 
in understanding the role of the region between 0-0.02 and 
0.81-0.83 m.u. in neurovirulence of both HSV-1 and HSV-2.
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